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Summary
Atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease com¬
monly seen in dogs and humans. Most cases involve hypersensitivity to the house
dust mites Dertnatophagoides farinae and D. pteronyssinus. This study has shown
that Dermatophagoides specific IgE and peripheral blood mononuclear cell (PBMC)
responses were largely restricted to skin test positive atopic dogs. Furthermore, im-
munoblotting and PBMC proliferation studies demonstrated that the major target of
immune recognition is a 98/104kD protein, rather than the low molecular weight
group 1 and 2 proteins important in humans. The close association between serologi¬
cal findings and PBMC proliferation implies that T-cells participate in the patho¬
genesis of canine AD by supporting IgE production. Human AD is associated with
T-helper 2 (TH2) type responses, although THi cytokines are present in chronic le¬
sions. In contrast, tolerance in healthy individuals is mediated by regulatory T-cells.
Using semi-quantitative reverse transcriptase-polymerase chain reactions, this study
found that canine AD is associated with over-production of the TH2 cytokine inter-
leukin (IL)-4, whilst tolerance in healthy individuals is associated with the immuno¬
suppressive cytokines transforming growth factor beta and EL-10. Higher levels of
the THi cytokines interferon gamma, tumour necrosis factor alpha and IL-2 seen in
lesional compared to non-lesional and healthy skin could be induced by subsequent
self-trauma and secondary infections. These results characterise the first spontane¬
ously occurring animal model of human AD.
- 2 -
List of abbreviations
APC Antigen presenting cell
BMMC Bone marrow derived mast cells
MCc Chymase mast cell
ConA Concanavalin A
cpm counts per minute
CLA Cutaneous lymphocye antigen
DLA Dog leucocyte antigen
D Dorsal
ELISA Enzyme linked immunosorbant assay
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GM-CSF Granulocyte macrophage colony stimulating factor
FceRI High affinity IgE receptor









FceRII Low affinity IgE receptor
MHC Major histocompatability complex
mRNA messenger RNA
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PG Prostaglandin
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
sd Standard deviation
sem Standard error of the mean
SE Staphylococcal enterotoxin
SCF Stem cell factor
Tc T cytotoxic cells
TCR T-celI receptor
Th T-helpercell
TARC Thymus and activation regulated chemokine
TSST Toxic shock syndrome toxin
TGF(3 Transforming growth factor beta
MCTc Tryptase-chymase mast ceil
TNFa Tumour necrosis alpha
VCAM Vascular cell adhesion molecule
V Ventral
-3-
List of tables and figures
Page
Chapter 1
Figure 1.1- Facial atopic dermatitis in an infant and flexural atopic dermatitis affect¬
ing the hand and wrist in an adult
11
Figure 1.2 - Chronic atopic dermatitis in a West Highland white terrier with extensive
excoriation, alopecia, lichenification and hyperpigmentation.
12
Figure 1.3 - Diffuse erythema of the ears and interdigital skin of a crossbred dog with
atopic dermatitis
13
Table 1.1 - Allergens identified in Dermatophagoides pteronyssinus and Dermato¬
phagoides farinae
22
Table 1.2 - Tm and JH2 type cytokines 30
Figure 1.4 - The functional effects of mast cell mediators released on activation 44
Chapter 2
Figure 2.1a - Informed consent form for dogs with atopic dermatitis 62
Figure 2.1 b - Informed consent form for healthy dogs 63
Figure 2.2 - Experimental animal release form 64
Figure 2.3 - Clinical record sheet 68
Table 2.1 - Intradermal test allergens 70
Table 2.2 - Source of the Dermatophagoides extracts 74
Figure 2.4 - Schematic representation of a single well gel 79
Figure 2.5 - Schematic representation of the western blot apparatus and procedure 80
Figure 2.6 Schematic representation of the MN28 miniblotter 81
Table 2.4 National Centre for Biotechnology Information accession numbers for ca¬
nine cytokine mRNA sequences
88
Table 2.5 - Cytokine primers and optimum conditions for polymerase chain reactions 89
Figure 2.7 - Schematic representation of capillary transfer of PCR products to nylon
hybridisation membranes
96




Table 3.1 - Age range (months) of the healthy and atopic dogs 104
Table 3.2 - The numbers of male and female dogs in the atopic and healthy groups 104
Table 3.3 - Breeds of dog included in the study 106
Table 3.4 - Skin test reactions in dogs with atopic dermatitis 108
Table 3.5a - Percentage of skin test positive atopic dogs with pruritus,
Malassezia overgrowth or pyoderma at each body site
110
Table 3.5b - Percentage of skin test negative atopic dogs with pruritus, Malassezia
overgrowth or pyoderma at each body site
112
Figure 3.1 - Distribution of pruritus in dogs with atopic dermatitis 114
Table 3.6a - Mean lesion scores at each body site in skin test positive atopic dogs 117
Table 3.6b - Mean lesion scores at each body site in skin test negative atopic dogs 119
Figure 3.2 - Distribution of erythema in dogs with atopic dermatitis 121
Figure 3.3 - Distribution of papules in dogs with atopic dermatitis 122
Figure 3.4 - Distribution of scaling in dogs with atopic dermatitis 123
Figure 3.5 - Distribution of seborrhoea in dogs with atopic dermatitis 124
Figure 3.6 - Distribution of lichenification in dogs with atopic dermatitis 125
Figure 3.7 - Distribution of hyperpigmentation in dogs with atopic dermatitis 126
Figure 3.8 - Distribution of Malassezia dermatitis and/or otitis in dogs with atopic
dermatitis
128
Figure 3.8 - Distribution of Staphylococcal pyoderma and/or otitis in dogs with atopic
dermatitis
129
Figure 3.10 - Comparison of clinical scores at body sites with and without staphylo¬
coccal pyoderma
131
Figure 3.11 - Comparison of clinical scores at body sites with and without
Malassezia dermatitis
134
Figure 12 - Representative histopathological sections of healthy, non-lesional atopic
and lesional atopic skin
139
Figure 3.13 - Morphometric analysis of dermal cell numbers in healthy, non-lesional
atopic and lesional atopic skin
142
Chapter 4
Table 4.1 - Intradermal test (IDT) reactions to Dermatophagoides farinae and D.
pteronyssinus in dogs with atopic dermatitis
162
Figure 4.1 - SDS-PAGE analysis of crude and purified Dermatophagoides extracts 164
Figure 4.2 - Representative immunoblots 170
Table 4.2 - Percentage of atopic and healthy sera that bound to western blots of
crude and purified Dermatophagoides allergens
172
Figure 4.3 - Percentage of atopic and healthy sera that bound to western blots of
Dermatophagoides allergens
175
Table 4.3 - Major and minor allergens identified in the Greer Dermatophagoides fari¬
nae and D. pteronyssinus extracts
179




Table 5.1 - Cell yields after PBMC isolation from whole blood 192
Figure 5.1 - Total number of PBMCs isolated with and without prior incubation with
carbonyl iron
192
Table 5.2 - PBMC cell population with and without prior incubation with carbonyl iron 193
Figure 5.2 - PBMC populations isolated from whole blood by density centrifugation
over 1,077g/L ficoll
194
Table 5.3 - PBMC responses to ConA 196
Figure 5.3 - Responses to ConA in PBMC cultures isolated with and without prior
incubation with carbonyl iron
197
Table 5.4 - PBMC responses to vaccine antigens at day five of culture 200
Table 5.5 - PBMC responses to vaccine antigens at day seven of
culture
202
Figure 5.4 - PBMC responses to vaccine antigens at day five of culture 204




Figure 6.1 - Purification of the 98/104kD major allergen from D. farinae 215
Table 6.1 - Peripheral blood mononuclear cell responses to ConA and vaccine anti¬
gens
216
Figure 6.2 - PBMC responses to D. farinae in atopic and healthy dogs 218
Table 6.2 - In vitro responses of PBMCs isolated from dogs with atopic dermatitis
and healthy dogs to crude and purified Dermatophagoides allergens
219
Figure 6.3 - PBMC responses to D. farinae, D. pteronyssinus and D. microceras
dogs with atopic dermatitis and healthy dogs
220
Figure 6.4 - PBMC responses to major and minor allergens purified from D. farinae 221
Chapter 7
Table 7.1 - Cytokine primers sequences and optimum conditions for polymerase
chain reactions
232
Table 7.2 - PCR optimisation buffers (PCR Optimisation Kit®; Roche) 235
Figure 7.1 - Abundance of gene transcripts after 26 - 44 PCR cycles 236
Table 7.3 Optimum length of PBMC cultures for isolation of cytokine mRNA 238
Figure 7.2 - Expression of cytokine gene transcripts by PBMCs cultured for
1 - 7 days
239
Figure 7.3 - Detection of cytokine gene transcription using positive control cDNA 243
Table 7.4 - Mean expression of cytokine mRNA relative to expression of GAPDH
mRNA in canine skin
244
- 5 -
Table 7.5 - Mean expression of cytokine mRNA relative to expression of GAPDH
mRNA in canine PBMCs
245
Figure 7.4 - Abundance of JH2 cytokine gene transcripts in atopic and healthy canine
skin
247
Figure 7.5 - Abundance of JH2 cytokine gene transcripts in atopic and healthy canine
PBMCs
248
Figure 7.6 - Abundance of Tm cytokine gene transcripts in atopic and healthy canine
skin
250
Figure 7.7 - Abundance of THi cytokine gene transcripts in atopic and healthy canine
PBMCs
253
Figure 7.8 - Abundance of immunosuppressive cytokine gene transcripts in atopic
and healthy canine skin
257
Figure 7.9 - Abundance of immunosuppressive cytokine gene transcripts in atopic
and healthy canine PBMCs
258
Figure 7.10 - Abundance of SCF and c-Kit gene transcripts in atopic and healthy ca¬
nine skin
260





1.1 Introduction to human and canine atopic dermatitis
Atopic dermatitis is a chronic, relapsing and pruritic inflammatory skin disease uni¬
versally recognised in humans and dogs. In both the human (Rothe and Grant-Kels
1996) and veterinary literature (Scott and others 2001a) the cause is defined as an in¬
herited predisposition to develop IgE antibodies specific for environmental allergens
that are non-pathogenic in healthy individuals.
1.1.1 Atopic dermatitis and allergic sensitisation
The persistent generation of IgE antibodies to environmental allergens is characteris¬
tic of type I hypersensitivity diseases (Brostoff and Hall 1998). Elevated levels of cu¬
taneous and circulating allergen-specific IgE can be demonstrated in most cases of
human and canine atopic dermatitis by serology, skin tests and basophil release tests
(Leung 2000; Scott and others 2001a). Furthermore, exacerbations and ameliorations
of human atopic dermatitis often follow exposure to environmental allergens
(Wistokat-Wulfing and others 1999).
There are, however, human (Halbert and others 1995; Akdis and others 1999a) and
canine (Scott and others 2001a) cases with no allergen-specific IgE or skin test reac¬
tivity that fulfil the clinical diagnostic requirements for atopic dermatitis. In humans,
it has been postulated that there are two forms of atopic dermatitis - an allergic (ex¬
trinsic) form with allergen specific IgE, mast cell reactivity and eosinophil rich cuta¬
neous infiltrates; and a non-allergic (intrinsic) form that is not associated with IgE,
mast cell reactivity or eosinophils (Halbert and others 1995; Hanifin 1996; Akdis and
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others 1999a; Tanaka and others 1999). T-cells dominate the cutaneous inflammatory
infiltrate in both forms, but allergen specific T-cells are present only in the allergic
form (Akdis and others 1999a). It is unclear if there are two forms of canine atopic
dermatitis, as the clinical and histopathological features of allergen reactive and non-
reactive dogs have not yet been studied in detail. However, recent reports speculate
that both an atopic constitution and altered skin reactivity are necessary for IgE-
mediated atopic dermatitis (Hyland 2001; Sinke and others 2002). Allergen reactive
healthy individuals could, therefore, have an atopic constitution without altered skin
reactivity, whereas non-IgE mediated atopic dermatitis could be associated with al¬
tered skin reactivity without an atopic constitution.
Possible pathogenic mechanisms for non-allergic atopic dermatitis include reduced
56-desaturase activity, arachidonic acid and di-homo gamma linoleic acid levels,
which have been detected in some atopic humans (Hanifin 1996). Furthermore, ab¬
normal lipid metabolism and bacterial ceramidase activity may decrease epidermal
ceramide levels (Ohnishi and others 1999; Hara and others 2000). This could impair
the cutaneous barrier and enhance inflammatory reactions to irritants, microorgan¬
isms and possibly allergens (Leung 2000).
The role of the epidermal lipid barrier in canine atopic dermatitis is unclear. Abnor¬
malities in 56 and 55-desaturase activity, decreased fat absorption and ultrastructural
abnormalities in the epidermal lipid barrier have been reported in atopic dogs
(Horrobin and others 1990; van den Broek and Simpson 1990; Scott and others 1997;
Taugbol and others 1998; Olivry and others 2000), but their pathogenic significance
is unclear.
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1.1.2 The incidence of allergic diseases in humans and dogs
Despite the pathogenetic heterogeneity, most cases of human (Leung 2000) and ca¬
nine (Scott and others 2001a) atopic dermatitis appear to be a type I hypersensitivity.
The incidence of human allergic disease in developed societies has increased dra¬
matically in the last 30 years (Holt 1998). 10-30% of children now suffer from aller¬
gies (Hopkin 1997; Thomas and others 1998a; Leung 2000) and 30-35% of all indi¬
viduals can be affected at some time in their lives (Holt and Macaubas 1997).
There is little robust epidemiological data for canine atopic dermatitis, but one stan¬
dard text estimates that up to 10% of all dogs are affected (Scott and others 2001a). A
recent review found that between 3 and 30% of all cases seen in private and univer¬
sity teaching hospitals were diagnosed with atopic dermatitis (Hillier and Griffin
2001). However, these findings are difficult to interpret as the data varied with geog¬
raphy, the case population (general population, all diseases, dermatological problems
etc.), the type of veterinary practice (general, private dermatology or teaching hospi¬
tal) and diagnostic criteria.
Whether the incidence has increased to the same extent as in humans is debatable, as
this period coincides with the development of improved diagnostic techniques in vet¬
erinary dermatology. However, dogs have changed from predominantly outdoor
working animals to indoor companion animals over the same time-scale and are now
exposed to the same environmental influences as humans. Early vaccination, parasite
control and antibiotic use have also increased. Canine atopic dermatitis could, there¬
fore, be a valuable spontaneous model for studying the human disease.
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1.2 Clinical features of atopic dermatitis
1.2.1 Human atopic dermatitis
Atopic dermatitis is part of an atopic syndrome that includes dermatitis, rhinitis, con¬
junctivitis and asthma (Rothe and Grant-Kels 1996; Leung 2000). 90% of cases de¬
velop in the first five years of life (Leung 2000). The clinical course often results in
complete remission by the late teens or early twenties, but clinical signs persist into
adulthood in up to 60% of sufferers (Hanifin 1996; Beltrani 1999a). A significant
proportion of children with atopic dermatitis will subsequently develop atopic asthma
(Leung 2000).
The clinical hallmark of human atopic dermatitis is pruritus. Primary skin lesions are
rare and limited to erythema and/or a mild papular eruption with hyperhidrosis or
xerosis (Rothe and Grant-Kels 1996). The typical eczematous lesions develop after
self-trauma or secondary infection (Beltrani 1999a). Chronic inflammation and self
trauma often lead to lichenification of affected skin (Halbert and others 1995; Rothe
and Grant-Kels 1996). Human atopic dermatitis typically affects the face, head and
neck, flexural limb surfaces and trunk, but can be generalised in severe cases
(Halbert and others 1995; Rothe and Grant-Kels 1996) (Figure 1.1). Some cases, par¬
ticularly in adults, can be focal or localised (Beltrani 1999a).
Allergens commonly implicated in atopic dermatitis include house dust mites, pol¬
lens, moulds, insects, foods, epithelia and fibres (Beltrani 1999a; Friedmann 1999).
Other provocative factors can be pyschological, contact irritants, hormonal, heat,
humidity and perspiration (Rothe and Grant-Kels 1996; Beltrani 1999a; Friedmann
1999). Colonisation of lesional skin with staphylococci and Malassezia yeasts is
common (Blaher and others 1995; Halbert and others 1995; Herz and others 1998).
- 10-
Figure 1.1 - Facia! atopic dermatitis in an infant (left) and flexural atopic der¬
matitis affecting the hand and wrist in an adult (right) (Thestrup-Pedersen
2000 by kind permission of Blackwell Science).
Atopic dermatitis can be a very distressing condition. The intense pruritus often dis¬
turbs sleep and disrupts normal development and family life, affecting quality of life
for both the patient and close family (Blaher and others 1995). The physical signs of
severe atopic dermatitis can also be disfiguring with consequent social implications
(Koblenzer 1999).
1.2.2 Canine atopic dermatitis
Dogs also spontaneously develop an atopy-like syndrome (Scott and others 2001a).
Most cases develop between six months and three years of age (Griffin and DeBoer
2001). Dermatitis is the most common manifestation, accounting for 50% of the der¬
matology referrals in one centre (Nuttall and others 1998). Conjunctivitis is occasion¬
ally seen, but respiratory symptoms are rare (Mason 1995; Griffin and DeBoer 2001;
Scott and others 2001a).
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As in humans, pruritus is the most important clinical sign and usually precedes secon¬
dary lesions such as erythema or a papular eruption (Mason 1995; Scott and others
2001a). Chronic lesions are often lichenified, hyperpigmented and alopecic, possibly
due to repeated self-trauma (Figure 1.2). Microbial colonisation and secondary infec¬
tion of affected skin with Staphylococcus intermedins and Malassezia pachydermatis
is also common (Scott and others 2001a).
Figure 1.2 - Chronic atopic dermatitis in a West Highland white terrier with
extensive excoriation, alopecia, lichenification and hyperpigmentation. This
dog also had well-established staphylococcal pyoderma and Malassezia der¬
matitis.
Typically affected sites include the face, ears, flexural surfaces, interdigital skin and
ventral body (Mason 1995; Scott and others 2001a) (Figure 1.3). These clinical signs
and sites have been suggested as clinical criteria for the diagnosis of atopic dermatitis
(Willemse 1986; Prelaud and others 1998). However, caution must be exercised as
dogs with other pruritic dermatoses may satisfy these criteria. Furthermore, studies
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describing the clinical signs did not use the same inclusion criteria nor necessarily
eliminate the possibility of other dermatoses (Griffin and DeBoer 2001).
Figure 1.3- Diffuse erythema of the ears and interdigital skin of a crossbred
dog with atopic dermatitis
Positive reactions to a range of house dust mite, pollen, epidermal, insect and mould
allergens are seen with intradermal skin tests or serology for specific IgG and IgE
(Sture and others 1995; Day and others 1996; Hill and DeBoer 2001; Scott and others
2001a). Other factors that can contribute to the pathogenesis include food intolerance,
poor quality diets, increased temperature and humidity, ectoparasites and endopara-
sites (Mason 1995; Scott and others 2001a).
Canine atopic dermatitis can be very distressing for both dogs and their owners. The
pruritus often interrupts sleep and activity patterns, interfering with the human-animal
bond. Pruritus and skin inflammation are also obvious and intrusive clinical signs that
owners can readily empathise with.
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1.3 Histopathology and immunohistochemistry of atopic dermatitis
1.3.1 Human atopic dermatitis
Histological changes are present in both non-lesional and lesional skin. Compared to
healthy skin, there is a sparse perivascular mononuclear, primarily T-cell, infiltrate into
non-lesional skin (Leung 1999; Leung 2000). Immunohistochemistry also demon¬
strates increased expression of T-cell and eosinophil surface markers (Langeveld-
Wildschut and others 2000). There can also be mild hyperkeratosis of the stratum
corneum (Leung 1999).
The histopathology of acute lesions is dominated by CD4 T-cell infiltration of the
epidermis and superficial dermis. Infiltrating T-cells are predominantly
CD45RO CD4 activated memory cells, which express cutaneous lymphocyte antigen
(CLA). There is also a marked perivascular dermal infiltrate of mononuclear cells and
macrophages with infrequent eosinophils, basophils and neutrophils. Increased num¬
bers of mast cells are occasionally observed, but increased degranulation is frequently
seen (Leung 1999; Leung 2000). There is often epidermal spongiosis, acanthosis and
exocytosis of T-cells and Langerhans' cells (Herz and others 1998; Leung 1999).
Mast cells, basophils, dendritic cells and Langerhans' cells are frequently positive for
IgE bound to high (FcsRI) and low (FceRII/CD23) affinity IgE receptors (Herz and
others 1998; Leung 2000).
Chronically inflamed skin exhibits greatly increased hyperkeratosis, acanthosis and
spongiosis. Dermal fibrosis may be present in severely affected areas (Herz and others
1998; Leung 1999). There are also increased numbers of IgE" Langerhans' cells and
dendritic cells in the epidermis and dermis respectively. The dermis is dominated by
perivascular to diffuse inflammatory infiltrates of CD4 and CD8" CLA" lymphocytes,
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cytes, monocytes, macrophages, neutrophils, eosinophils and mast cells, which show
increased degranulation (Cooper 1994; Hanifin 1996; Leung 1999). The intensity of
the infiltration generally correlates with the severity of the skin lesions (Leung 2000).
1.3.2 Canine atopic dermatitis
Like human atopic dermatitis, non-lesional canine atopic skin is characterised by
sparse superficial perivascular infiltrates of lymphocytes, monocytes, dendritic cells
and mast cells (Nimmo Wilkie and others 1990; Olivry and others 1997). There may
also be mild epidermal spongiosis (Olivry and others 1997; Olivry and others 1999a).
In lesional skin the degree of epidermal spongosis, acanthosis and hyperkeratosis is
related to the severity of the clinical signs (Olivry and others 1997). There is a super¬
ficial to deep, perivascular to diffuse dermal infiltration of CD4+ and CD8+ T-cells,
monocytes, eosinophils, neutrophils, mast cells and plasma cells that also correlates
with the severity of the clinical signs (Olivry and others 1997). The epidermis exhib¬
its increased numbers of IgE+ Langerhans' cells (Day 1996), CD4+ and, to a lesser
(Sinke and others 1997) or greater (Olivry and others 1997) extent, CD8+ T-cells.
The number of IgE+ Langerhans' cells correlates with serum IgE levels (Olivry and
others 1999a). Dermal mast cells are also frequently IgE+ (Olivry and others 1997).
yd T-cells, which are rare in humans, are seen in the epidermis and dermis in canine
atopic dermatitis. Whether they have any activity as effector or regulatory cells is,
however, unknown (Olivry and others 1999a).
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1,4 Genetic factors in atopic dermatitis
1.4.1 Human atopic dermatitis
A family history is a characteristic feature of human atopic diseases (Rothe and
Grant-Kels 1996; Torres-Galvan and others 1999). The likelihood of having atopy
progressively increases if neither, one or both parents have an atopic history (Rothe
and Grant-Kels 1996). There is also an increased incidence in monozygotic compared
to dizygotic twins (Rothe and Grant-Kels 1996). These findings suggest that genetic
factors are important in developing atopic dermatitis. However, identifying these fac¬
tors and their mode of inheritance has proved elusive and controversial. It is likely
that atopic traits involve several genes, which could be dominant, recessive or display
incomplete penetrance (Torres-Galvan and others 1999).
Reactivity to pollens has been associated with certain human leucocyte antigen
(HLA) haplotypes (Cookson 1998). Increased magnitude, but not frequency, of re¬
sponses to Der p 2 has been linked to HLA-DQ haplotypes (O'Brien and others
1995), although it has proved difficult to link other allergens with HLA haplotypes
(Mitsuyasu and others 1999; Torres-Galvan and others 1999). It is also possible that
different peptides within an allergen are restricted by different HLA haplotypes, per¬
mitting sensitisation in a range of individuals (Cookson 1998).
Other candidates include genes that regulate the expression and activity of cytokines
and cytokine receptors, IgE and IgE receptors, antigen processing or T-cells (Leung
1998; Cookson 1998; Torres-Galvan and others 1999). Associations to atopic dis¬
eases have been made with up regulation of the tumour necrosis factor alpha (TNFa)
promoter region and increased signalling by the interleukin (IL)-4 receptor and CD23
(Cookson 1998; Mitsuyasu and others 1999). Serum IgE levels and bronchial re-
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sponses have also been linked with particular alleles of chromosome 5q23-31, which
contains genes for EL-3, 4, 5, 9, 12 and 13, and chromosome llql2-13, which gov¬
erns FceRI expression (Cookson 1998; Torres-Galvan and others 1999). Polymor¬
phisms of the FceRI|3 subunit may amplify allergen/IgE mediated signals, whilst
those of the a subunit could increase IgE binding affinity (Bieber 1997). Other links
have been made to polymorphisms of chromosome 12q and genes for interferon
gamma (IFNy) and stem cell factor (SCF) (Cookson 1998).
None of these findings have proved consistent, and it is thought that atopic traits
could differ between gene pools (Cookson 1998; Leung 1998). However, although
the prevalence of atopic dermatitis varies between countries, no link to any ethnic
group has been established (Leung 2000). This suggests that environmental factors
are more important than genetic traits. Furthermore, the recent rise in the incidence of
atopic diseases has been too rapid to explain by genetic mechanisms alone (Polosa
1999). Atopic traits could have evolved to cope with high parasite burdens and could,
therefore, be widespread in modem humans (Monticelli and others 1998; Erb 1999).
1.4.2 Canine atopic dermatitis
Well-recognised breed predispositions (e.g. West Highland White Terriers, Labra-
dors and Boxers) suggest that a familial tendency also exists in canine atopic derma¬
titis (Scott and others 2001a). However, in one study only 13 progeny of 72 affected
parents developed atopic dermatitis (Schwartzman 1984). Furthermore, in a Beagle
colony with an autosomal dominant high IgE response, the propensity to develop per¬
sistent IgE responses and clinical signs depends on early and repeated allergen expo¬
sure (de Week and others 1997).
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Dog leucocyte antigen (DLA) haplotypes for class II major histocompatibility com¬
plex molecules (MHCII) have recently been identified (Kennedy and others 1999).
There is considerable interbreed variation in haplotype and allele frequency, although
none identified so far are specific to any one breed. Up to 35% of dogs are homozy¬
gous, reflecting the high degree of inbreeding in many breeds (Kennedy and others
1999). The DLA haplotype alleles DRB 1*00201 and DRB 1*00101 have been asso¬
ciated with polyarthritis and hypothyroidism respectively (Kennedy and others 2001).
Serological typing in an earlier study linked a combination of DLA3 and R15 with
atopy, but not with serum IgE levels (Vriesendorp and others 1975). Large-scale
studies of DLA linkage with clinical atopic dermatitis have yet to be performed.
These findings suggest that, similarly to humans, canine atopic dermatitis is the end
result of a complex interaction between genetic traits and environmental influences.
However, studies of genetic traits in dogs are limited and need further investigation.
1.5 Atopic dermatitis and house dust mite allergens
1.5.1 House dust mite specific skin tests and serum IgE in atopic dermatitis
Atopic dermatitis may be associated with reactions to a variety of potential allergens
including house dust mites, insects, pollens, epithelia, fibres, moulds and foods
(Rothe and Grant-Kels 1996; Scott and others 2001a). Recent studies have also de¬
scribed reactions to human skin extracts in human atopic dermatitis (Valenta and
others 2000). However, both human (Leung 2000) and canine (Sture and others
1995) atopic dermatitis are predominantly house dust mite mediated.
Human atopic dermatitis is strongly associated with house dust mite exposure. Posi¬
tive skin tests and allergen specific serum IgE titres are found in 40-80% of patients
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(Halbert and others 1995). In one study, 90% of patients with positive skin tests were
exposed to house dust mite antigen levels greater than 2pg/g of dust, which is re¬
garded as the threshold for sensitisation (Ricci and others 1999). House dust specific
T-cells have been cloned from atopic skin and patch test sites (Leung 2000). House
dust mite allergen-specific proliferation of peripheral blood mononuclear cells
(PBMCs), furthermore, correlates with atopy patch test results and serum specific IgE
levels in atopic, but not healthy, patients (Blaher and others 1995; Horneff and others
1996; Kawamura and others 1998; Wistokat-Wulfing and others 1999).
House dust mite allergens are of similar importance in canine atopic dermatitis. 60-
90% of cases in the UK (Sture and others 1995), Japan (Masuda and others 2000),
mainland Europe and the US (Scott and others 2001a) have positive skin tests or se¬
rum IgE specific for house dust mite allergens. In another study, house dust mite spe¬
cific proliferation was seen in PBMCs isolated from atopic, but not healthy, dogs
(Shaw 2000).
1.5.2 Atopy patch tests and house dust mite allergens
Atopy patch tests, in which there is direct application of allergens to the skin, mimic
natural percutaneous allergen exposure. The clinical appearance and histopathology
of positive sites closely matches human (Grewe and others 1998) and canine (Sinke
and others 1998) atopic dermatitis. Patch tests in humans appear to be IgE mediated,
as positive tests correlate with the number of epidermal IgE+ cells, although not
FceRI expression (Langeveld-Wildschut and others 2000).
Although it is not commonly performed, patch testing with house dust mite allergens
is highly specific for human (Grewe and others 1998) and canine (Sinke and others
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1998) atopic dermatitis, although an early study in dogs failed to show any associa¬
tion (Frank and McEntee 1995). Despite this, 60-70% of atopic patients have nega¬
tive patch tests, possibly due to low levels of epidermal IgE or non-percutaneous al¬
lergen uptake (Grewe and others 1998). Sensitivity can be increased by scarification
of test sites (Wistokat-Wulfing and others 1999), suggesting that the epidermal bar¬
rier also blocks allergen uptake. There is no clinical difference between human pa¬
tients with positive or negative patch tests (Grewe and others 1998).
1.5.3 Increasing exposure to house dust mites
Changes in Western lifestyles may have dramatically increased exposure to indoor al¬
lergens like house dust mites. Furthermore, insulation, central heating and reduced
ventilation have raised indoor temperatures and humidity, which significantly in¬
creases house dust mite populations (Hirsch and others 2000).
1.5.4 The importance of Dermatophagoides species house dust mites
The major house dust mite species in temperate areas are Dermatophagoides farinae
and D. pteronyssinus. D. pteronyssinus prefers more humid conditions than D. fari¬
nae and is most common in the UK (Thomas and others 1998a). A third species, D.
microceras, is rarely found in the UK (O'Hehir 1988). Despite this, skin test reactions
to D. farinae are more frequent than D. pteronyssinus in atopic dogs in the UK (Sture
and others 1995). However, having a dog is positively correlated with household Der
f 1 levels (Gross and others 2000). Canine squames may be a particularly good sub¬
strate for D. farinae, or dog owning households may have microclimates favouring
this species. A study in an area of Brazil thought to have low numbers of D. farinae
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found equal levels of indoor Der f 1 and Der p 1 (Sopelete and others 2000). The au¬
thors speculate that seasonal population fluctuations could lead to an artificially low
estimate of D. farinae numbers.
1.5.5 Dermatophagoides species allergens
1.5.5.1 Allergens relevant to humans
Dermatophagoides species house dust mites are the most important allergens in hu¬
man atopic dermatitis (Thomas and Smith 1999). More than 16 different Dermato¬
phagoides allergens have been identified (Table 1.1). The most important are the
group 1 and 2 allergens Der p 1 and 2, and Der f 1 and 2 from D. pteronyssinus and
D. farinae respectively. High IgE titres to these are present in 70-80% of atopic hu¬
man sera, whereas variable titres to other groups are found in 40-50% of sera (Le
Mao and others 1998; Thomas and others 1998a).
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1.5.5.2 Allergens relevant to dogs
Dermatophagoides species are equally important in canine atopic dermatitis (Sture
and others 1995), although the spectrum of Dermatophagoides allergens relevant to
dogs is less clear. Most atopic dogs in one study had positive skin tests and serum
specific IgGd to crude D. farinae and D. pteronyssinus extracts, but not to purified
group 1 and 2 allergens (Noli and others 1996). IgGd binding proteins with molecular
weights of 65-70kD and 90kD were identified on western blots, but no binding to
group 1 or 2 allergens was seen (Noli and others 1996). Another study used recombi¬
nant canine FceRIa to detect IgE binding proteins on western blots of D. farinae.
Eighty-five per cent of the atopic sera recognised 60, 98 and 109kD allergens, but
69% of the atopic sera also recognised Der f 1 (McCall and others 1999). Homology
of the 98kD protein with published sequences suggests it is a chitinase. It has recently
been cloned, expressed and named Der f 15 (McCall and others 2000). An independ¬
ent investigation using FceRIa found that the majority of atopic sera also recognised
98 and 109kD allergens in D. pteronyssinus (Shaw 2000). A study using monoclonal
anti-canine IgE in enzyme linked immunosorbent assays and dot blots, however, re¬
ported that 50% of atopic sera recognised Der p 1 and 2, and Der f 1 and 2 (Masuda
and others 1999).
1.5.5.3 Homology and polymorphisms of D. pteronyssinus and
D. farinae allergens
There is generally 80-90% homology between D. pteronyssinus and D. farinae aller¬
gens (Mueller and others 1998; Smith and others 1999). However, spontaneous
polymorphisms of group 1 and group 2 allergens are recognised (O'Brien and others
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1995). Regional polymorphisms could account for the differences in IgE binding ca¬
pacity between allergen extracts (van Neerven and others 1996; Thomas and others
1998b). Interestingly, the most polymorphic regions of Der p 1 and Der p 2 coincide
with the immunodominant peptide sequences (O'Brien and others 1995). These po¬
lymorphic sequences could permit sensitisation to group 1 and 2 allergens across a
range of HLA haplotypes. In contrast, more stringent HLA restriction for the highly
conserved group 5 allergens might explain why sensitisation to these allergens is less
prevalent (O'Brien and others 1995).
1.5.6 Allergenic properties of Dermatophagoides allergens
1.5.6.1 Structural properties
Only a minority of proteins induce an allergic response, which suggests that they pos¬
sess intrinsic allergenic properties (Comoy and others 1999). Despite this, there are
few common patterns. Allergenic proteins tend to be stable in the environment and in
vivo (Bufe 1998; Huby and others 2000), which enhances allergen exposure, uptake
and processing. Disulphide bonds appear to be important in stabilising the three di¬
mensional structure of IgE epitopes, as their disruption abrogates allergenicity (Huby
and others 2000). Many allergens, including Der f 15, the 98kD chitinase important
in canine atopic dermatitis, are also glycosylated. Glycosylation increases IgE bind¬
ing affinity, B-cell recognition, and antigen uptake and presentation by APCs (Huby
and others 2000). Allergens may also directly influence the immune system. Group
11 allergens, for example, can inhibit complement activation (Tsai and others 1999;
Tsai and others 2000). Group 1 and 2 allergens can also induce expression of MHC13
and CD80 on keratinocytes, rendering them capable of presenting antigens to acti-
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vated T-cells in vitro (Wakem and others 2000). Protein allergens can also inhibit IL-
12 by stimulating IL-10 production (Bellinghausen and others 1999).
1.5.6.2 Enzymatic activity
Much interest has focused on the biological activity of allergens. Most Dermato-
phagoides allergens are enzymes that retain protease activity in the environment and
in vivo (Shakib and Furmonaviciene 2000). Group 1 allergens are cysteine proteases
with stable proteolytic activity in vivo and in vitro, even when complexed with spe¬
cific antibody (Schulz and others 1999). Der p 1 cleaves occludin/claudin family tight
junction proteins and E-cadherin, resulting in disruption of epithelial cell architecture
and detachment of epithelial cell monolayers in vitro (Wan and others 1999; Wan
and others 2000). This could impair barrier defences, increasing allergen uptake and
microbial colonisation. Der p 1 also inactivates al-antitrypsin, enhancing exogenous
and endogenous protease activity (Bufe 1998; John and others 2000). Furthermore,
Der p 1 specifically cleaves surface CD23 and CD25, the IL-2 receptor. Decreased
negative feedback from surface CD23 and increased soluble CD23 enhances IgE
production by B-cells (Bufe 1998; Schulz and others 1999; Tsicopoulos and Joseph
2000). Loss of CD23 also inhibits monocyte and macrophage activation (Bufe 1998;
Schulz and others 1999). Cleavage of CD25 strongly inhibits proliferation of acti¬
vated T-cells and IFNy production in vitro (Bufe 1998; Schulz and others 1999). Der
p 1 can also activate mast cells in an IgE independent manner (John and others 2000).
Blocking the proteolytic activity of Der p 1 in mouse models of asthma resulted in
decreased IgE production and ameliorated airway pathology (John and others 2000;
Shakib and Gough 2000).
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1.6 Immunoglobulins in atopic dermatitis
1.6.1 IgE
IgE plays a pivotal role, both at the effector level through binding to FceRI on mast
cells and basophils and in enhancing allergen presentation via binding to FceRI and
CD23 on Langerhans' cells, dendritic cells, monocytes and B-cells (Leung 1998). On
subsequent exposure to allergen, cross-linking of surface IgE triggers synthesis and
release of inflammatory mediators, immunoglobulins, receptor expression, allergen
uptake, processing and presentation (Maggi 1998; Okudaira and Mori 1998). Cross-
linking of surface IgE by allergen, furthermore, induces FceRI and IgE synthesis
(Helm and others 1998).
Total serum IgE is significantly correlated with atopy in humans, particularly infants
(Leung 1999), but not in dogs, where a high level of parasitism may mask differences
(Hill and others 1995; Racine and others 1999). Serum IgE levels in dogs rise up to
four years of age and then plateau, which coincides with the peak age of onset for
atopic dermatitis (Racine and others 1999). Female dogs have higher IgE levels
(Racine and others 1999), but no consistent female bias in atopic dermatitis has been
found (Scott and others 2001a).
Levels of allergen specific IgE are frequently elevated in human and canine atopic
dermatitis and are considered a hallmark of the disease (Leung 2000; Halliwell and
DeBoer 2001). Furthermore, serological or skin tests are routinely employed to iden¬
tify allergens for avoidance or specific immunotherapy (Pachlopnik and others 1999;
Scott and others 2001a). However, allergen specific serum IgE is also present in
healthy dogs and humans, suggesting that heterogeneous IgE antibodies with variable
receptor binding affinities exist (Halliwell and others 1998; Griot-Wenk and others
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1999; Marone and others 1999). Recent findings suggest that two distinct subtypes of
canine IgE exist (Peng and others 1993). The presence of positive skin tests in some
healthy individuals though (Halliwell and others 1998; Lian and Halliwell 1998;
Beltrani 1999b), suggest that other tolerogenic mechanisms are also present.
1.6.2 IgG
It is likely that most, if not all, individuals are exposed and respond to allergens as
specific IgG is found in both atopic and healthy humans (Upham and others 1995)
and dogs (Day and others 1996). The role of IgG in atopic dermatitis is unclear. Al¬
lergen-specific and anti-idiotype IgG antibodies may block IgE activity in healthy in¬
dividuals (Griot-Wenk and others 1999). Eighty per cent of human atopic patients
have IgG/IgE complexes (Marone and others 1999), although it is unclear whether
these are biologically irrelevant, block the functional activity of IgE or induce pro¬
inflammatory mediator release.
Allergen-specific IgG levels correlate with IgE levels in canine atopic dermatitis. Ele¬
vated IgE titres to dust and mite allergens were detected more frequently than IgG ti-
tres, although the reverse was true for insect mix and mould allergens (Day and oth¬
ers 1996). Responses to mite allergens were dominated by the IgG4 subclass,
whereas IgGl antibodies dominated responses to Timothy grass (Phleum pratense).
This difference may be due to the biological nature of the allergens, route of exposure
or antigen processing and presentation. However, it is unclear if this has any patho¬
logical significance.
It has also been suggested that IgGd subclass antibodies are also capable of inducing
mast cell degranulation in dogs and that allergen-specific IgGd antibodies are largely
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specific to canine atopic dermatitis (Willemse and others 1985). However, mono¬
clonal antibody specific for IgGd did not bind to any of the canine IgG subclasses 1-4
in one study (Mazza and others 1993). A recent study of allergen specific IgGd and
IgE in both atopic and healthy dogs found that levels of IgE correlated better with the
diagnosis of canine atopic dermatitis (Lian and Halliwell 1998). These findings, plus
a lack of reverse cutaneous anaphylaxis and basophil histamine release prompted a
recent review to conclude that there is only circumstantial evidence that IgG is in¬
volved in the pathogenesis of canine atopic dermatitis (Halliwell and DeBoer 2001).
1.7 Antigen presenting cells and allergen presentation in atopic
dermatitis
Immunoglobulin synthesis by B-cells is dependent on interaction with a CD4+ T-
helper cell (TH cell) activated by an antigen-presenting cell (APC) (Huston 1997).
Non-professional APCs (including macrophages, endothelial cells, keratinocytes and
B-cells) are incapable of stimulating naive cells, and are more important in present¬
ing antigen to activated T-cells in peripheral tissues (Huston 1997; Kapsenberg and
others 1998; Robert and Kupper 1999). In particular, B-cells bearing IgE bound to
CD23 are very effective at presenting allergen to T-cells (Mudde and others 1996). In
contrast, only professional APCs, such as epidermal Langerhans' cells and dermal
dendritic cells, can activate naive T-cells in draining lymph nodes (Mudde and others
1996; Kapsenberg and others 1998).
In peripheral tissues, APCs are geared towards antigen uptake and processing.
Langerhans' cells in both human and canine atopic dermatitis express FceRI (Bieber
1997; Olivry and others 1999a). IgE binding enhances allergen uptake 100-1000 fold
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(Bieber 1997; Cox and others 1998). The phagocytosed allergens are then exposed to
lysosomal acid proteases and cathepsins. By a process of low pH, reduction, oxida¬
tion, unfolding, and proteolysis, these degrade the allergens into 10-15 amino acid
peptides that include the T-cell receptor (TCR) epitopes (Carrasco-Marfn and others
1998). The peptides are assembled with MHCII molecules and are transported to the
cell surface for presentation to CD4+ TH cells (Kalish and Askenase 1999).
On exposure to allergen and inflammatory cytokines, Langerhans' cells and dendritic
cells down regulate surface adhesion molecules and migrate to the local lymph node.
Here they lose the ability to process antigens, but have enhanced antigen presenting
capacity expressing MHCII/peptide complexes and co-stimulatory molecules (Bieber
1997; Kapsenberg and others 1998; Kimber and others 1998).
1.8 The role of T-cells in atopic dermatitis
1.8.1 Recruitment and activation of CD4+ cells
Nai've (CD45RA+ in humans) CD4+ Th cells express ligands for L-selectin on pe¬
ripheral lymph node high endothelial venules, where they come into contact with
APCs (Huston 1997). Allergen/MHCII complexes are recognised by specific
TCR/CD4 complexes on Th cells. Ligation of CD80/86 with CD28, CD40/CD40L
and cytokine expression provide the accessory signals necessary for differentiation
into activated (CD45RO+ in humans) CD4+ Th cells (Delves and Roitt 2000). Acti¬
vated CD4+ Th cells then migrate into the peripheral tissues. T-cells in atopic derma¬
titis express CLA, a ligand for E-selectin expressed on dermal blood vessels, as well
as ligands for other selectins and chemokines in inflamed skin (Leung 1998; Tu and
others 1999).
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1.8.2 THi and TH2 Cells
Subsets of Th cells were first described in mice and rats (Arthur and Mason 1986;
Mosmann and Coffman 1987), when clones supporting cell mediated immune re¬
sponses (Thi) were distinguished from clones providing B-cell help (Th2)- Since then
THi and TH2-like cells have been found in humans and other species (Romagnani
1991; Maggi 1998).
1.8.2.1 Thi responses
Tm-type cytokines (Table 1.2) mediate delayed (type IV) hypersensitivity reactions,
activate macrophages, cell mediated immune responses, production of opsonising
and complement fixing IgG and IgM, and antibody dependent cell-mediated cytotox¬
icity (Abbas and others 1996). Their primary role is in clearing infectious agents, par¬
ticularly intracellular organisms, tumours, endogenous and insoluble antigens (Abbas
and others 1996; Kalish and Askenase 1999). However, THi responses can damage
host tissues, especially in chronic inflammatory and immune-mediated diseases
(Leung 1998; Maggi 1998).
Table 1.2 - THi and TH2 type cytokines






EL-2 promotes lymphocyte proliferation, survival and differentiation (Helfand and
others 1992). Autocrine EL-2 secretion drives expansion of THi clones (Maggi 1998).
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IL-12 drives THi differentiation of nai've Th cells (Maggi 1998). Functional EL-12 is a
heterodimer, consisting of a p35 and p40 subunit (McDyer and others 1998). p35
dimers are biologically inactive, whilst the p40 dimer blocks IL-12 activity (Piccotti
and others 1996). IL-12 is produced primarily by APCs and macrophages, but also by
B-cells, neutrophils, keratinocytes and eosinophils (McDyer and others 1998). Stim¬
uli for IL-12 synthesis and release include specific antigens, intracellular pathogens
and fFNy (McDyer and others 1998; Kimber and others 2000). In contrast, IL-4 and
IL-10 inhibit IL-12 production (McDyer and others 1998; Camporota and Holloway
1999; Kimber and others 2000).
IL-18 supports Thi differentiation and cell mediated inflammation, and inhibits IgE
production with IL-12 (Kimber and others 1998; McDyer and others 1998; Dinarello
1999), but supports IL-4 mediated activity in the absence of EL-12 (Yoshimoto and
others 2000).
IFNy up regulates expression of MHCII, adhesion molecules, pro-inflammatory cyto¬
kines and chemokines by keratinocytes and dermal cells. These molecules are impor¬
tant in attracting, retaining and activating T-cells, macrophages and other inflamma¬
tory cells (Maggi 1998; Pastore and others 1998). IFNy also inhibits mast cell FceRI
expression, cytokine release (Tachimoto and others 2000) and encourages apoptosis
(Rossi and others 1998).
TNFa is produced by THi cells, macrophages, mast cells and basophils (Maggi 1998;
Kobayashi and others 2000). It is strongly pro-inflammatory and levels correlate with
the severity of clinical signs in allergic respiratory disease (Kobayashi and others
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2000). TNFa also increases the activity of dendritic cells (Skok and others 1999) but
inhibits mast cells, FceRI expression and cytokine release (Rossi and others 1998).
1.8.2.2 T/i2 responses
TH2 cytokines (Table 1.2), in contrast, promote mast cell, eosinophil and B-cell
growth and development, production of IgA, IgE, and non-opsonising and comple¬
ment fixing IgG and IgM (Abbas and others 1996; Till and others 1997; de Vries
1998). They also induce adhesion molecules on endothelial cells (Ramirez and others
1998; Sherman and others 1999). Th2 responses are less effective against infectious
agents, but are important in responses to parasites and soluble antigens (Abbas and
others 1996). They are also less damaging to the host under normal circumstances,
and may help to regulate Thi responses (Leung 1998; Maggi 1998).
IL-4 and the closely related cytokine IL-13 induce IgE production, antigen presenta¬
tion, expression of MHCII, CD23 and adhesion molecules, and eosinophil chemo-
taxis and activation (Monticelli and others 1998; Corry 1999; Luttmann and others
1999). They inhibit the production of opsonising and complement fixing IgG and
IgM, and macrophage activation (Fiorentino and others 1989; Abbas and others
1996; Ryan 1997). In humans, IL-4 induces FceRI expression, whereas it is inhibitory
in mice (Bieber 1997; Ryan and others 1998). IL-4 also increases mast cell prolifera¬
tion and cytokine release (Rossi and others 1998; Yamaguchi and others 1999;
Tachimoto and others 2000).
Th2 differentiation is dependent on EL-4. Early sources of IL-4 could include TH2
cells, NK cells, mast cells, eosinophils, basophils and APCs (Bottomly 1988; Ryan
1997; de Vries 1998; Maggi 1998; Haas and others 1999). It possible that IL-4 is
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produced by cells of the innate immune system, such as basophils and mast cells in
response to allergen contact (Haas and others 1999). However, this does suppose
prior TH2 differentiation and sensitisation with allergen-specific IgE. Other studies
have shown that naive CD4+ cells can produce LL-4 on priming, suggesting that TH2
differentiation is determined by autocrine secretion of IL-4 (Bullens and others
1999). Subsequent expansion of TH2 clones depends on autocrine IL-4, which en¬
hances responses to IL-2 (van Reijsen and others 1992).
IL-13 is produced by Th2 cells, B-cells, dendritic cells, mast cells, basophils, NK
cells and keratinocytes (de Vries 1998; Corry 1999). It probably plays little role in
differentiation of CD4+ cells, which lack IL-13 receptors (de Vries 1998; Corry
1999). However, epicutaneous sensitisation can still induce Th2 differentiation in IL-
4 knockout mice, implying that IL-13 might provide an IL-4 independent pathway for
TH2 differentiation in the skin (Herrick and others 2000). IL-13 also synergises with
SCF to promote mast cell growth, differentiation and activity (de Vries 1998). In
humans, IL-13 is produced by Thi cells in late phase inflammation, which may allow
cross-regulation of THi and TH2 responses (de Vries 1998). Recombinant canine IL-
13 also stimulates IgE production by PBMCs isolated from dogs sensitised to flea al¬
lergens (Tang and others 2001), suggesting that IL-13 is also an important mediator
of IgE production in canine allergic disease.
EL-5 recruits and activates eosinophils, which is crucial in late phase inflammatory
responses (Okudaira and Mori 1998; O'Byrne and Wood 1999). IL-5 also supports
IgE synthesis by IL-4 stimulated B-cells and enhances basophil histamine release
(Lalani and others 1999). EL-5 secretion by Th2 cells, mast cells and eosinophils is
stimulated by IL-2, histamine, PGE2 and IgE. Secretion is inhibited by transforming
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growth factor beta (TGF(3), EL-10, IFNy and IL-12 (Lalani and others 1999; O'Byrne
and Wood 1999).
Many cells, including APCs, macrophages, mast cells, TH2 cells, fibroblasts, endothe¬
lial cells and keratinocytes, produce IL-6. It primarily supports B-cell development,
IgG and IgE production. However, it also induces IL-4 and antagonises IL-12, and
may therefore be an early TH2 differentiating signal (Kirman and Le Gros 1998; Skok
and others 1999).
1.8.2.3 THi and THz cytokine profiles
Whilst murine Th cells have a restricted cytokine profile, in human cells this is much
less so. Individual cells often secrete a complex set of cytokines including EL-2, IL-4,
IL-5, IL-10, IFNy and TGF(3 (Abbas and others 1996; Neumann and others 1996;
Umetsu and DeKruyff 1997; Grewe and others 1998). However, THi (high EFNy) and
Th2 (high IL-4) polarised responses can still be distinguished (Abbas and others
1996; Borish and Rosenwasser 1997; Maggi 1998).
1.8.2.4 Antagonism of THi and TH2 responses
THi and TH2 differentiation in mice is mutually antagonistic (Fiorentino and others
1989; Abbas and others 1996). Furthermore, human patients with multiple sclerosis
(a Thi mediated disease) have a low risk for atopy (Umetsu and DeKruyff 1997),
whereas atopic patients have a low incidence of allergic contact dermatitis (also THi
mediated) (Cooper 1994). Depressed cutaneous cell mediated immunity has also
been reported in canine atopic dermatitis (Nimmo Wilkie and others 1991). Despite
this, other studies have shown that human atopic patients with TH2 skewed responses
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to house dust mite allergens still mount a normal THi response to PPD antigen (Nurse
and others 2000). THi and Tm responses to independent antigens, furthermore, can
co-exist in healthy individuals (Ismail and Bretscher 1999), implying that normally
there is a THi/Th2 balance. Pathological imbalances, however, could lead to an inap¬
propriate THi (e.g. immune-mediated diseases) or Tm (e.g. hypersensitivity diseases)
responses (Umetsu and DeKruyff 1997).
1.8.2.5 The role ofAPCs in THi and TH2 differentiation
Th cell differentiation is directed by signals in the local microenvironment during an¬
tigen presentation and activation. The expression of cytokines and co-stimulatory
molecules by APCs is determined by the dose, type and route of allergen exposure, as
well as other inherent and environmental factors (Kapsenberg and others 1998; Ris-
soan and others 1999; Bottomly 1999).
In mice, IL-12 and IFNy support maturation of type 1 dendritic cells (DC1) that in¬
duce THi responses, whilst PGE2 promotes DC2 maturation and Th2 responses
(Kapsenberg and others 1998). Elevated PGE2 levels due to increased phosphodi¬
esterase activity have been observed in PBMCs from atopic humans (Hanifin 1996)
and APCs from atopic individuals produce less EL-12 than those from healthy indi¬
viduals (De Becker and others 1998; Stumbles and others 1998; van Neerven and
others 1998).
The potency of allergen/TCR/MHCII ligation is also important. Low potency TCR
signals drive TH2 differentiation, whereas high potency signals favour THi (Maggi
1998; Grakoui and others 1999; Leitenberg and Bottomly 1999). Potency is deter¬
mined by affinity and density. It is thought that low density and/or affinity stimulate
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low cytokine levels permissive of IL-4 mediated TH2 differentiation. At higher densi¬
ties or affinity IL-12 production overcomes IL-4 inhibition and drives THi expansion
(Grakoui and others 1999), although very low affinity allergens are density independ¬
ent (Rocken and others 1992).
It is also likely that the proteolytic enzyme repertoire of APCs influences T-cell dif¬
ferentiation (Bufe 1998). Inhibitors of cathepsin B, a lysosomal protease involved in
antigen processing, switched T-cell differentiation from Th2 to Thi in a mouse model
of Leishmaniasis (Maekawa and others 1998).
Neuropeptides such as somatostatin, substance P and vasoactive intestinal polypep¬
tide can also influence allergen presentation, Th cell activation, cytokine secretion
and expression of adhesion molecules (Levite 1998). This may allow neuro¬
endocrine networks to fine tune immune responses.
1.8.3 The Thi/TH2 hypothesis in atopic dermatitis
1.8.3.1 TH2 cytokines in human atopic dermatitis
Numerous studies have associated human atopic dermatitis with TH2 polarisation.
Non-lesional skin and acute lesions exhibit increased transcription of mRNA for IL-4
and IL-13 compared to healthy skin (Leung 2000). Furthermore, successful immuno¬
therapy is associated with a switch from a TH2 dominant pattern to a THi dominant
pattern (Renz 1995; Smith and Sly 1998).
Several studies have isolated allergen specific Th2 clones from PBMCs and the skin
of atopic patients (van der Heijden and others 1991; Cooper 1994; Renz 1995; Neu¬
mann and others 1996; Ochi and others 1996; Poulsen and others 1996; Ferry and
others 1997; Koning and others 1997a; Koning and others 1997b; Maggi 1998).
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These clones over-express the Th2 cytokines EL-4 and IL-5 and under-express the Thi
cytokines EFNy and IL-2 compared to T-cell clones from healthy individuals. In con¬
trast, stimulation of PBMCs with non-allergenic antigens expands non-polarised or
Thi clones (Romagnani 1998).
In some studies, however, whilst TH2 cytokine production was still elevated, Thi cy¬
tokine expression was similar to that in healthy individuals (Till and others 1997;
Lonati and others 1999). In others, THi cytokine production was reduced with no ef¬
fect on Th2 cytokines (Poulsen and others 1996). These results probably reflect dif¬
ferences in experimental design, methodology and kinetics of THi and TH2 cytokine
production, as the net effect in each case was TH2 polarisation.
Several studies suggest that allergen specific Th2 polarisation is important in the
pathogenesis of atopic dermatitis. The frequency of Th2 clones isolated from the skin
usually exceeds that from PBMCs (Grewe and others 1998), suggesting there is either
selective recruitment of TH2 cells or local TH2 differentiation in the skin. Patch test¬
ing, furthermore, generates allergen specific TH2 clones within 24 hours (van der Hei-
jden and others 1991; van Reijsen and others 1992; Werfel and others 1996) and TH2
polarisation is most prominent in patients with high IgE levels (Ochi and others
1996; Rodriguez and others 1998; Sato and others 1998; Kimura and others 2000).
1.8.3.2 THi cytokines in human atopic dermatitis
Thi-type cytokines are also expressed in atopic patients. Whereas IL-4+ cells pre¬
dominate in acute lesions, IFNy+ cells dominate chronic lesions (Werfel and others
1996). Furthermore, IFNy levels correlate with the clinical severity and are reduced
after successful immunotherapy (Werfel and others 1996; Grewe and others 1998).
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Patch testing with house dust mite allergens demonstrated that IL-4+/IFNy" cells pre¬
dominate up to 24 hours and then decline. Peak levels of IL-4+/IFNy+ and IL-47IFNy+
cells were attained at 24 and 48 hours respectively and then maintained (Thepen and
others 1996; Grewe and others 1998; Junghans and others 1998). TNFa is also over
expressed in chronic lesional compared to healthy skin (Junghans and others 1998).
1.8.3.2 THi and TH2 cytokine expression in mouse models of atopic
dermatitis
Acute inflammation was associated with IL-4 and EL-5 in two mouse models of
atopic dermatitis induced by cutaneous application of ovalbumin. Chronic inflamma¬
tion and skin thickening, in contrast, was driven by EFNy (Spergel and others 1999;
Vestergaard and others 1999). IFNy knockout mice, furthermore, exhibit a marked
reduction in skin thickening (Leung 2000).
Other evidence suggests that Thi cytokines potentiate established patterns of Th2 in¬
flammation and vice versa. Administration of IL-4 worsened experimental allergic
encephalomyelitis (a THi model of multiple sclerosis) and supported proliferation of
activated Thi cells, whilst IFNy worsens Th2 induced bronchial hyper-reactivity
(Hansen and others 1999; Oriss and others 1999).
1.8.3.4 Sequential cytokine expression in human atopic dermatitis
These findings suggest a sequential pattern of TH cell activation and cytokine produc¬
tion. Naive TH cells differentiate into Th2 cells under the influence of allergen presen¬
tation by IgE+ APCs in the lymph nodes and possibly skin. Th2 cells initiate IgE pro¬
duction by B-cells, which further primes mast cells and APCs. On contact with aller-
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gen, IgE+ mast cells degranulate, triggering immediate and late phase inflammatory
reactions, which recruit eosinophils and mononuclear cells. Subsequent IL-12 and
IFNy production initiates differentiation of allergen specific (Werfel and others 1996)
or non-specific (Cooper 1994) Thi cells and chronic cell mediated inflammation
(Borish and Rosenwasser 1997; Grewe and others 1998), without affecting IgE pro¬
duction. Human TH2 cells are resistant to activation-induced apoptosis (Carbonari and
others 2000), which may favour the development of stable Th2 populations.
IL-12 expression precedes that of EFNy and coincides with eosinophil and macro¬
phage infiltration (Grewe and others 1998). These cells are recruited by IL-4 and IL-5
and may provide signals for the switch to THi mediated chronic inflammation (Grewe
and others 1998). Histamine also induces IL-18 expression, which promotes Thi dif¬
ferentiation and EFNy production in human PBMCs (Kohka and others 2000).
Thi-type cell recruitment could also be due to a variety of non-specific mechanisms.
Keratinocytes rapidly release TNFa, EFNy, IL-1 and granulocyte-monocyte colony
stimulating factor (GM-CSF) in response to trauma (Leung 2000). Levels of GM-
CSF are increased in atopic compared to healthy keratinocytes (Leung 2000), which
would enhance the survival of mononuclear cells and eosinophils.
1.8.3.5 Thi and TH2 cytokine expression in canine atopic dermatitis
Studies of the cytokine profile in canine atopic dermatitis have been limited. One
study (Olivry and others 1999b) demonstrated a THi-like pattern in 25% of healthy
skin samples, a TH2-like pattern in 25% of atopic samples, and a mixed cytokine pat¬
tern in the rest. Another detected IL-4 in atopic lesional skin (Sinke and others 1998)
and patch test sites (Rutten and others 2001). However, one study failed to detect IL-
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4 (Maeda and others 2002) and it remains to be proven that canine atopic dermatitis
is associated with THi/TH2 polarisation similar to that described in humans.
1.8.4 CD8+ cells in atopic dermatitis
IFNy rich (Tci) and IL-4 rich (Tc2) CD8+ subsets have also been identified in humans
(Kemeny 1998; Maggi 1998; Akdis and others 1999b; Kalish and Askenase 1999).
However, their role in atopic dermatitis is unclear. Tci cells could mediate chronic in¬
flammation and/or limit TH2 mediated IgE production (Renz 1995; Kemeny 1998). In
contrast, Tc2 cells could support TH2 differentiation and IgE production during
chronic inflammation (Kemeny 1998). CD8+ cells are MHCI restricted (Huston
1997), which implies that these cells are not allergen specific (Akdis and others
1999b), or if allergen specific (O'Brien and others 2000), that exogenous allergens
can also be presented with MHCI molecules (Kemeny 1998), blurring the distinction
between type I and type IV hypersensitivity.
1.9 Mast cells in atopic dermatitis
Mast cells are sentinels at interfaces with the external environment, such as the gas¬
trointestinal tract, respiratory tract and skin. They play a central role in normal tissue
metabolism and turnover, bacterial infections, sterile inflammation, parasite infesta¬
tions, wound healing and remodelling (Welle 1997; Galli and others 1999). They
trigger immediate phase innate responses, but also regulate long term inflammatory
reactions by linking the innate and acquired immune systems, vascular and neuro¬
endocrine systems (Church and Levi-Schaffer 1997; Welle 1997; Brody and Metcalfe
1998; Galli and others 1999).
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1.9.1 Mast cell development
CD34+ precursors of haemapoietic origin migrate out of the circulation and mature in
peripheral tissues under the influence of IL-3, EL-4, IL-9 and EL-10. However, liga¬
tion of the c-Kit receptor on mast cells by SCF, is crucial in mast cell recruitment,
development and survival (Church and Levi-Schaffer 1997; Welle 1997; Galli and
others 1999; Williams and Galli 2000). SCF or c-Kit gene knockout mice are mast
cell deficient and mutations in c-Kit and SCF may be important in mast cell tumours
(London and others 1996; Yongsheng and others 1999).
SCF is produced by fibroblasts, keratinocytes, endothelial cells, epithelial cells,
Langerhans' cells, mast cells and lymphocytes (Church and Levi-Schaffer 1997). In
humans, there are both soluble and membrane bound forms, which may be important
direct cell-cell interactions (de Paulis and others 1999).
c-Kit is expressed by mast cells, melanocytes, cord blood mononuclear cells, foetal
hepatocytes and bone marrow progenitor cells (Church and Levi-Schaffer 1997; de
Paulis and others 1999). Its presence on intraepithelial lymphocytes may be important
in SCF mediated regulation of gastro-intestinal tract lymphocytes (Wang and others
2000a). Inhibition of c-Kit expression by SCF, IL-4 and EL-10 may be a feedback
mechanism to limit mast cell activity (Mirmonsef and others 1999).
c-Kit and SCF are expressed by canine mast cells and stromal cells respectively
(London and others 1996; Kapsenberg and others 1998). Structural similarities sug¬
gest that regulation of mast cell development is similar to that in humans and rodents,
although studies of functional activity in dogs are limited.
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1.9.2 Cutaneous mast cell phenotypes in humans and dogs
Two types of mast cells have been identified in humans - tryptase (MCt) and tryp-
tase-chymase (MCtc) (Church and Levi-Schaffer 1997; Welle 1997). Mixed popula¬
tions occur in most tissues, although MCt are mostly mucosal and MCtc are pre¬
dominantly located in connective tissue (Church and Levi-Schaffer 1997). Whilst
both express FceRI, MCt are thought more important in allergic and parasitic reac¬
tions, whilst MCtc regulate angiogenesis and tissue repair (Church and Levi-Schaffer
1997; Welle 1997). IL-4 is expressed by both MCtc and MCt, but IL-5 and IL-6 are
exclusive to MCt (Welle 1997).
MCt and MGrc-like cells have also been described in canine skin (Caughey 1990;
Welle and others 1999). Selective degranulation of MCr-like cells in atopic skin
(Welle and others 1999) suggests that these cells play a specific role in canine atopic
dermatitis.
1.9.3 FceRI expression and IgE binding
FceRI is expressed by mast cells early in differentiation (Williams and Galli 2000)
and is dependent on IL.-4 (Chen and others 1999; Tachimoto and others 2000). IgE
binding to FceRI in the skin, ocular and pulmonary mucosa is stable, outlasting de¬
tectable serum levels of IgE in experimentally sensitised dogs (Zeman and others
2002). IgE also up regulates FceRI expression on human PBMCs (Yamaguchi and
others 1999) and canine mast cells (Brazfs and others 2002) in vitro.
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1.9.4 Mast cell degranulation
There is strong evidence of IgE dependent mast cell responses to specific allergens in
canine and human atopic skin (Leung 2000; Hill and Olivry 2001). Cross-linking of
surface IgE by allergens triggers the release of a variety of preformed and stored me¬
diators that initiate immediate phase inflammatory responses, inflammatory cell infil¬
trates and late phase reactions (Brody and Metcalfe 1998; Williams and Galli 2000)
(Figure 1.4). The immediate phase inflammatory response is largely mediated by the
release of preformed vasoactive mediators, such as histamine, kallikrein and heparin.
Late phase reactions are mediated by newly synthesised inflammatory eicosanoids,
chemokines and cytokines that recruit and activate eosinophils, mononuclear cells and
lymphocytes (Maggi 1998; Okudaira and Mori 1998; Leung 2000).
Immediate phase reactions are dependent on mast cell degranulation and are abro¬
gated in mast cell deficient mice. Late phase responses involving T-cells, macrophages
and eosinophils can be mast cell independent, but mast cell activation is necessary for
the co-ordinated expression of immediate and late phase inflammation (Williams and
Galli 2000). Late phase responses in atopic dogs can be induced by either specific al¬
lergen or anti-canine IgE (Olivry and others 2001), suggesting that they are also initi¬
ated by IgE mediated mast cell degranulation. Mast cell degranulation tends to be
abrupt and complete in acute inflammation, whereas chronic inflammation is associ¬

























































































1.9.5 The role of mast cells in atopic dermatitis
Allergen induced activation of mast cells is widely believed to initiate inflammatory
reactions in atopic skin (Welle 1997). However, it is unclear whether they actively
participate in the development of atopic dermatitis or whether they are simply acti¬
vated in an inappropriate context (Brody and Metcalfe 1998).
Increased mast cell density and histamine concentrations have been detected in hu¬
man (Irani and others 1989) and canine atopic dermatitis (Nimmo Wilkie and others
1990). In healthy dogs, mast cell numbers are enhanced in the pinnae, ventral and in-
terdigital skin (Auxilia and Hill 2000), which are all predilection sites for atopic
dermatitis. Another study demonstrated that mast cells numbers in the dorsal and
ventral body are significantly increased in atopic compared to healthy skin (Nimmo
Wilkie and others 1990). Furthermore, mast cells isolated from atopic canine skin
contained more histamine and were more reactive to concanavalin A than mast cells
from healthy skin (de Mora and others 1996). However, the role of histamine in
atopic dermatitis is uncertain. Antihistamines are only of limited benefit in humans
(Beltrani 1999b) and dogs (Scott and others 2001a), and other studies in humans
have failed to show an increase in plasma or cutaneous histamine (Beltrani 1999b).
In addition, in vitro sensitised mast cells from atopic and normal canine skin had a
similar response to anti-IgE, suggesting in vivo sensitisation was more important than
inherent activity (Brazfs and others 1998).
Bone marrow derived mast cells (BMMC) in mice express MHCI and II with
CD80/CD86 and can present allergens to activated CD4+ cells in vitro. The in vivo
significance of this, however, is unclear (Rossi and others 1998; Mekori and Met-
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calfe 1999). Murine BMMC can also induce T-cell independent B-cell activation and
IgE production in vitro (Rossi and others 1998).
Mast cells could also contribute to the EL-4 dominated cytokine milieu in atopic skin
(Church and Levi-Schaffer 1997; Sherman and others 1999). Human and rodent mast
cells constitutively store IL-4 (Brody and Metcalfe 1998; Sherman and others 1999).
Furthermore, the majority of IL-4+ cells in human (Kobayashi and others 2000) and
canine (Sinke and others 1998) atopic skin appear to be mast cells.
1.9.6 The role of SCF and c-Kit in atopic dermatitis
SCFIc-Kit interactions enhance in vitro survival, proliferation, granularity and cyto¬
kine expression of canine (Brazis and others 2000) and human (Welle 1997) mast
cells. In human atopic dermatitis there is a correlation between SCF expression, mast
cell numbers and dermal histamine content (Rossi and others 1998; Galli and others
1999). A recent study also found higher levels of SCF in atopic compared to healthy
canine skin (Hammerberg and others 2001).
SCF can potentiate IgE dependent degranulation in rat mast cells (Hill and others
1996) and both IgE dependent and independent mast cell activation in atopic humans
(Brody and Metcalfe 1998; Galli and others 1999; Kanbe and others 1999). SCF en¬
hanced FceRI mediated degranulation and cytokine synthesis in canine mast cells, but
was not capable of triggering mast cell activation by itself (Brazis and others 2000).
SCF/c-Kit interaction also up regulates integrin receptor expression in human mast
cells. This increases mast cell adherence to the dermal matrix (Brody and Metcalfe
1998), which is important in mast cell recruitment and activation during inflamma¬
tion (Williams and Galli 2000).
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1.10 Cutaneous micro-organisms and atopic dermatitis
1.10.1 Staphylococci and superantigens
Microbial colonisation and infection play a significant role in atopic dermatitis. Up to
80% of human cases are colonised with Staphylococcus aureus (Bunikowski and
others 1999). Colonisation of lesional skin can reach 90%, but numbers of staphylo¬
cocci are also elevated on non-lesional skin (Skov and Baadsgaard 2000). Further¬
more, colonisation correlates with the severity of clinical signs in human atopic der¬
matitis (Herz and others 1998). S. intermedius can be recovered from muco¬
cutaneous sites in many healthy dogs, but atopic dogs exhibit both higher counts and
greater adherence of staphylococci to keratinocytes (DeBoer and Marsella 2001).
Severe human atopic dermatitis is associated with superantigen producing strains
(Zollner and others 2000). 55-65% of S. aureus strains produce superantigens includ¬
ing staphylococcal enterotoxin (SE)A, SEB, SEC and toxic shock syndrome toxin
(TSST)-l (Bunikowski and others 1999; Zollner and others 2000). Toxic shock syn¬
drome survivors are predisposed to atopic dermatitis (Michie and Davis 1996; Torres
and others 1998) and SEB induces and exacerbates lesions (Skov and others 2000).
Superantigens activate T-cells bearing the appropriate Vf3 TCR chain by directly
linking MHCII and TCR molecules in a non-antigen specific manner (Huston 1997).
This activates a polyclonal pool of CD4+ and CD8+ cells 10-100 times larger than
that activated by specific allergens (Bunikowski and others 1999; Skov and Baads¬
gaard 2000). In humans there is an association between these V(3 elements and house
dust mite specific TCRs (Herz and others 1998).
Staphylococcal superantigens are strongly pro-inflammatory. They activate mast cells
and basophils in vitro (Bunikowski and others 1999), up regulate expression of EL-1,
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GM-CSF, EL-12 and TNFa from mononuclear cells and T-cells (Strickland and oth¬
ers 1999; Leung 2000). They also induce CD23 and MHCII expression on keratino-
cytes, monocytes, dendritic cells and T-cells (Herz and others 1998; Skov and others
2000). In humans and mice, staphylococcal superantigens induce CLA expression on
T-cells (Abbas and others 1996; Strickland and others 1999) and up regulate endo¬
thelial intercellular adhesion molecule (ICAM)-l and vascular cell adhesion mole¬
cule (VCAM)-l, enhancing leucocyte adhesion and migration (Herz and others
1998). TSST-1 induces MHCEI and co-stimulatory molecules on B-cells, augmenting
IgE production (Hofer and others 1999).
SEA, B, C, D, E and TSST-1 have been detected in up to 40% of S. intermedins
strains isolated from dogs (Adesiyun and Usman 1983; Hirooka and others 1988), but
a role in canine atopic dermatitis remains to be established.
Superantigens may also act as conventional allergens. Serum superantigen-specific
IgE is found in 50-80% of human atopic patients and has been linked to clinical se¬
verity in some studies (Herz and others 1998; Bunikowski and others 1999; Leung
2000; Breuer and others 2000), but not others (Zollner and others 2000). Anti-
staphylococcal IgE has been identified in canine atopic dermatitis complicated by re¬
current staphylococcal pyoderma (Morales and others 1994), but its significance is
unclear.
1.10.2 Malassezia and atopic dermatitis
A proportion of human patients with atopic dermatitis develop a hypersensitivity re¬
sponse to cutaneous Malassezia (Nordvall and Johansson 1990; Broberg and others
1992; Jensen-Jarolim and others 1992). High serum levels of Malassezia specific IgE
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found in patients with atopic dermatitis were not found in sera from either healthy pa¬
tients or non-atopic patients with Malassezia dermatoses (Wessels and others 1991).
Immediate and late phase skin reactivity, and lymphocyte proliferation in response to
Malassezia extracts were also demonstrated in atopic but not non-atopic patients
(Kieffer and others 1990; Nordvall and Johansson 1990; Rokugo and others 1990;
Wessels and others 1991; Tengvall Linder and others 1998). However, no evidence
for superantigen activity or polyclonal activation of T-cells has been found
(Johansson and others 1999).
Malassezia dermatitis and otitis are well recognised in canine dermatology and fre¬
quently complicate atopic dermatitis (Mason and Evans 1991; Plant and others 1992;
Bond and others 1996). Intradermal test reactivity to a crude Malassezia extract has
been observed in atopic, but not healthy, dogs (Morris and others 1998). Atopic dogs
with Malassezia dermatitis also developed larger wheals than those without. Recent
findings have also shown that atopic dogs have significantly higher serum levels of
Malassezia specific IgE than healthy dogs, which are not dependent on the presence
of elevated cutaneous numbers of Malassezia (Nuttall and Halliwell 2001; Chen and
others 2002). Together, these data suggest that a proportion of atopic dogs are sensi¬
tised to Malassezia antigens. Despite this, recent findings suggest that PBMCs iso¬
lated from atopic and healthy dogs have similar responses to Malassezia extracts in
vitro (Morris and others 2002).
1.11 Skin homing in atopic dermatitis
The route of allergen exposure may determine the clinical spectrum of atopic reac¬
tions - inhaled allergens trigger rhinitis and asthma, whilst percutaneous exposure
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triggers dermatitis (Friedmann 1999; Wistokat-Wulfing and others 1999). Human pa¬
tients often have respiratory symptoms as well as dermatitis, but atopy patch tests are
rarely positive in patients without dermatitis (Wistokat-Wulfing and others 1999).
In dogs, clustering of IgE+ Langerhans' cells, T-cells and eosinophils within the epi¬
dermis is consistent with epidermal antigen capture (Olivry and others 1997). Af¬
fected skin is predominantly ventral and sparsely haired, which could also facilitate
allergen uptake. Furthermore, atopy patch tests closely resemble late phase reactions
(Rutten and others 2001) and genetically predisposed dogs develop both specific IgE
and skin lesions following cutaneous application of allergens (McCall and others
2002). In contrast, nasal allergen exposure generally fails to exacerbate the disease
(Olivry and Hill 2001).
Why respiratory disease is uncommon in dogs is unclear. Their complex nasal turbi¬
nates may prevent allergen penetration to the lower airways or there may be differen¬
tial expression of adhesion molecules or inflammatory mediators in skin and mucosal
sites. The propensity to develop dermatitis may also depend on the level of CLA ex¬
pression and relative proportions of skin and respiratory mucosa homing T-cells. In
human atopic dermatitis allergen specific cells are CLA+, whereas they are predomi¬
nantly CLA" in atopics without dermatitis (Leung 2000). Cutaneous T-cell attracting
chemokine (CTACK or CCL27) and IL-16, both important in CLA+ T-cell recruit¬
ment, are up regulated in human atopic skin (Leung 2000).
IL-1, IL-4 and TNFa increase endothelial expression of E-selectin (the CLA ligand),
ICAM-1 and VCAM-1 in humans (Leung 1999). ICAM-1 is also expressed on kerati-
nocytes in human (Leung 2000) and canine (Olivry and others 1999a) atopic dermati¬
tis. P-selectin, another endothelial ligand for leucocyte adhesion molecules, is up
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regulated in canine inflammatory skin diseases, including atopic dermatitis (Chenier
andDore 1998).
Chemokines such as RANTES (regulated on activation normal T-cell expressed and
secreted), MCP-4 (macrophage chemotactic protein 4) and eotaxin are also up regu¬
lated in atopic skin. Furthermore, their receptors, including CCR3, are preferentially
expressed on TH2 cells and eosinophils (Leung 2000).
1.12 Tolerance in healthy individuals
It is unlikely that THi differentiation inhibits Th2 responses in healthy individuals, as
allergen induced cell-mediated inflammation is absent and THi cytokines participate
in chronic atopic dermatitis. Healthy individuals must, therefore, develop cutaneous
tolerance (Borish and Rosenwasser 1997). Experimental models of autoimmune and
allergic diseases suggest that the immunosuppressive cytokines IL-10 and TGFpl are
important in tolerance (Yeo and Lamb 1995; Muraille and Leo 1998; Massey and
others 2001).
1.12.1 T-regulatory cells
EL-10 and TGFpi induce differentiation of allergen specific T-regulatory cells (TR,
Treg, Th3 or T-suppressor cells) that down regulate inflammatory responses (Yeo and
Lamb 1995; Kapsenberg and others 1998; Mason and Powrie 1998; Schmidt-Weber
and others 1999; Hoyne and others 2000; Koulis and Robinson 2000). T-regulatory
cells could inhibit THi and TH2 activation by direct interaction of the notch-delta sig¬
nalling pathway (Hoyne and others 2000), which may be a mechanism for acquiring
tolerance to different allergens presented by the same APC ('linked suppression').
1.12.2 The role of TGFp
The TGF(3 family of cytokines are involved in cell growth and development, regulat¬
ing inflammation and tissue remodelling, and initiating early immune responses
(Ling and Robinson 2002). They are produced by a wide range of cells and have a va¬
riety of stimulatory and inhibitory effects on T-cell differentiation, activation, prolif¬
eration, apoptosis and APC activity depending on the cell types and their state of dif¬
ferentiation and activation (Cottrez and Groux 2001). TGFpl is particularly anti¬
inflammatory - knockout mice exhibit spontaneous and widespread inflammation that
is rapidly fatal (Sumiyoshi and others 2002). It is thought to suppress a variety of in¬
flammatory disorders and appears to be important in the regulation and resolution of
inflammatory reactions (Ling and Robinson 2002). TGF(3l inhibits B and T-cell acti¬
vation and inflammatory cytokine production (Lingnau and others 1998; Skok and
others 1999), mast cell development and degranulation (Mekori and Metcalfe 1999),
as well as eosinophil survival, expression of adhesion molecules and IgE production
(Sumiyoshi and others 2002). TGF(3l activity is dependent on TGF[3 receptor II ex¬
pression, which is induced by IL-10 (Cottrez and Groux 2001).
1.12.3 The role of IL-10
IL-10 is produced by a wide variety of cells including keratinocytes, TH cells, B-cells,
mast cells, eosinophils, monocytes and APCs in response to IL-2, EL-4, IL-6 and EL-
12 (Borish 1998; Muraille and Leo 1998; Sato and others 1998; Koulis and Robinson
2000). EL-10 inhibits production of pro-inflammatory cytokines and chemokines by
macrophages, neutrophils, eosinophils, mast cells, lymphocytes, keratinocytes and
endothelial cells, as well as immunoglobulin synthesis, MHCII and co-stimulatory
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molecule expression, antigen presentation, and chemotaxis (Borish 1998; Muraille
and Leo 1998; Asadullah and others 1999; Schmidt-Weber and others 1999; Skok
and others 1999; Koulis and Robinson 2000).
Decreased IL-10 expression is associated with inflammatory diseases. EL-10 deficient
mice develop severe skin, gut and airway inflammation (Borish 1998; Tournoy and
others 2000). There is also decreased IL-10 in skin and PBMCs from atopic com¬
pared to healthy children (Koning and others 1997b). Furthermore, it has been sug¬
gested that successful immunotherapy is associated with up regulation of EL-10 ex¬
pression (Smith and Sly 1998; Akdis and Blaser 1999).
EL-10 is a potent inhibitor of IL-12 (Muraille and Leo 1998; Asadullah and others
1999; Koulis and Robinson 2000) and could also potentiate Tm responses. Increased
levels of IL-10 have been found in human atopic skin, airways and PBMCs after al¬
lergen challenge (Laberge and others 1998; Sato and others 1998; Hanifin and Chan
1999; Koulis and Robinson 2000) and in a mouse model of atopic dermatitis
(Vestergaard and others 1999).
The kinetics of IL-10 expression may govern its balance of biological activities. In
atopic humans and a mouse model, EL-10 is constitutively expressed in healthy skin,
but only during the late phase response in atopic skin (Muraille and Leo 1998; Wang
and others 1999), probably in response to IL-12 and EFNy production. Late expres¬
sion of IL-10 in mice may contribute to atopic inflammation by supporting IgE and
IgG production by IL-4 stimulated B-cells, and mast cell differentiation and activity
(Sato and others 1998; Asadullah and others 1999; Tournoy and others 2000). In
parasitised humans, IL-10 is thought to both support parasite-directed TH2 responses
and suppress systemic allergic responses (van den Biggelaar and others 2001).
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1.13 The development of sensitisation versus tolerance
Sensitisation versus tolerance is probably determined by allergen exposure at critical
time points (Holt and others 1998). For instance, in high IgE responder beagles, sen¬
sitisation by seven days of age generates a persistent high IgE response, whereas
there is only a transient peak after sensitisation at 3-4 months (de Week and others
1997). Recent interest has focused on why allergen exposure leads to sensitisation in
atopic individuals and tolerance in healthy individuals.
1.13.1 TH2 polarisation in human infants
Virtually all human infants develop TH2 polarised responses to environmental aller¬
gens in utero (Holt 1995; Prescott and others 1998). Cord blood mononuclear cells
typically express high levels of IL-4, IL-5 and IL-10, and low levels of IFNy (Prescott
and others 1997), although Th2 differentiation is particularly marked in children with
atopic parents (Piccinni and others 1996; Prescott and others 1997). Inhibition of Thi
differentiation by IL-4, IL-10, PGE2 and progesterone might protect the foeto-
placental unit from cell mediated immune responses (Holt and Macaubas 1997; Pres¬
cott and others 1997). Tolerance is associated with post-natal maturation of THi-type
immunity (Prescott and others 1999). In contrast, TH2 responses persist in atopic chil¬
dren (Holt and others 1998; Prescott and others 1999), although only a proportion
develop clinical signs (Holt 1995).
1.13.2 The hygiene hypothesis in THi development
Lack of exposure to micro-organisms and their products (e.g. fungi, gut flora myco¬
bacteria, lipopolysaccharides, endotoxins, etc.) could delay post-natal development of
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Thi responses and APC maturation (Holt 1995; Holt and Macaubas 1997; Hopkin
1997; Romagnani and others 1997; Holt 1998; Lewis 2000). Bacterial CpG DNA
motifs are particularly potent inducers of THi responses (Parronchi and others 2000).
Decreased exposure to gram-negative endotoxin in house dust was also associated
with positive skin tests to environmental allergens and reduced numbers of CD4+
IFNy+ cells in human infants (Gereda and others 2000). Furthermore, exposure to
farm animals and consumption of more 'live' or 'natural' compared to processed
foods confers protection from atopy, although the effect was most marked for out¬
door allergens (Kilpelainen and others 2000; Riedler and others 2000). An inverse
correlation of atopic diseases and exposure to hepatitis A, Helicobacter pylori and
Toxoplasma gondii, but not airborne viruses, suggests that gut flora or gut-borne in¬
fections are particularly important in Thi development and tolerance (Matricardi and
others 2000). Similar studies have not been performed in dogs, although viral vac¬
cines were shown to enhance IgE production (Frick and Brooks 1983). Interestingly
though, many dogs in Western societies live in relatively sterile indoor environments,
are fed processed food and receive multiple vaccinations and antibiotic courses.
1.13.3 Pollution and TH2 polarisation
Pollution has also been associated with TH2 responses (Nel and others 1998). How¬
ever, atopic sensitisation is less common in the more polluted, but less affluent Baltic
states compared to Scandinavia (Erb 1999). Furthermore, atopic diseases in East Ger¬
many increased after reunification, despite decreased pollution (Erb 1999; Von
Ehrenstein and others 2000). Vehicle, particularly diesel, emissions, however, are
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greater in affluent societies. These have been associated with Th2 polarisation and
may be more important than overall pollution (Polosa 1999; Diaz-Sanchez 2000).
1.14 Aims and objectives of this project
1.14.1 Introduction
Compared to humans and mouse models, our understanding of canine atopic dermati¬
tis is relatively poor. Until recently, most publications have concentrated on the clini¬
cal signs, skin testing, serology and treatment options. The aim of these studies,
therefore, is to further characterise the immunological mechanisms that underlie ca¬
nine atopic dermatitis. Individual studies will look in detail at the clinical features of
atopic dermatitis, allergen specific IgE responses, major and minor Dennato-
phagoides allergens, PBMC responses and the expression of Thi, Th2 and immuno¬
suppressive cytokines in skin and PBMCs.
1.14.2 Clinical features of skin test positive and skin test negative canine
atopic dermatitis
Distinct allergic and non-allergic forms of human atopic dermatitis appear to exist
(Akdis and others 1999a). It is, however, unclear if there are two forms of canine
atopic dermatitis, as the clinical and histopathological features of allergen reactive
and non-reactive dogs have not been studied in detail. Clinical and histopathological
data from skin test positive and negative dogs with a clinical diagnosis of atopic
dermatitis were therefore compared.
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1.14.3 Major and minor Dermatophagoides allergens in canine atopic
dermatitis
It is clear that Dermatophagoides species house dust mites are the most important al¬
lergens in both human and canine atopic dermatitis (Cooper 1994; Sture and others
1995). Previous studies suggest that different Dermatophagoides allergens are recog¬
nised by dogs and humans (Noli and others 1996; McCall and others 2000), although
other findings refute this (Masuda and others 1999).
These studies all used different antisera, allergen extracts and protocols. The allergen
content of extracts varies depending on the source, mite life cycle and proportion of
mites to media (Le Mao and others 1998). Different antisera can vary in specificity
and sensitivity (Steward and Male 1998). Some protocols, furthermore, involve re¬
ducing agents that can denature IgE epitopes (Lombardero and others 1990).
Crude and purified Dermatophagoides extracts obtained from a number of sources
were, therefore, compared using reducing and non-reducing sodium dodecyl sul-
phate-polyacrylamide electrophoresis (SDS-PAGE) gels. Major and minor allergens
were identified and compared by probing reduced and non-reduced western blots of
each extract with monoclonal and polyclonal anti-canine IgE antibodies.
1.14.4 Isolation and culture of canine PBMCs
PBMC cultures are routinely used to investigate lymphocyte responses to specific al¬
lergens (Steward and Male 1998). A key aim of this study is to investigate PBMC re¬
sponses to Dermatophagoides allergens in atopic and healthy dogs. However, to do
so requires a robust technique for the isolation and culture of canine PBMCs. Density
centrifugation over 1.077 g/L ficoll has been used to isolate canine PBMCs in a
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number of studies (Kristensen and others 1982a; Martinez-Moreno and others 1995;
Corato and others 1997; Poitout and others 1997), but other papers report that this re¬
sults in granulocyte contamination (Letwin and Quimby 1987; Rivas and others
1995). These authors used carbonyl iron to eliminate the neutrophils, although this
could also deplete the mononuclear phagocytic cells necessary for antigen presenta¬
tion in PBMC cultures (Krakowka and Ringler 1985).
A preliminary study was therefore undertaken to compare PBMC yield and culture
after density centrifugation with and without incubation with carbonyl iron.
1.14.5 PBMC responses to Dermatophagoides allergens
Canine atopic dermatitis has traditionally been viewed as an IgE/mast cell mediated
disease. IgE production, however, is dependent on B-cell interaction with allergen
specific CD4+ Th cells (Lydyard and Grossi 1998). Infiltration of CD4+ and CD8+
lymphocytes into lesional skin, furthermore, is observed in both atopic dogs (Olivry
and others 1997) and humans (Leung 2000). Several studies in humans have demon¬
strated PBMC proliferation to crude Dermatophagoides extracts and purified aller¬
gens (Leung 2000). Despite this, investigation of PBMC responses in atopic dogs has
been limited. One unpublished report suggested that PBMCs from atopic dogs prolif¬
erated in response to stimulations with cmde D. pteronyssinus extract and major al¬
lergens identified on western blots, but not to Der p 1 or Der p 2 (Shaw 2000). Re¬
sponses to D. farinae, however, were not investigated.
The aim of this study was to determine if allergen specific T-cells are involved in the
pathogenesis of canine atopic dermatitis by investigating PBMC responses to D. fari¬
nae in dogs with atopic dermatitis that were skin test positive and skin test negative
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to D. farinae, and healthy dogs. The responses of PBMCs isolated from skin test
positive dogs to major and minor allergens purified from D. farinae, and crude ex¬
tracts of D. farinae, D. pteronyssinus and D. microceras were also compared.
1.14.6 Characterisation of cytokine expression in canine atopic dermatitis
Several studies have observed Th2 polarisation in the skin and PBMCs of atopic hu¬
mans (van der Heijden and others 1991; van Reijsen and others 1992; Neumann and
others 1996; Koning and others 1997a; Koning and others 1997b) and mouse models
of atopic dermatitis (Spergel and others 1999; Vestergaard and others 1999). Despite
this, Tai-type cytokines have been detected in chronic lesions (Werfel and others
1996) and dominate atopy patch test sites after 48 hours (Thepen and others 1996). In
contrast, tolerance in healthy individuals may be mediated by the immunosuppressive
cytokines IL-10 and TGF|3l (Muraille and Leo 1998; Hoyne and others 2000; Koulis
and Robinson 2000). Studies of cytokine expression in canine atopic dermatitis are
limited. EL-4 has been detected in lesional atopic skin by immunohistochemistry and
U-4 mRNA by RT-PCR (Sinke and others 1998). Another study using non-
quantitative RT-PCR demonstrated a TH2-type cytokine pattern in 25% of atopic and
a Tni-type pattern in 25% of healthy skin samples (Olivry and others 1999b).
Several authors suggest that up regulation of the SCFIc-Kit pathway enhances mast
cell development and cytokine expression in both human (Brody and Metcalfe 1998;
Galli and others 1999) and canine (Brazfs and others 2000) atopic dermatitis. In hu¬
man atopic dermatitis there is a correlation between SCF expression, mast cell num¬
bers and dermal histamine content (Rossi and others 1998; Galli and others 1999).
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We, therefore aimed to use semi-quantitative RT-PCR to compare the expression of
mRNA encoding the THi-type cytokines IFNy, TNFa, EL-2 and IL-12, the Tn2-type
cytokines IL-4 and EL-6, the immunosuppressive cytokines IL-10 and TGF(3l, as well
as SCF and c-Kit in atopic and healthy canine skin, as well as resting, mitogen and
specific allergen stimulated PBMCs isolated from atopic and healthy dogs.
1.15 Conclusions
The significance of these studies is threefold. Firstly, they should advance our under¬
standing of canine atopic dermatitis, a very common and distressing condition. Sec¬
ondly, canine atopic dermatitis could be a valuable, spontaneous model for studying
the human disease. Finally, establishing the immunological mechanisms underlying
tolerance will allow us to further develop canine atopic dermatitis as a powerful
model to explore new approaches to therapy in dogs and humans. Identifying the key
mediators will also allow us to utilise molecular techniques to investigate genetic
polymorphisms in between atopic and healthy dogs.
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2. Materials and methods
2.1 Atopic and healthy dogs - inclusion criteria and clinical findings
2.1.1 Source of dogs
Dogs with atopic dermatitis (n=45) were recruited from the dermatology clinic at the
University of Edinburgh Hospital for Small Animals, Easter Bush Veterinary Centre,
Easter Bush, Midlothian, EH25 9RG, UK. Control samples were taken from healthy
dogs, either belonging to staff and students (n=10), or presented for euthanasia at the
University of Edinburgh Hospital for Small Animals (n=16). Euthanasia was per¬
formed with intravenous sodium pentobarbitone (Euthetal®; Merial, Harlow, UK.).
All procedures were performed with Home Office approval (project licence no.
60:2336) and were subject to the Animals (Scientific Procedures) Act 1986. In¬
formed consent from the owners of all animals, except the euthanasia cases, was ob¬
tained prior to entry into the study (Figure 2.1 a and b). All animals, with the excep¬
tion of the euthanasia cases, were returned to the owners on completion of the proce¬
dure (Figure 2.2). Permission to take samples from the euthanasia cases was obtained
from each owner. All procedures on these animals were carried after effective eutha¬
nasia, as assessed by the lack of cardiac activity, respiration and central reflexes.
2.1.2 Inclusion criteria for the healthy control dogs
None of the healthy dogs had a history of pruritic skin disease or systemic conditions
likely to affect immune function. All the dogs were clinically ascertained to be free
of lesions at the time of sampling. No topical or systemic anti-inflammatory medica¬
tions were given for at least three weeks (eight weeks for injectable depot prepara¬
tions) prior to examination.
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Informed consent 1 - Atopic Dogs
Canine Allergy Study
1. 1 understand that in order to advance our understanding of allergic skin diseases in dogs, and to develop
new treatments, there is a need to determine how dogs respond to allergens (substances such as house dust
mites that lead to allergies),
2. This can be investigated by injecting allergens into the skin (an intradermal allergy test); by investigating
how cells in the blood respond to allergens (blood test); and by determining how cells in the skin respond to
allergies (skin biopsy).
3. I understand that the protocol involved in this study involves three tests: an intradermal allergy test, a
blood test and skin biopsies.
4. I understand that 1he intradermal allergy test involves mild sedation with xylazinc which is a widely used
drug in veterinary' practice. A low dose will be used and, apart from the possibility of vomiting, the
incidence of adverse reactions is exceedingly rare. A patch of hair (approximately 15cm x 25 cm) will be
shaved off, and 60-70 small intradermal injections given. I understand that no adverse reactions, apart from
possibly mild irritation for 1-2 days at one or more of the sites, are to be anticipated
5.1 understand that a blood sample will be obtained, but no adverse effects arc to be anticipated.
6.1 understand that a small volume of local anaesthetic will be injected under the skin at a number of sites
(up to 5). Small skin biopsies will be obtained with a punch and a single suture will be placed in the skin
afterwards. I understand that skin biopsies do not appear to cause adverse effects in dogs. Some mild
discomfort may be felt at the injection site of the local anaesthetic but this is very transient. The biopsy
procedure itself causes no discomfort. I understand that there are virtually no clinical problems associated
with taking skin biopsies in dogs. I also understand that if my dog removes its own sutures, the wounds will
normally heal without any problems and are not likely to require further treatment. However, if any
problems occur, I will contact the clinic at the Royal (Dick) School of Veterinary' Studies for advice.
7. I understand that the results of the intradermal allergy test and some of the biopsies will be used to make
a diagnosis of my dog's skin disease. I also understand that the blood sample and some of the biopsies will
be used for research purposes to further investigate allergic skin diseases in dogs. In view of the importance
of the study in helping dogs with skin disease, I consent to the above procedures.
8. 1 understand that my own dog may not benefit immediately from this research, but the results of the study
may benefit mine, or other dogs, in the future.
9. I understand that the protocol for this study has been approved by the Home Office.
Signed Date
PPL version 3.2 4/91 Paqfi 14
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Figure 2.1b - Informed consent form for healthy dogs
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Informed consent 2 - Normal dogs
Canine Allergy Study
1. I understand that in order to advance our understanding of allergic skin diseases in dogs, and to develop
new treatments, there is a need to determine how normal dogs respond to allergens (substances such as
house dust miles that lead to allergies).
2. As far as I am aware, my pet does not, and has not suffered from allergic skin disease.
3. 1 understand that the study protocol involves mild sedation with xylazine which is a widely used drug in
veterinary practice. A low dose will be used and, apart from the possibility of vomiting, the incidence of
adverse reactions is exceedingly rare.
4. I understand that a small area (approximately 4cm x 25 cm) of hair will be shaved off, and 12-15 small
intradermal injections given.
5. I understand that no adverse reactions, apart from possibly mild irritation for 1-2 days at one or more of
the sites, arc to be anticipated.
6. 1 understand that a blood sample will be obtained, but no adverse effects are to be anticipated.
7. In view of the importance of the study in helping dogs with skin disease, I consent to the above
procedures.
8. I understand that as my own dog is healthy, it will not benefit from the study unless it should later
develop allergies.
9. I understand that the protocol for this study has been approved by the Home Office.
Signed Date
PPL version 3.2 4/91 Page IS
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Figure 2.2 - Experimental animal release form
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DEPARTMENT of VITI RINARY CLINICAL STUDIES
RovaI (Dick) School of Veterinary Studies
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The afore-mentioned animal has been certified as fit for release to the owner.
Signed
Emma Keeble BVSc CertZooMed MRCVS
Named Veterinary Surgeon
Gidona Goodman BSc MScfVetmed) MSc MRCVS
Named Veterinary Surgeon
Ml At) I I* IH I'Ml I Ml VI ft..!...* H I W IUII.-..C MA VnMH IUI MRCVS
OitUCTOR or HOSWTAt A G lUiriw; IIVMAS I3VR MRCVS
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2.1.3 Inclusion criteria for the dogs with atopic dermatitis
A clinical diagnosis of atopic dermatitis was based on a history of chronic, perennial
pruritus that was responsive to glucocorticoids, but non or only partially responsive
to antimicrobial and antiparasitic treatment, and exclusion of other causes of pruritus
(Willemse 1986; Nuttall and others 1998; DeBoer and Hillier 2001).
Multiple coat brushings and skin scrapings were used to eliminate the possibility of
an ectoparasite infestation. All dogs were placed on a rigorous flea control pro¬
gramme for a minimum of six weeks using topical fipronil (Frontline®; Merial) or
selamectin (Stronghold®; Pfizer Animal Health, Sandwich, UK). Other trial antipara¬
sitic therapy with an appropriate product was employed where there was a high index
of suspicion, despite a lack of diagnostic clinical findings. Dogs that experienced
complete resolution of clinical signs after treatment were excluded.
All dogs underwent a six-week, home cooked or commercial diet trial to eliminate
food intolerance. Novel single carbohydrate and protein sources were selected on the
basis of previous dietary history. Provocative exposure to the normal diet was used to
confirm food intolerance in dogs that clinically improved on the trial diet. Dogs that
completely responded to the diet trial were excluded.
Staphylococcal pyoderma was managed with appropriate systemic antibiotics and
topical treatment with either 2.5% benzoyl peroxide (Paxcutol®; Virbac, Bury
St.Edmonds, UK) or 10% ethyl lactate (Etiderm®; Virbac). Malassezia dermatitis
was treated with a 2% miconazole/2% chlorhexidine shampoo (Malaseb®; Leo Ani¬
mal Health, Princes Risborough, UK). Otitis externa was treated with topical polyva¬
lent and/or systemic anti-microbial products according to the requirements of each
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case. Dogs that experienced a complete resolution of pruritus after antimicrobial
treatment were excluded.
No topical or systemic anti-inflammatory or antimicobial medication was given for at
least three weeks (eight weeks for injectable depot preparations) before examination.
2.1.4 Scoring of clinical lesions
Clinical signs of erythema, papules, scaling, seborrhoea, hyperpigmentation and
lichenification at multiple body sites were subjectively assessed by a single investi¬
gator (T.J. Nuttall) and scored from 0-5, with 0 defined as lesion free (Figure 2.3).
Erythema was defined as reddening of the skin that could be blanched by digital
pressure. Papules were defined as small, focal and erythematous raised lesions with¬
out gross evidence of crusting or pustule formation. The degree of scaling was based
on the amount of cornified debris accumulated on the hairs and skin surface. Sebor¬
rhoea in this study was used to denote excessive greasiness of the skin and coat.
Lichenification was defined as the degree of skin thickening and Assuring compared
to unaffected skin, ignoring pressure point calluses. Hyperpigmentation referred to
darkening of the skin compared to the colour of unaffected skin in each individual.
The presence or absence of pruritus at any body site was determined from the clinical
history taken from the owner by the clinician in charge of each case (P.B. Hill, A.W.
Carter, P. Forsythe, S. Colombo, R.E.W. Halliwell or K.L. Thoday; Dermatology
Service, University of Edinburgh Hospital for Small Animals). Because of the sub¬
jective nature of these data no attempt to assess the degree of pruritus was made.
The clinician in charge of each case also determined the presence or absence of
staphylococcal pyoderma and Malassezia dermatitis at each body site. The presence
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of pustules, crusted papules, epidermal collarettes and, where performed, typical
staphylococcal organisms on Diff-Quik® (Dade AG; Diidingen, Switzerland) stained
cytological preparations were used to diagnose staphylococcal pyoderma. The pres¬
ence of erythema, seborrhoea, lichenification and hyperpigmentation together with
microscopic observation of greater than five organisms per x400 field on Diff-Quik®
stained tape-strips or smears was used to diagnose clinically significant Malassezia
dermatitis and otitis. As multiple investigators assessed these data, the severity or
degree of infection was not recorded.
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Figure 2.3 - Clinical record sheet








































































2.1.5 Intradermal skin tests
All dogs with a clinical diagnosis of atopic dermatitis were intradermally tested with
56 allergens (Table 2.1) as follows. Dogs were sedated with 0.15mg/kg xylazine
(Virbaxyl®; Virbac) injected intramuscularly. Hair was clipped from the lateral flank
and 0.05ml of each allergen extract, O.lmg/ml histamine (positive control) and saline
with phenol diluent (negative control) were injected intradermally via a 25-gauge
needle. The degree of swelling, erythema and induration at each injection site were
subjectively assessed after 20 minutes. The saline and histamine wheals were arbi¬
trarily assigned scores of 0 and +4 respectively. The degree of erythema and swelling
at each test site was subjectively scored 0, +1, +2, +3 or +4 in comparison to the
negative and positive control sites. Reactions greater than or equal to +2 were con¬
sidered positive (Nuttall and others 1998).
The intradermal skin tests were performed and assessed according to these standard
criteria by the clinician in charge of each case (P.B. Hill, A.W. Carter, P. Forsythe, S.
Colombo, R.E.W. Halliwell or K.L. Thoday; Dermatology Service, University of Ed¬
inburgh Hospital for Small Animals). These criteria provide a robust differentiation
between positive and negative sites (T.J. Nuttall and K.L. Thoday; unpublished data)
but the use of multiple clinicians precluded any statistical analysis of the test sites.
Serum from dogs with negative skin tests was submitted to a commercial laboratory
for measurement of allergen specific IgE using recombinant canine FceRIa (Heska
Allercept® provided by Axiom Laboratories, Teignmouth, UK). Dogs with a negative
skin test but positive serology were excluded from the study.
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Table 2.1 - Intradermal test allergens
Greer - Greer laboratories, Lenoir, NC, USA; ARTU - Artuvetrin, Leyden, The
Netherlands; PNU - protein nitrogen units; NE - nitrogen equivalents.
Allergen extract Source Concentration
Dust and dust mites
Dermatophagoides farinae Greer 100pg/ml
Dermatophagoides pteronyssinus Greer lOOpg/ml
Tyrophagus putresceantiae ARTU 100 NE/ml
Acarus siro ARTU 100 NE/ml
Euroglyphus maynei ARTU 100 NE/ml
House dust Greer lOpg/ml
Epithelia
Cat epithelia Greer 500PNU/ml
Human epithelia ARTU 500PNU/ml
Mixed feathers Greer 500PNU/ml
Cotton linters Greer 250PNU/ml
Horse epithelia Greer 500PNU/ml




Mixed moths Greer 500PNU/ml
Mosquito Greer 500PNU/ml
American cockroach Greer 500PNU/ml
German cockroach Greer 500PNU/ml
Culicoides midge Greer 500PNU/ml
Tree pollens
Elder ARTU 1000 NE/ml
Box elder Greer lOOOPNU/ml
Elm ARTU 1000 NE/ml
American elm Greer lOOOPNU/ml
Alder ARTU 1000 NE/ml
Tag alder Greer lOOOPNU/ml
Ash ARTU 1000 NE/ml
White ash Greer lOOOPNU/ml
Beech ARTU 1000 NE/ml
American beech Greer lOOOPNU/ml
Birch ARTU 1000 NE/ml
White pine Greer lOOOPNU/ml
White oak Greer lOOOPNU/ml
Eastern sycamore Greer lOOOPNU/ml
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Allergen extract Source Concentration
Weed pollens
Red clover Greer lOOOPNU/ml
Lamb's quarter Greer lOOOPNU/ml
Chrysanthemum spp. Greer lOOOPNU/ml
Yellow dock Greer lOOOPNU/ml
Jerusalem oak Greer lOOOPNU/ml
Common mugwort Greer lOOOPNU/ml
Brassica spp. Greer lOOOPNU/ml
English plantain Greer lOOOPNU/ml
Grass pollens
Couch Greer lOOOPNU/ml
Red top Greer lOOOPNU/ml
Kentucky blue Greer lOOOPNU/ml
Meadow fescue Greer lOOOPNU/ml
Perennial rye Greer lOOOPNU/ml
Orchard Greer lOOOPNU/ml
Sweet vernal Greer lOOOPNU/ml
Timothy Greer lOOOPNU/ml






Oak smut Greer lOOOPNU/ml
Barley smut Greer lOOOPNU/ml
-71 -
2.2 Sample collection
2.2.1 Blood samples for serum collection
10-20 ml blood samples for serum were collected into plain glass tubes by jugular
venepuncture in live dogs or cardiac puncture immediately after euthanasia. The
tubes were kept at room temperature for 1-2 hours to allow clot retraction. The serum
was then separated by centrifugation at 2200g for five minutes and stored at -20°C.
2.2.2 Blood samples for PBMC isolation
20-40 ml blood samples for PBMC isolation were collected into 1.2% tri-sodium cit¬
rate in sterile 50ml polypropylene centrifuge tubes (Fisher Scientific, Loughborough,
UK) by jugular venepuncture in live animals or cardiac puncture immediately after
euthanasia. Samples were kept on ice and processed (Chapter 2.6) within two hours.
2.2.3 Tissue samples from dogs with atopic dermatitis
Skin samples were taken whilst the dogs were sedated for intradermal testing (Chap¬
ter 2.1.5) as follows. 0.5-1.0ml of 1% lignocaine (Xylocaine®; Astra-Zeneca, Kings
Langley, UK) was infiltrated into the subcutis under the biopsy sites, which were
marked with a circle in indelible pen. 2-4 biopsies were taken from each dog depend¬
ing on whether lesion skin was present. Biopsies were not taken from dogs where
permission was not given. Non-lesional skin biopsies, with no clinical evidence of
excoriation or inflammatory skin disease, were taken from the flank. Lesional skin
biopsies were taken from areas of erythema and macular-papular dermatitis on the
trunk or proximal limbs, with no evident excoriation, staphylococcal pyoderma or
Malassezia dermatitis (Chapter 2.1.4). The skin biopsies were taken with a six milli-
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metre biopsy punch (Stiefel Laboratories, High Wycombe, UK) and placed immedi¬
ately into RNA-later® (Ambion Inc.; Austin, TX, USA) to prevent degradation of
ribonucleic acid (RNA). Samples in RNA-later® were kept at 4°C for 24 hours, then
stored at -20°C. Duplicate biopsies from lesional and non-lesional sites were placed
in 4% formalin for histopathology (Chapter 2.8). The biopsy sites were closed with a
single interrupted polyglactin suture (Vicryl®; Ethicon Inc., Somerville, NJ, USA).
2.2.4 Control tissue samples from healthy dogs
Healthy dogs were sedated and skin biopsies were collected into RNAlater® as pre¬
viously described (Chapter 2.2.3). Skin biopsies were taken from the euthanasia
cases immediately after euthanasia. Popliteal lymph nodes and tonsils were also ex¬
cised from these dogs to act as positive control material for the amplification of gene
transcripts (Chapter 2.7). These tissues were divided into 5mm portions and stored
in RNAlater® as described (Chapter 2.2.3).
2.3 Dermatophagoides species house dust mite extracts
Freeze-dried Dermatophagoides species mite extracts were obtained from a number
of sources (Table 2.2). These were reconstituted in 1ml sterile phosphate buffered
saline (80mM Na2HP04, 20mM NaH2P04.2H20, lOOmM NaCl, pH 7.5) (PBS). The
protein content of each extract was determined using an enzymatic protein assay ac¬
cording to the manufacturer's instructions (BCA Protein Assay; Pierce Laboratories,
Rockford, IL, USA). Each extract was then diluted to lmg/ml in sterile PBS and
stored at -20°C.
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Table 2.2 - Source of the Dermatophagoides extracts
Greer - Commercially available from Greer Laboratories, Lenoir, NC, LISA.
ALK - Kindly provided by ALK-Abello, Hprsholm, Denmark.
AP - Kindly provided by Allergo-Pharma, Hamburg, Germany.
IG - Purified from used Dermatophagoides pteronyssinus culture media at the Im-
munobiology Group, MRC Centre for Inflammation Research, University of Edin¬
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2.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE)
2.4.1 Buffers and solutions
Resolving buffer 1M Tris-HCl pH8.8
Stacking buffer 0.5M Tris-HCl pH6.8
Tank buffer 25mM Tris-HCl pH8.3
0.2M glycine
1.0% Sodium dodecyl sulphate
Reducing loading buffer 0.125M tris/HCl pH6.8




Non-reducing loading buffer 0.125M tris/HCl pH6.8
4% Sodium dodecyl sulphate
20% glycerol
0.005% bromophenol blue






Resolving buffer (ml) 2.5
Stacking buffer (ml) 1.4 -
Acrylamide (ml) 0.72 3.35
Deionised water (ml) 2.95 3.05




Ammonium persulphate (pi) 100 100
Coomassie blue staining
Coomassie blue 0.1% Coomassie brilliant blue
25% methanol
5% acetic acid
Destain 1 25% methanol
7.5% acetic acid




Fixer 1 10% acetic acid
50% methanol
Fixer 2 7% acetic acid
5% methanol
Reducer 0.0005% dithiothreitol




The gel apparatus was assembled according to the manufacturer's instructions (Mini-
Protean II ; Biorad Laboratories Ltd.), using the 4% stacking and 10% resolving
gels. 10p.l (i.e. lOpg) of the Dermatophagoides species extracts were diluted 1:1 in
either the reducing or non-reducing loading buffer, heated at 95°C for five minutes
and added to the appropriate wells of the stacking gel. 5pl of the molecular weight
markers diluted 1:20 in the reducing loading buffer were similarly heated and added
to wells two and nine. Wells one and ten were not used, as these outer lanes distort
during electrophoresis (A.D. Pemberton, Department of Veterinary Clinical Studies,
University of Edinburgh, UK; personal communication). The gel apparatus was dis¬
mantled and the gels placed in the electrophoresis tank according to the manufac¬
turer's instructions (Mini-Protean II®), filling the inner compartment with the tank
buffer. Enough tank buffer was added to the outer compartment to cover the base of
each gel. Electrophoresis was carried out at 200V for 40 minutes, or until the leading
edge of the loading dye was within 2mm of the bottom of the gel.
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2.4.3 Staining and imaging
2.4.3.1 Coomassie blue
Gels were stained in 2.5% Coomassie Blue for ten minutes, then briefly immersed in
destain 1. The gels were then rinsed in destain 2 with frequent changes of solution
until the background was clear.
2.4.3.2 Silver staining
Completed gels were bathed in fixer 1 at room temperature for 15 minutes, rinsed
twice in fixer 2 for ten minutes and finally washed twice in deionised water for five
minutes. The fixed gels were then reduced at room temperature for 15 minutes and
washed three times in deionised water for five minutes. Reduced gels were bathed in
the silver solution for 20 minutes at room temperature, then briefly rinsed in deion¬
ised water before developing. Once fully developed, the reaction was stopped by
adding crystalline citric acid monohydrate to effect and rinsing in deionised water.
2.4.3.3 Imaging of stained gels
Coomassie blue or silver stained gels were transilluminated with white light and pho¬
tographed (The Imager; Appligene Oncor, Chester-le-Street, UK).
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2.5 Immunoblotting
2.5.1 Buffers and solutions
Skimmed milk 0% fat dried milk powder, J. Sainsbury
pic, Straiton, UK.
Tris-buffered saline (TBS) 20mM tris-HCl
0.5M NaCl
pH 7.5
Lower anode buffer 0.3M tris-HCl pH 10.4
20% methanol
Upper anode buffer 25mM tris-HCl pH 10.4
20% methanol
Cathode buffer 25mM tris-HCl pH 9.4
40mM 6-amino-n-hexonic acid
20% methanol
Blocking buffer 5% skimmed milk/TBS
Diluting buffer 1% skimmed milk/TBS
Washing buffer 0.05% tween 20/TBS
'Goat polyclonal anti-canine IgE (IgG) A40-125; Bethyl Laboratories, Mont¬
gomery, AL, USA.
'Mouse monoclonal anti-canine IgE
(IgGl)
D9#31116; Kindly provided by Dr. D.J.
Deboer, University of Wisconsin, Madi¬
son, WI, USA.
'Horseradish peroxidase conjugated
mouse monoclonal anti-goat IgG
GT-34; Sigma, Poole, UK
'Horseradish peroxidase conjugated bo¬
vine monoclonal anti-mouse IgGl
MCA1421; Serotec, Kidlington, UK
Horseradish peroxidase substrate Luminol (ECL; Amersham-Pharmacia
Biotech, Little Chalfont, UK)
'Bethyl Laboratories, Sigma, Serotec and Dr. D.J. DeBoer confirmed the specificity
of these reagents (data on file). In addition, they did not bind to western blots of puri¬
fied canine IgG (T.J. Nuttall and T.-A. Chen; unpublished observations). Preliminary
studies also confirmed that there was no non-specific binding to the membranes, al¬




200jj.l of the crude D. farinae, D. pteronyssinus and D. microceras extracts, and
1 OOja.1 of the purified group 1 and 2 extracts (i.e. 200pg and lOOpg respectively) were
diluted as before in reducing and non-reducing loading buffer (Chapter 2.4.2). SDS-
PAGE was performed as previously described (Chapter 2.4.2) using a single well to
resolve the proteins into bands across the width of the gel (Figure 2.4).






Jl resolve into bands
across the width of
the gel
Proteins from unstained gels were transferred to polyvinylidene difluoride (PVDF)
membranes (Immobilon-P; Millipore, Bedford, MA, USA). The PVDF membranes
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were pre-soaked in methanol for 15 seconds, then rinsed in tris buffered saline (TBS)
for two minutes prior to blotting. Two sheets of blotting paper (Whatman no.3;
Whatman International Ltd., Maidstone, UK) soaked in the lower anode buffer and a
single sheet soaked in the upper anode buffer were laid on the anode surface of the
western blot apparatus (Transblot SD®; Biorad Laboratories Ltd.). The PVDF mem¬
brane was placed on top of these sheets and the unstained gel placed over the mem¬
brane. Three sheets of blotting paper soaked in the cathode buffer were then placed
on top of the gel. The apparatus was assembled and run at 80mA (not greater than
25V) per gel according to the manufacturer's instructions (Figure 2.5). After blotting
the apparatus was dismantled and the gels stained with Coomassie blue (Chapter
2.4.3) to ensure protein transfer had occurred. The PVDF membranes were air-dried
and stored at 4°C.




I 3x filter papers soaked
[ in cathode buffer
<— Unstained gel
<4— PVDF membrane
■ 1x filter paper soaked
in upper anode buffer
" ■ ^ ^2x filter papers soaked
in lower anode buffer
+
Anode
Current 80mA (not greater than
25V) per gel for one hour
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2.5.2.2 Immunoblotting
The stored PVDF membranes were briefly immersed in methanol then rinsed in TBS
for two minutes. The molecular weight markers and a narrow strip to identify protein
bands were removed. The remaining portion of the PVDF membrane was incubated
with the blocking solution for one hour at room temperature, briefly rinsed in TBS,
then placed in an MN28 Miniblotter® (Immunectics, Cambridge, MA, USA), follow¬
ing the manufacturer's instructions. This device exposes narrow strips of the mem¬
brane to discrete channels that prevent cross contamination (Figure 2.6).









on top of foam pad
Individual channels in
top plate
a - Expanded cross section
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The appropriate channels were incubated for one hour at room temperature with 85pi
of appropriately diluted serum samples, then 85pl of either the mouse monoclonal or
the goat polyclonal anti-canine IgE in the dilution buffer. Blanks and control chan¬
nels with no serum or no anti-canine IgE were included in each assay. Channels were
washed with 10ml of the washing buffer after each step. The miniblotter was then
dismantled and the membranes incubated at room temperature for one hour with
20ml of the horseradish peroxidase conjugated bovine monoclonal anti-mouse IgG or
mouse monoclonal anti-goat IgG in dilution buffer. The membranes were then
washed three times for five minutes in the washing buffer and rinsed twice for five
minutes in TBS. The optimal serum and reagent dilutions were determined in the se¬
ries of experiments described in Chapter 4.
2.5.3 Staining and imaging
The molecular weight markers and the protein strip from each membrane were
briefly immersed in Coomassie blue stain (Chapter 2.4.3), then rinsed in destain 2
(Chapter 2.4.3) with frequent changes of solution until the backgrounds were clear.
The strips were then air-dried.
The protein surface of each probed membrane was covered with the luminol solution
for one minute. The luminol was then poured off and each blot placed protein side
down on the lightproof image plate of an IS440CF imaging system (Kodak; Roches¬
ter, NY, USA). Luminescence was recorded using Kodak ID software (NEN® Life
Science Products, Zaventem, Belgium).
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2.6 PBMC isolation and culture











1.007g/ml polysucrose/sodium diatrizoate solution
(Histopaque®-1077; Sigma)
Complete medium Dulbecco's modified Eagle's medium (Sigma)
10% foetal calf serum (FCS) (Serotec, Kidlington,
UK)
2mM L-glutamine (Life Technologies, Paisley, UK)
50pM 2-mercapto-ethanol (Life Technologies)
lOOIU/ml penicillin
100pg/ml streptomycin
0.25|ig/ml amphotericin B (lOOx antibiotic-
antimycotic solution; Sigma)
1% non-essential amino acids (Life Technologies)
Canine vaccine antigens Parvovirus (Parvo C®; Intervet UK Ltd., Milton
Keynes, UK)
Distempter virus, adenovirus 1 and 2, parvovirus
and parainfluenza virus (DHPPi®; Intervet UK Ltd.)
Leptospira (L®; Intervet UK Ltd.)
Bordetella bronchiseptica (Intrac®; Schering-
Plough Animal Health, Uxbridge, UK)




Lysis buffer Tri-reagent® (Sigma)
Tritiated thymidine l.OmCi/ml methyl-^H thymidine (CRK120; Amer-
sham-Pharmacia Biotech)
A single batch of FCS, tested for its ability to support cell culture (E.M. Thornton,
Department of Veterinary Clinical Studies, University of Edinburgh, UK; personal




The optimal conditions for isolation of canine PBMCs were established in the ex¬
periments described in Chapter 5. Blood samples from atopic and healthy dogs
(Chapter 2.2.2) were diluted 1:1 in citrated PBS. 20ml of each sample was carefully
layered over 20ml of the density centrifugation solution in sterile 50ml polypropyl¬
ene centrifuge tubes (Fisher Scientific). Each tube was then centrifuged at 440g for
20 minutes at 20°C. Cells were collected from the interface, placed in clean sterile
50ml polypropylene centrifuge tubes and washed with a lOx volume of chilled cit¬
rated PBS. The tubes were then centrifuged at 250g for ten minutes at 4°C and the
supernatant discarded. The cell pellet was re-suspended in 9ml of sterile distilled wa¬
ter for 30 seconds to lyse any remaining erythrocytes, before adding 1ml of lOx PBS.
The cell suspension was then washed in a 3x volume of chilled citrated PBS, centri¬
fuged at 200g for ten minutes at 4°C and the supernatant discarded. The cell pellet
was re-suspended in 5ml of the complete medium and kept on ice.
2.6.2.2 Cell viabilitv
j
10|il of the cell suspension in complete medium was diluted 1:1 with trypan blue
(Sigma). Viable cells were counted in a modified Neubauer haemacytometer. Cell
suspensions with less than 95% viability were discarded. The cell suspension was
then adjusted to lxlO6 viable cells/ml in complete medium and kept on ice. 100pl of
this suspension was centrifuged onto a glass slide at lOg for three minutes (Cyto-
spin3®; Shandon, Pittsburgh, PA, USA). Slides were air-dried and stained with Diff-
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Quik®. The cell population was assessed on morphological characteristics and the
numbers of lymphocytes, monocytes, neutrophils and eosinophils recorded.
2.6.2.3 PBMC culture for in vitro proliferation studies
The Dennatophagoides allergen extracts (Chapter 2.3), canine vaccine antigens and
mitogens were appropriately diluted in complete medium. lOOpl of each dilution was
added to the appropriate wells of a 96 well U-bottomed tissue culture plate (Nunclon
Microwell®; Fisher Scientific). Wells with lOOpl of complete medium were included
as negative controls. lOOpl of the lxlO6 cells/ml suspension (i.e. lxlO5 cells) was
added to each of these wells. Wells with 200pl of complete medium only were in¬
cluded as background. All wells were set up in triplicate. The appropriate dilutions
for all the reagents were established in the experiments described in Chapter 5.
Plates were cultured at 38°C in 5% CO2 for three to seven days. 0.5pCi tritiated thy¬
midine was added to each well for the final six hours of culture. The cells in each
well were then captured on a glass-fibre sheet (Microbeta® 1450-472; Wallac, Turku,
Finland) using a cell harvester (Harvester 96®; Tomtec, Orange, CA, USA). The
sheets were air-dried and sealed in counting bags with 4ml scintillant (Optiscint
HiSafe®; Wallac). The counting bags were placed in cassettes (1450-472; Wallac)
and loaded into a beta emission counter (Microbeta Plus® 1450; Wallac). The activity
of each well was recorded as counts per minute (cpm).
2.6.2.4 In vitro culture of PBMCs for RNA extraction
1.0ml of the Greer D. farinae extract at 50pg/ml in complete medium or concana-
valin A (ConA) at 0.5pg/ml in complete medium were added to the appropriate wells
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of a 24-well flat-bottomed tissue culture plate (Nunclon Multidish®; Fisher Scien¬
tific). These were the optimum concentrations established by experiments described
in Chapters 5 and 6. 1.0ml of the cell suspension in complete medium (i.e. lxlO6
cells) was added to each well. The plates were cultured at 38°C in 5% CO2 for either
one or five days before harvesting. At the end of this period, the plates were centri-
fuged at 170g for five minutes. The supernatant was carefully aspirated and 300pl of
the lysis buffer added to each well. The plates were then gently agitated at room
temperature for five minutes.
Freshly isolated PBMCs were harvested in a similar way. The cell suspension of
lxlO6 cells/ml in complete medium was centrifuged in a sterile 50ml polypropylene
centrifuge tube at 170g for five minutes and the supernatant aspirated. 300pl of the
lysis buffer/lxlO6 cells was added and the cells gently agitated at room temperature
for five minutes.
The lysed cell suspensions from cultured and freshly isolated PBMCs were collected
and stored in 1ml aliquots at -20°C.
2.7 Expression of cytokine gene transcripts
2.7.1 Buffers, solutions and reagents
Digoxigenin labelling kit 3' end labelling kit (Roche Molecular
Biochemicals, Lewes, UK)
Stop solution 0.2mg/ml glycogen
0.2mM EDTA
Lysis buffer Tri-reagent® (Sigma)
Hybridisation buffer Rapid-Hyb® (Amersham-Pharmacia Bio¬
tech)
RNase/DNase free water Promega Corp., Madison, WI, USA.
DNase I DNA-free® (Ambion Inc.)
Heparinase Heparinase I (Sigma)





5mM sodium acetate pH 5.2
ImMEDTA pH 8.0
glacial acetic acid to pH7.0
Northern loading buffer 50% glycerol
O.lmg/ml Bromophenol blue
RNA ladder 0.24 - 9.5kB RNA ladder (Life Tech¬
nologies)
Reverse transcription Reverse Transcriptase System (Promega
Corp.)
Deoxynucleotide triphosphates Mixed dUTP, dATP, dCTP, dGTP
(Promega Corp.)
Deoxyribonucleic polymerase Taq DNA polymerase (Roche Molecular
Biochemicals
Loading buffer 6x gel loading dye (Promega Corp.)
DNA ladder lOObp DNA ladder (Promega Corp.)
Denaturing solution 1.5M NaCl
0.5M NaOH






Hybridisation wash buffer 1 2x SSC
0.1% tween 20
Hybridisation wash buffer 2 lx SSC
0.1% tween 20




Blocking solution Blocking reagent (Roche Molecular Bio¬
chemicals)
Anti-digoxigenin antibody Alkaline phosphatase labelled anti-
digoxigenin antibody (Roche Molecular
Biochemicals)
Alkaline phosphatase substrate CDP-Star® (Roche Molecular Biochemi¬
cals)






2.7.2.1 Forward and reverse primers
Forward and reverse primers (Tables 2.4 and 2.5) were designed from published ca¬
nine mRNA sequences for glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
IL-2, IL-4, IL-6, IL-10, IL-12p35, IL-12p40, IFNy, SCF, c-Kit, TNFa and TGFpl
(Genbank®; National Centre for Biotechnology Information, URL
www.ncbi.nlm.nih.gov/). The optimum reaction conditions were determined in the
series of experiments described in Chapter 7.
Table 2.4 National Centre for Biotechnology Information accession numbers
for canine cytokine mRNA sequences
















































































































The primer sequences were designed using 01igo6® software (Molecular Biology
Insights, Cascade, CO, USA) to maximise priming efficiency and optimise annealing
temperature, whilst minimising hairpin formation and annealing to self or comple¬
mentary primers. The primer sequences were screened against known sequences to
eliminate any cross-reactive oligonucleotides (BLAST®; National Centre for Bio¬
technology Information; URL - www.ncbi.nlm.nih.gov/). The primers were gener¬
ated by Cruachem Ltd. (Glasgow, UK), diluted to 20pmol/ml in RNAse-free water
(Promega Corp., Madison, WI, USA) and stored at -20°C.
2.7.2.2 Digoxigenin labelling of internal sequence oligonucleotides
Internal sequence oligonucleotides (Table 2.5) were designed as previously described
(Chapter 2.7.2.1). lOOpmol of each oligonucleotide in 10pl deionised water was in¬
cubated with 4pl tailing buffer (1M potassium cacodylate, 0.125M tris-HCl, 1.25
mg/ml bovine serum albumin, pH 6.6), 4pl 25mM CoCl2, lfll ImM digoxigenin-
ddUTP solution and lpl (2.5IU) terminal transferase (3' end labelling kit; Roche
Molecular Biochemicals, Lewes, UK) for 15 minutes at 37°C. The reaction was
stopped on ice with 2p,l of the stop solution. The labelled oligonucleotides were di¬
luted in 10ml hybridisation buffer and stored at -20°C.
2.7.3 RNA extraction
2.7.3.1 Technique
The skin biopsy and positive control (lymph node and tonsil) samples stored in
RNA-later® were thawed, thinly sliced and placed in 2.0ml of the lysis buffer. The
samples were then homogenised on ice in 30-second cycles until fully dissociated
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(Ultra-turrax 125®; Janke and Kunkel IKA, Staufen, Germany). The PBMC suspen¬
sions stored in the lysis buffer were thawed and thoroughly mixed.
The homogenised samples were allowed to stand at room temperature for five min¬
utes before thoroughly mixing 1.0ml volumes with 0.2ml of chloroform. The solu¬
tions were allowed to stand at room temperature for a further five minutes, then cen-
trifuged at 9500g for 15 minutes. The upper layer was collected into fresh tubes and
precipitated with 0.5ml isopropanol at room temperature for 60 minutes. The tubes
were then centrifuged at 3500g for ten minutes and the supernatant discarded. The
RNA pellet was washed in 75% ethanol, centrifuged at 3500g for five minutes and
the supernatant again discarded. The washed RNA pellet was dissolved in 50-100pl
RNase/DNase free water at 60°C for ten minutes, then chilled on ice.
Genomic DNA was removed by incubating with 4IU DNAse I per 50p,l RNA solu¬
tion at 37°C for one hour. DNAse I was removed by incubating with the inactivating
reagent (DNA-free®; Ambion Inc.) at room temperature for two minutes, then centri-
fuging at 3500g for two minutes.
The RNA concentration was quantified by ultra-violet absorbance at 260nm (DU650
spectrophotometer; Beckman-Coulter, Fullerton, CA, USA), using the formula:
• RNA ng/pl = OD260nm x 40 x dilution factor
The extraction process was repeated for samples with an OD 260nm:OD 280nm ratio
of less than 1.5. Samples with a ratio persistently less than 1.5 were discarded. The
RNA solutions were stored at -70°C before use.
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2.7.3.2 Gel analysis of extracted RNA (Northern gel)
6jxl of each RNA solution was mixed with 12.5p,l deionised formamide (Sigma),
2.5pl lOx MOPS buffer and 4pl 37% formaldehyde. The RNA solutions were incu¬
bated at 65°C for ten minutes, then chilled on ice and 2.5pl Northern loading buffer
and 0.5pl of 5% ethidium bromide added to each solution. The RNA samples were
then loaded into the appropriate wells of a 0.4% agarose gel in MOPS buffer and
1.85% formaldehyde. 3|ll of the RNA markers were mixed with 2.5pl Northern load¬
ing buffer and 0.5pl of 5% ethidium bromide and then placed in lane 1 of each gel.
Each gel was run for 60 minutes at 70V according to the manufacturer's instructions
(Submarine Agarose Gel Unit HE33; Hoeffer Scientific Instruments UK Ltd., New-
castle-under-Lyme, UK). Completed gels were placed on the image plate of an
IS440CF imaging system and viewed under 590nm ultra-violet light. Fluorescence
was recorded using Kodak ID software.
2.7.4 Heparinase treatment
Heparin has been shown to inhibit polymerase chain reactions (Izraeli and others
1991). It was likely that heparin would be present in the skin biopsy and positive
control (lymph node and tonsil) samples. Any contamination was therefore elimi¬
nated by incubating 4p.g RNA with lpl (40IU) RNAse inhibitor, 4pl of tris-HCl (pH
7.5), lpl of 4mM CaCh and 4pl (4IU) heparinase I in a total volume of 40pl at 25°C
for two hours. The reaction was quenched on ice and the heparinased RNA stored at
-70°C before use. Heparinase treatment of RNA derived from PBMCs was not per¬
formed, as it was highly unlikely that these samples would be contaminated with
heparin (McAleese and others 1998).
-93-
2.7.5 Reverse transcription
lpg of the heparinased (skin, lymph node and tonsil) or non-heparinased (PBMCs)
RNA was incubated with 4pl of 5mM MgCl2, 2pl of lOmM tris-HCl (pH 8.8), 2pl of
ImM mixed deoxynucleotide triphosphates, 0.5pl (20IU) RNAse inhibitor, 0.5pil
(15IU) avian myeloma virus reverse transcriptase and lpl (0.5pg) oligo(dT)i5 primer
(Reverse Transcriptase System; Promega Corp.) in a total volume of 20pl at 42°C for
50 minutes. Incubating at 99°C for five minutes and quenching on ice stopped the
reaction. The complementary DNA (cDNA) solution was then diluted to 200pl in
RNAse free water, lpg of heparinased or non-heparinased RNA was diluted to 200pl
in RNase free water without reverse transcription as a negative control for each sam¬
ple. cDNA and negative control preparations were stored at -20°C.
2.7.6 Polymerase chain reactions
Polymerase chain reactions (PCRs) were carried out in 50pl volumes containing
lOmM Tris-HCl, 2.5IU Taq deoxyribonucleic acid polymerase (Roche Molecular
Biochemicals), 200pM deoxynucleotide triphosphates, 200nM of each primer pair
and 50ng cDNA. The optimum MgC^ concentration for each primer pair (Table 2.5)
was established in the series of experiments described in Chapter 7.
The reaction conditions consisted of initial denaturing at 94°C for two minutes, then
cycles of denaturing at 94°C for 30 seconds, annealing for 30 seconds and elongation
at 72°C for one minute, before a final elongation at 72°C for seven minutes (Ge-
neAmp® PCR System 2400; Perkin-Elmer, Cambridge, UK). The optimum number
of cycles and annealing temperatures for each primer pair (Table 2.5) were estab¬
lished in the experiments described in Chapter 7.
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GAPDH was used as the positive control housekeeping gene. PCRs using GAPDH
specific primers were performed for each cDNA and negative control preparation.
Samples with no GAPDH signal or a positive GAPDH signal from a negative control
preparation were discarded.
2.7.7 Analysis of polymerase chain reaction products (Southern gel)
lOp.1 of each PCR reaction was mixed with 2pl of the loading buffer and placed in
the appropriate well of a 1.2% agarose gel containing 0.5pg/ml ethidium bromide
(Sigma). 2.5pl of the DNA ladder was mixed with 0.5p.l of the loading buffer and
placed in lane 1 of each gel. Gels were run for 45 minutes at 100V according to the
manufacturer's instructions (Horizon IIK gel system; Life Technologies). Completed
gels were placed on the image plate of an 1S440CF imaging system and imaged un¬
der 590nm ultra-violet light. The net intensity of fluorescence (net band intensity) of
each PCR product was recorded using Kodak ID software.
2.7.8 Southern blotting and hybridisation
PCRs for each primer pair using positive control cDNA were performed as described
previously (Chapter 2.7.6). After imaging the PCR gels were incubated with the de¬
naturing solution at room temperature for 30 minutes. The gels were first rinsed in
the neutralising solution for 15 minutes at room temperature, and then for a further
30 minutes in fresh neutralising solution, before a final brief rinse in 6x SSC. The
PCR products were then transferred to nylon membranes (Hybond N ; Amersham
International, Amersham, UK) by overnight capillary transfer (Figure 2.7).
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After transfer, the hybridisation membranes were rinsed in 6x SSC, air-dried and
fixed under 294nm ultra-violet light. They were then incubated in the hybridisation
buffer at 40°C for 45 minutes, before incubating for a further three hours at 40°C
with the appropriate digoxigenin-labelled internal oligonucleotide sequence in 10ml
of the hybridisation buffer. The hybridised membranes were then washed twice for
five minutes in wash buffer 1, and twice for 15 minutes in wash buffer 2 at 40°C.
Figure 2.7 - Schematic representation of capillary transfer of PCR products
to nylon hybridisation membranes (Southern blot)
500g
Plastic support
2.5cm of dry paper
towels
5x dry filter papers





The hybridised and washed membranes were blocked at room temperature for 30
minutes, before incubating with the alkaline phosphatase labelled anti-digoxigenin
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antibody diluted 1:20,000 in the blocking solution for one hour at room temperature.
Membranes were rinsed with wash buffer 3 between each step.
The hybridised membranes were developed by covering the PCR product side with
CDP-Star® (Roche diagnostics) diluted 1/1000 in substrate buffer for five minutes.
The CDP-Star® solution was then poured off and the membrane placed PCR product
side down on the image plate of an IS440CF imaging system. Luminescence was re¬
corded using Kodak ID software.
2.8 Histopathology and morphometric analysis of the skin biopsy
specimens
2.8.1 Processing and staining of the histopathology sections
Skin biopsies of atopic and healthy skin in neutral buffered formalin were embedded
in paraffin wax. 4pm sections were oriented parallel to the lie of the hair follicles.
After fixing to glass slides, the sections were stained with haematoxylin and eosin
(University of Edinburgh Department of Veterinary Pathology, Veterinary Field Sta¬
tion, Easter Bush Veterinary Centre, Easter Bush, Midlothian, EF125 9RG, UK).
2.8.2 Imaging and analysis of the histopathology sections
The identity of each section was concealed during subsequent analysis and a single
investigator (T.J. Nuttall) assessed all the histopathology sections. Bright field im¬
ages were acquired with a Sony DXC-390P 3CCD colour video camera (Scion Cor¬
poration, Frederick, VI, U.S.A.) mounted on an Axiovert 100 inverted microscope.
The RGB video signal from the camera was digitised using Scion Image (Scion Cor¬
poration) installed in a G4 Macintosh computer (Apple Computer, Cupertino,
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U.S.A.) fitted with a CG-7 RGB 24-bit colour frame grabber (Scion Corporation).
Scion Image is a freeware image acquisition and analysis software package, based on
NIH Image (URL - www.scioncorp.com).
Five x400 images of the superficial interfollicular dermis were recorded for quantita¬
tive analysis. Prior evaluation showed that five images could be obtained from each
section by starting at the left edge (epidermis uppermost) and moving across by half
a graticule division per image (Figure 2.8). Fields that included adnexal structures
were discarded.
Images were prepared for analysis using Object-Image, a public domain software
package based on NIH Image developed by Norbert Vischer (The University of Am¬
sterdam, Amsterdam, The Netherlands) (URL - www.simon.bio.uva.nl/ object-
image.html). The image software was used to compute the proportion of each image
area that consisted of cell nuclei compared to cytoplasm and extracellular matrix.
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Figure 2.8 - Diagram illustrating image capture for morphometric analysis of
the superficial interfollicular dermis (healthy skin; haematoxylin and eosin
stain; x20 magnification)
2.8.3 Histological descriptions of healthy and atopic skin
After image capture (Chapter 2.8.2) each section was scanned in its entirety at xlOO
and x400 magnification and the histological findings subjectively described. These
assessments were then combined to give a summary of the histopathological features
of skin biopsies taken from the healthy and atopic dogs in this study. No analysis was
attempted because of the subjective nature of this data.
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2.9 Data analysis
Graphical and descriptive statistical analysis of raw data was performed using Prism®
(Graphpad Inc., San Diego, CA, USA; URL - www.graphpad.com) and Excel 2000®
(Microsoft Corp., Seattle, WA, USA; URL - www.microsoft.com). Excel 2000® was
also used to generate standard curves and regression equations. Photodraw 2000
(Microsoft Corp.) was used to illustrate the distribution of clinical lesions.
Data sets with overlapping standard error bars were assumed to show no significant
difference (H.Motulsky; The link between error bars and statistical significance,
Graphpad Insight, Autumn 2000, URL - www.graphpad.com/articles/errorbars.htm).
This minimised the number of tests performed and the chances of a type 1 statistical
error (i.e. false positive).
Proportional data were analysed in contingency tables using Fisher's exact tests with
significance set at p<0.05 (Instat®; Graphpad Inc.). Normality tests were used to as¬
sess whether or not continuous data followed a Gaussian distribution (Kolmogorov-
Smirnov test with the Dallal and Wilkinson approximation of the p value; Instat®),
with the caveat that testing of small samples is only approximate. T-tests with
Welch's correction for unequal variance and Mann-Whitney tests were used to com¬
pare two sets of Gaussian and non-Gaussian data respectively (Instat®). Paired T-
tests and Wilcoxon matched pairs tests were used to analyse matched sets of Gaus¬
sian and non-Gaussian data respectively (Instat®). One-way analyses of variance with
Tukey's post-tests and Kruskal-Wallis tests with Dunn's post-tests were used to
compare three or more Gaussian and non-Gaussian data sets respectively (Instat®).
The level of significance in each case was set at p<0.05.
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3. Clinical and histopathological findings in
dogs with atopic dermatitis
3.1 Introduction
Canine atopic dermatitis is essentially a clinical diagnosis. Despite this, the clinical
signs have not yet been characterised in detail. Previous studies must be interpreted
with caution, as the inclusion criteria often differ or are ill defined (Griffin and De-
Boer 2001). Commonly used inclusion criteria include positive intradermal tests or
serology. Some dogs, however, fulfil a clinical diagnosis of atopic dermatitis, yet
remain persistently negative with these tests.
Colonisation and infection with staphylococcal bacteria and Malassezia yeasts are
common in both human and canine atopic dermatitis (Rothe and Grant-Kels 1996;
Scott and others 2001a). Microbial colonisation correlates with the severity of clini¬
cal signs in human atopic dermatitis (Broberg and others 1992; Herz and others
1998). However, although Malassezia dermatitis and staphylococcal pyoderma are
widely regarded as exacerbating factors in canine atopic dermatitis (Mason 1995;
Scott and others 2001a), colonisation has not yet been correlated with the severity of
clinical signs.
The aim of this study, therefore, was to evaluate the clinical and histopathological
features of allergen reactive and non-reactive dogs with atopic dermatitis. The sig¬
nificance of microbial colonisation was assessed by comparing the clinical severity
of lesions in atopic skin with and without secondary infection.
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3.2 Materials and methods
3.2.1 Animals and samples
Forty-five dogs with atopic dermatitis and 26 healthy dogs were recruited according
to the inclusion criteria described in Chapter 2.1. The age, sex, breed and clinical
scores were recorded as described in Chapter 2.1.4 and Figure 2.3. All the dogs with
a clinical diagnosis of atopic dermatitis had an intradermal test with 56 allergens
(Table 2.1) performed as described in Chapter 2.1.5. Dogs with a clinical diagnosis
of atopic dermatitis were divided into those with least one positive intradermal test
reaction (n=34) and those with a negative intradermal test (n=l 1). Dogs with a nega¬
tive skin test also had negative serology (Chapter 2.1.5). Sera from atopic dogs that
had a positive intradermal test were not submitted for an ELISA for financial and
clinical reasons.
Skin biopsies of non-lesional (n=23) and lesional (n=13) skin were collected from
the atopic dogs as previously described (Chapter 2.2.3). Skin biopsies were similarly
collected from the healthy dogs (n=12). These were processed for histopathology as
described in Chapter 2.8.1. Morphometric analysis of dermal cell numbers was per¬
formed as described in Chapter 2.8.2.
3.2.2 Clinical scores
The mean lesion scores for erythema, papules, scaling, seborrhoea, lichenification
and hyperpigmentation (as defined in Chapter 2.1.4) at each body site examined were
calculated for the atopic dogs with positive and negative intradermal tests. The pres¬
ence or absence of pruritus as reported by the owner of each dog was also recorded
for each body site (Chapter 2.1.4).
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The presence or absence of staphylococcal pyoderma and Malassezia dermatitis at
each body as determined by the clinician in charge of each case was recorded as de¬
scribed in chapter 2.1.4. To enable valid comparisons only matched body sites that
underwent similar clinical and cytological investigation to identify microbial infec¬
tion were used for statistical analysis.
3.3.3 Data analysis
One-way analyses of variance with Tukey's post-tests were used to analyse the age
distribution and Fisher's exact tests used to analyse the number of males and females
in the three groups of dogs (Chapter 2.9).
The results at each body site were displayed graphically on a schematic dog outline
for the two groups of atopic dogs (Chapter 2.9). No analysis was performed with the
healthy dogs, since by definition these animals were lesion-free (Chapter 2.1.2). The
percentage of atopic dogs in each group that exhibited pruritus, staphylococcal
pyoderma or Malassezia dermatitis at each body site were also calculated and simi¬
larly displayed. Again, no analysis was performed with the healthy dogs.
The clinical lesion scores at each body site on the intradermal test positive and nega¬
tive dogs, and clinical lesion scores at each body site with and without staphylococ¬
cal pyoderma and Malassezia dermatitis were compared using Wilcoxon matched
pairs tests (Chapter 2.9).
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3.3 Results
3.3.1 Age, sex and breed of the healthy and atopic dogs
The dogs included in this study ranged from 12 - 96 months of age. There was no
significant difference in the mean age between healthy dogs, intradermal test positive
atopic dogs and intradermal test negative atopic dogs (p>0.05) (Table 3.1).









Mean 46.6 38.6 32.7
Standard deviation 20.8 19.5 17.2
Range 18-78 12-96 18-60
More males than females were present in each of the two groups of atopic dogs. In
contrast, female dogs outnumbered males in the healthy group (Table 3.2). There
were, however, no statistically significant differences between the numbers of male
and female dogs in each group (p>0.05).
Table 3.2 - The numbers of male and female dogs in the atopic and healthy
groups
Healthy dogs Intradermal test Intradermal test
(n=26) positive atopic negative atopic
dogs (n=34) dogs (n=11)
Male 12 21 6
Female 14 13 5
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Twenty-six breeds of dog were included in this study. The atopic dogs were drawn
from 22 different breeds, the most common of which were Labradors, followed by
German Shepherd Dogs, Jack Russell Terriers, West Highland White Terriers and
Dachshunds (Table 3.3). Fewer Labradors and more crossbreds and Springer Span¬
iels were seen in the healthy group, although the low number of individuals seen of
each breed did not permit statistical analysis. There were, however, no major differ¬
ences in the range of breeds seen in each group. The lack of robust epidemiological
data for the reference population precluded any analysis of relative risk.
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Labrador 7 3 10 2
German Shepherd Dog 1 3 4 4
Jack Russell Terrier 3 0 3 2
West Highland White Ter¬
rier 2 1 3 1
Dachshund 3 0 3 0
Boxer 2 0 2 1
Border Collie 1 1 2 1
Mastiff 1 1 2 0
Field Spaniel 1 1 2 0
Staffordshire Bull Terrier 0 2 0
English Bull Terrier 1 0 1 0
Springer Spaniel 1 0 1 4
Standard Poodle 1 0 1 0
Rottweiler 1 0 1 1
Cocker Spaniel 1 0 1 1
Bearded Collie 1 0 1 0
Border Terrier 1 0 1 0
Dalmatian 1 0 1 0
Shih Tzu 1 0 1 0
Golden Retriever 1 1 0
Shar Pei 1 0 1 0
Crossbred 1 0 1 4
Irish Wolfhound 0 0 0 2
St. Bernard 0 0 0 1
Greyhound 0 0 0 1
Doberman 0 0 0 1
3.3.2 Intradermal test results
The intradermal test results are summarised in Table 3.4. Positive reactions were de¬
fined as an erythematous wheal with a subjective score of +2 compared to the hista¬
mine positive control and saline negative control sites, which were given scores of
+4 and 0 respectively (Chapter 2.1.5). Reactions to house dust and forage mites were
most common. 75.6% of all the clinically atopic dogs and 100% of the intradermal
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test positive atopic dogs had at least one reaction to this group of allergens. 58.8% of
the intradermal test positive atopic dogs had reactions only to house dust and forage
mites; the remainder also exhibited reactions to other allergens (see below). The most
important species were Dermatophagoid.es farinae and D. pteronyssinus with posi¬
tive reactions seen in 94.1 and 82.4% of the intradermal test positive atopic dogs re¬
spectively, although reactions to Tyrophagus putresceantiae, Acarus siro and Euro-
glyphus maynei were also observed. Reactions to a crude house dust extract were
common, but none were seen in the absence of responses to other specific allergens.
Reactions to other allergens were much less common. Responses to epithelial and
insect allergens were seen in 17.6% and 25.6% of the intradermal test positive dogs
respectively. Positive reactions to pollens were less common still, although responses
to weed pollens, seen in 23.5% of the intradermal test positive dogs, were more
common than reactions to either tree or grass pollens (8.8%). Reactions to one or
more mould allergens made up 14.7% of positive intradermal tests.
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Table 3.4 - Skin test reactions in dogs with atopic dermatitis
All dogs with a clinical diagnosis of atopic dermatitis were skin tested
with 56 allergen extracts. The number of positive reactions for each ex¬
tract are expressed as percentage of all atopic dogs tested (n=45) and all
skin test positive dogs (n=34)
% of all skin test
% of all atopic positive atopic
Allergen extract dogs (n=45) dogs (n=34)
Dust and dust mites 75.6 100.0
Dermatophagoidesfarinae 71.1 94.1
Dermatophagoides pteronyssinus 62.2 82.4
Tyrophagus putresceantiae 42.2 55.9
Acarus siro 37.8 50.0
Euroglyphus maynei 26.7 35.3
House dust 71.1 94.1
Epithelia 13.3 17.6
Cat epithelia 8.9 11.8
Human epithelia 6.7 8.8
Mixed feathers 2.2 2.9
Cotton linters 2.2 2.9
Horse epithelia 0.0 0.0




Mixed moths 6.7 8.8
Mosquito 6.7 8.8
American cockroach 2.2 2.9
German cockroach 2.2 2.9
Culicoides midge 0.0 0.0
Tree pollens 6.7 8.8
Elder 4.4 5.8
Tag alder 4.4 5.8
Elm 4.4 5.8
Box elder 2.2 2.9
Alder 2.2 2.9
Ash 2.2 2.9
American beech 2.2 2.9
White oak 2.2 2.9
Birch 2.2 2.9
Eastern sycamore 2.2 2.9
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Table 3.4 continued - Skin test reactions in dogs with atopic der¬
matitis
% of all skin test
% of all atopic positive atopic
Allergen extract dogs (n=45) dogs (n=34)
White pine 2.2 2.9
White ash 0.0 0.0
Beech 0.0 0.0
American elm 0.0 0.0
Weed pollens 17.8 23.5
Red clover 13.3 17.6
Lamb's quarter 6.7 8.8
Chrysanthemum spp. 6.7 8.8
Yellow dock 4.4 5.8
Jerusalem oak 4.4 5.8
Common mugwort 4.4 5.8
Brassica spp. 2.2 2.9
English plantain 0.0 0.0
Grass pollens 6.7 8.8
Couch 6.7 8.8
Red top 4.4 5.8
Kentucky blue 4.4 5.8
Meadow fescue 4.4 5.8
Perennial rye 2.2 2.9
Orchard 2.2 2.9
Sweet vernal 2.2 2.9
Timothy 2.2 2.9




Oat smut 4.4 5.8
Altenaria 2.2 2.9
Penicillium 2.2 2.9
Barley smut 2.2 2.9
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3.3.3 Clinical findings in canine atopic dermatitis
3.3.3.1 Pruritus
The percentages of intradermal test positive and negative atopic dogs that exhibited
pruritus at each body site are summarised in Tables 3.5 a and b respectively. Pruritus
was observed in most body regions apart from the dorsal neck and, in intradermal
test negative dogs, the dorsal body. However, it most frequently affected the feet,
ears, muzzle and ventral body in both groups of dogs (Figure 3.1 a and b). There
were no significant differences in the proportion of intradermal test positive and
negative atopic dogs that exhibited pruritus at any body site (p>0.05).
Table 3.5a - Percentage of skin test positive atopic dogs with pruritus,
Malassezia overgrowth or pyoderma at each body site (n=34)
Body sites Pruritus Malassezia Pyoderma
Muzzle 68 2 0
Head 24 2 3
Left ear 91 35 9
Right ear 91 35 9
Dorsal neck 0 0 0
Ventral neck 15 9 0
Dorsal body 3 0 3
Left axilla 32 15 12
Right axilla 32 15 12
Left flank 18 0 0
Right flank 18 0 0
Ventral body 59 15 32
Left groin 59 15 41
Right groin 59 15 41
Perineum 15 0 3
Tailhead 3 0 0
Leftfore:
Upper limb 6 3 3
Distal limb 3 3 0
Metacarpals 24 3 0
Dorsal foot 94 26 3
Ventral foot 94 26 6
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Table 3.5a continued - Percentage of skin test positive atopic dogs
with pruritus, Malassezia overgrowth or pyoderma at each body site (n=34)
Body sites Pruritus Malassezia Pyoderma
Right Fore:
Upper limb 6 3 3
Distal limb 3 3 0
Metacarpals 24 3 0
Dorsal foot 94 26 3
Ventral foot 94 26 6
Left hind:
Upper limb 6 3 6
Distal limb 3 3 0
Metatarsals 24 3 0
Dorsal foot 94 26 3
Ventral foot 94 26 6
Right hind:
Upper limb 6 3 6
Distal limb 3 3 0
Metatarsals 24 3 0
Dorsal foot 94 26 3
Ventral foot 94 26 6
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Table 3.5b - Percentage of skin test negative atopic dogs with pruritus,
Malassezia overgrowth or pyoderma at each body site (n=11)
Body sites Pruritus Malassezia Pyoderma
Muzzle 73 0 0
Head 9 0 0
Left ear 91 9 0
Right ear 91 9 0
Dorsal neck 0 0 0
Ventral neck 9 0 9
Dorsal body 0 0 0
Left axilla 36 18 18
Right axilla 36 18 18
Left flank 18 0 9
Right flank 18 0 9
Ventral body 64 18 18
Left groin 55 27 18
Right groin 55 27 18
Perineum 0 0 0
Tailhead 0 0 0
Left fore:
Upper limb 9 0 9
Distal limb 9 0 0
Metacarpals 36 9 0
Dorsal foot 100 27 0
Ventral foot 91 27 0
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Table 3.5b continued - Percentage of skin test negative atopic dogs with pruri¬
tus, Malassezia overgrowth or pyoderma at each body site (n=11)
Body sites Pruritus Malassezia Pyoderma
Right Fore: 0 0 0
Upper limb 9 0 9
Distal limb 9 0 0
Metacarpals 36 9 0
Dorsal foot 100 27 0
Ventral foot 91 27 0
Left hind:
Upper limb 9 0 9
Distal limb 9 0 0
Metatarsals 36 9 0
Dorsal foot 100 27 0
Ventral foot 91 27 0
Right hind:
Upper limb 9 0 9
Distal limb 9 0 0
Metatarsals 36 9 0
Dorsal foot 100 27 0
Ventral foot 91 27 0
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Figure3.1-Distributionofpr ritusind gswi hatopicerma ti a-IDTpositivedogs(n=34)
b-IDTnegativedo s(n=11)
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3.3.3.2 Erythema, papules, seborrhoea, lichenification and
hyperpigmentation
The mean clinical lesion scores for erythema, papules, scaling, seborrhoea, lichenifi¬
cation and hyperpigmentation at each body site in the intradermal test positive and
negative atopic dogs are summarised in Tables 3.6a and b respectively.
Erythema was the most prominent clinical sign in both intradermal test positive (Fig¬
ure 3.2a) and negative (Figure 3.2b) atopic dogs. It was most intense on the ears,
feet, metacarpals, metatarsals, axillae, groin, ventral body and muzzle. There was
also occasional erythema of the head, trunk and limbs, but with a mean score of less
than 1.0 in each case.
Papules, scaling, seborrhoea, lichenification and hyperpigmentation were all much
less common than erythema in both intradermal test positive and negative dogs. Pap¬
ules (Figure 3.3 a and b) were mostly found on the ventral body and less commonly
on the limbs and head. Scaling (Figures 3.4 a and b) was an uncommon finding in
both groups, but, where seen, was confined to the trunk, head and lower limbs. Seb¬
orrhoea was generalised in the intradermal test positive dogs (Figure 3.5a), but
largely truncal in intradermal test negative dogs (Figure 3.5b). In both groups, how¬
ever, the mean clinical score at each body site was less than 1.0. There was slight
lichenification of the ventral body and limbs of both groups of dogs, and the head
and ears in the intradermal test positive dogs (Figure 3.6 a and b respectively). There
was mild hyperpigmentation of the feet, head, ears and ventral body in intradermal
test positive dogs (Figure 3.7a). In contrast, hyperpigmentation was more prominent
in the groin of the intradermal test negative dogs and absent from the head and ears
(Figure 3.7b).
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There were no significant differences in the clinical scores for any of these lesions
between matched body sites on the intradermal test positive and intradermal test
negative atopic dogs (p>0.05).
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3.3.3.3 Malassezia dermatitis and staphylococcal pyoderma
The proportions of intradermal test positive and intradermal test negative atopic dogs
with clinically significant Malassezia or staphylococcal pyoderma at each body site
are summarised in Table 3.5 a and b respectively. There was no assessment of the
Malassezia numbers present in the healthy dogs, although it is likely that the major¬
ity of these dogs will have had small commensal populations (Nuttall and Halliwell
2001).
Clinically and cytologically significant Malassezia dermatitis was largely restricted
to the feet, metacarpals and metatarsals, groin, ventral body and ears (Figure 3.8a and
b). However, in the intradermal test positive dogs, Malassezia dermatitis was occa¬
sionally observed on the limbs and head.
Staphylococcal pyoderma was most frequently seen on the ventral abdomen and
groin in both groups of atopic dogs (Figure 3.9a and b). Pyoderma was also infre¬
quently found on the head and ears, back, flanks, upper limbs and feet.
There were no significant differences between the proportion of intradermal test
negative and intradermal test positive atopic dogs that exhibited staphylococcal
pyoderma ox Malassezia dermatitis at any body site (p>0.05).
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3.3.3.4 Clinical significance of staphylococcal pyoderma and
Malassezia dermatitis
As no significant differences were found in the distribution and frequency of clinical
signs and microbial colonisation between the intradermal test positive and intrader¬
mal test negative atopic dogs, these data were combined for subsequent analysis.
There was a significant increase in mean clinical lesion scores for erythema, scaling,
papules, lichenification and hyperpigmentation at body sites with staphylococcal
pyoderma compared to matched body sites without staphylococcal pyoderma (Figure
3.10). Lesion scores for seborrhoea at sites with pyoderma were also raised, but in
this case there was no significant difference between the two groups.
Mean clinical lesion scores for erythema, papules, seborrhoea and lichenification
were also significantly raised at body sites with clinical evidence of Malassezia der¬
matitis compared to matched body sites without Malassezia dermatitis (Figure 3.11).
Mean lesion scores for scaling and pigmentation were also raised, although not sig¬
nificantly.
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Figure 3.10 - Comparison of clinical scores at body sites with and without
staphylococcal pyoderma
# - Body sites without clinical and cytological evidence of staphylococcal
pyoderma; # - body sites with clinical and cytological evidence of staphylococcal























Figure 3.11 - Comparison of clinical scores at body sites with and without
Malassezia dermatitis
0 - Body sites without clinical and cytological evidence of Malassezia dermatitis;
# - body sites with clinical and cytological evidence of Malassezia dermatitis;


















































3.3.4 Histopathology of healthy, non-lesional atopic and lesional atopic skin
3.3.4.1 Healthy skin
There were few histopathological findings of note in the biopsies of healthy skin
(Figure 12a). There was usually a thin basket-weave stratum corneum overlying an
epidermis that was typically 2-3 cells deep. Hair follicles, sebaceous glands, arrector
pili muscles, sweat glands and blood vessels were of normal appearance and abun¬
dance. The dermis was otherwise occupied by a loose array of fibres with a sparse
infiltrate of fibrocytes, mast cells and mononuclear cells.
3.3.4.2 Non-lesional atopic skin
There were mild differences between non-lesional atopic and healthy skin. There was
occasional mild basket weave orthokeratotic hyperkeratosis overlying a mildly acan-
thotic epidermis. Where present, acanthosis and hyperkeratosis was more pro¬
nounced in the follicular infundibula. Occasional lymphocyte exocytosis throughout
the epidermis was observed in a few samples. Dermal structures were unremarkable,
although a mild superficial, perivascular mononuclear cell infiltrate was present in
most sections. Mast cells were also frequently seen, but neutrophils and eosinophils
were rare (Figure 12b).
3.3.4.3 Lesional atopic skin
Lesional atopic skin (Figure 12c) was characterised by moderate to severe, basket
weave to lamellar orthokeratotic hyperkeratosis, although no microorganisms were
observed. There was also moderate to severe acanthosis with focal spongiosis. There
was pronounced acanthosis and hyperkeratosis of the follicular infundibula, which
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occasionally plugged the follicular ostia. Pseudo-rete peg formation was seen in a
few sections. Lymphocyte exocytosis was frequently observed, occasionally forming
clusters within the epidermis. Increased amounts of sebaceous tissue compared to
healthy skin were noted in a few sections, but otherwise the dermal structures ap¬
peared largely normal. There was, however, a moderate to marked cellular infiltrate
in all the sections. These were largely superficial, ranging from perivascular to inter¬
stitial. The cellular infiltrate largely consisted of mononuclear cells and mast cells,
but moderate to large numbers of eosinophils and neutrophils were present in several
sections. Focal areas of subepidermal dermal fibrosis were occasionally observed.
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Figure 12 - Representative histopathological sections of healthy, non-lesional
atopic and lesional atopic skin (haematoxylin and eosin stain; x200 magnifi¬
cation)
a - Healthy skin
b - Non-lesional atopic skin
- 139 -
c - Lesional atopic skin
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3.3.4.4 Morphometric analysis of dermal cell numbers
No histopathological or morphometric differences were noted between non-Iesional
or lesional atopic skin from intradermal test positive and intradermal test negative
atopic dogs. Data from the two groups were, therefore, combined for subsequent
analysis. Morphometric analysis revealed that there were significantly greater num¬
bers of cells present in the dermis of lesional atopic skin than in either non-lesional
or healthy skin (p<0.05). There were more cells present in the dermis of non-lesional
atopic compared to healthy skin, but the differences between these two groups were
not statistically significant (Figure 3.13).
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Figure 3.13 - Morphometric analysis of dermal cell numbers in healthy, non-
lesional atopic and lesional atopic skin
■- Healthy skin sections (n=12); - Non-lesional atopic skin sections (n=23);




These results characterise in detail the clinical and histopathological findings in the
atopic and healthy dogs used in this series of studies. The aim was to ensure that
comparisons made between the three groups of dogs and conclusions drawn in later
experiments were valid. However, the findings also shed some light on the patho¬
genesis of canine atopic dermatitis.
3.4.1 The clinical signs of canine atopic dermatitis
The most prominent clinical signs in this study were pruritus and erythema. The
other clinical signs, papules, scaling, seborrhoea, lichenification and hyperpigmenta-
tion, were much less frequent. These findings support the textbook adage that 'atopic
dermatitis is an itch that rashes rather than a rash that itches' (Mason 1995; Scott and
others 2001a). A recent review also concluded that the primary lesions largely con¬
sist of erythema (Griffin and DeBoer 2001).
Pruritus is also a hallmark of human atopic dermatitis (Rothe and Grant-Kels 1996).
It is triggered by many mediators including histamine, serotonin, trypsin, chymase,
bradykinin, substance P and vasoactive intestinal peptide (Koblenzer 1999). Pruritus
is deeply unpleasant and patients will often self-traumatise to the point where it is
replaced with pain (Koblenzer 1999). Human atopic patients may also have erythema
or a mild papular eruption, but other lesions are usually secondary to self-trauma and
microbial infection (Beltrani 1999a).
The distribution of clinical signs was similar to that widely accepted as compatible
with canine atopic dermatitis (Willemse 1986; Mason 1995; Prelaud and others 1998;
Griffin and DeBoer 2001; Scott and others 2001a). The most commonly affected
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sites, the muzzle, ears, interdigital skin, palmar metacarpals, plantar metatarsals, axil¬
lae, ventral body and groin largely correspond to analogous sites affected in human
atopic dermatitis (Beltrani 1999a). However, the clinical picture is less close to in¬
fantile human atopic dermatitis, where the face and scalp is predominantly involved
(Rothe and Grant-Kels 1996; Beltrani 1999a).
The clinical appearance of intradermal test positive and intradermal test negative
dogs with atopic dermatitis was very similar. Sensitisation is not necessarily pathog¬
nomic for atopic dermatitis, as healthy animals can have positive intradermal tests
and elevated IgE titres without clinical signs (DeBoer and Hillier 2001; Scott and
others 2001a). However, these results do suggest that there may be two clinically in¬
distinguishable syndromes of atopic dermatitis in dogs, as postulated in humans
(Halbert and others 1995). It is unlikely that these dogs represent false negative re¬
sults as the tests were performed by experienced dermatologists who monitored al¬
lergen quality and inhibition by previous therapy. Furthermore, all the dogs with
negative intradermal tests also had allergen specific IgE titres beneath the accepted
threshold for sensitisation established for a commercial ELISA incorporating recom¬
binant canine FceRIa (Heska Allercept® test provided by Axiom Laboratories,
Teignmouth, UK). In addition, all the atopic dogs had perennial disease and were
tested whilst they exhibited clinical signs, making it unlikely that seasonal fluctua¬
tions in IgE levels were responsible for negative test results.
This group of dogs may, therefore, represent a subset of patients with non-specific
cutaneous hyper-reactivity. There are also cases of human atopic dermatitis that fulfil
the clinical diagnostic requirements but where no allergen-specific IgE or skin test
reactivity can be demonstrated (Halbert and others 1995; Akdis and others 1999a).
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Allergen specific T-cells, furthermore, are not found in these individuals, despite the
fact that CLA+ T-cells dominate the cutaneous inflammatory infiltrate (Akdis and
others 1999a; Schmid-Grendelmeier and others 2001).
These findings have lead to the suggestion that there are two forms of atopic dermati¬
tis in humans - an allergic (extrinsic) form with allergen specific IgE and mast cell
reactivity; and a non-allergic (intrinsic) form that is not associated with IgE or mast
cell reactivity (Halbert and others 1995; Hanifin 1996; Akdis and others 1999a; Ta-
naka and others 1999). In humans, the clinical and epidemiological features of ex¬
trinsic and intrinsic atopic dermatitis are very similar, although the onset of symp¬
toms is later in the intrinsic form (Schmid-Grendelmeier and others 2001).
The pathogenesis of intrinsic atopic dermatitis is unclear. Abnormal lipid metabolism
and bacterial ceramidase activity, which decrease epidermal ceramides (Fartasch and
Diepgen 1992; Ohnishi and others 1999; Hara and others 2000), reduced 86-
desaturase activity, arachidonic acid and di-homo gamma linoleic acid levels
(Hanifin 1996) could compromise epidermal barrier function. Abnormalities in 86
and 85 destaurase activity, decreased fat absorption and ultastructural abnormalities
in the epidermal lipid barrier have also been observed in atopic dogs (Horrobin and
others 1990; van den Broek and Simpson 1990; Scott and others 1997; Taugbol and
others 1998; Olivry and others 2000). An impaired cutaneous barrier could enhance
inflammatory reactions to irritants and microorganisms (Leung 2000). Auto-antigens
could also play a role in the pathogenesis of intrinsic atopic dermatitis (Schmid-
Grendelmeier and others 2001).
The predilection sites identified in this study predominantly involve ventral and/or
sparsely haired skin. This may expose these sites to percutaneous allergen uptake or
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to irritants in the putatively allergic and non-allergic forms respectively. Some of
these sites are also subject to increased temperature and humidity, and frictional
trauma that may make them particularly vulnerable to environmental allergens, irri¬
tants and secondary infection.
The results from this study provide evidence for a non-allergic form of atopic derma¬
titis that is clinically indistinguishable from allergic atopic dermatitis. However, it is
still possible that these dogs are sensitised to allergens not included in the intrader¬
mal test and serology panels, and further studies are needed to elucidate the patho¬
genic mechanisms in these animals.
3.4.2 The role of microbial colonisation in canine atopic dermatitis
The present study shows that the development of chronic lesions in canine atopic
dermatitis is associated with secondary microbial infection as Malassezia dermatitis
or staphylococcal pyoderma significantly increased clinical lesion scores. Colonisa¬
tion with staphylococci significantly worsened all of the clinical signs except sebor-
rhoea, and Malassezia all except scaling and hyperpigmentation. Furthermore, apart
from erythema, mean lesion scores at body sites without clinical or cytological evi¬
dence of secondary infection were less than 1.0. These findings further indicate that,
in its pure form, canine atopic dermatitis is a pruritic and erythematous condition.
Papules were rarely observed in the absence of secondary infection. They are not,
however, regarded as a primary lesion in atopic dermatitis, although they are com¬
monly observed in bacterial pyoderma and Malassezia dermatitis (Scott and others
2001a). Scaling, which has been associated with both atopic dermatitis and bacterial
pyoderma (Scott and others 2001a), was significantly worsened by staphylococcal
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infection. In contrast, the degree of scaling was not significantly altered by
Malassezia dermatitis, in which it is a less common feature (Mason and Evans 1991).
Similarly, seborrhoea, which is a feature of both atopic dermatitis and Malassezia
dermatitis, was significantly worsened by the presence of Malassezia, but not staphy¬
lococcal pyoderma, where it is less common (Scott and others 2001a). Lichenifica-
tion and hyperpigmentation frequently complicate chronic atopic dermatitis as well
as bacterial pyoderma and Malassezia dermatitis (Mason and Evans 1991; Scott and
others 2001a). However, in this study, lichenification and hyperpigmentation were
strongly associated with microbial infection, suggesting that this plays an important
role in the pathogenesis of chronic atopic dermatitis.
Exacerbation of human atopic dermatitis by Staphylococcus aureus is associated
both with specific IgE and superantigen production (Bunikowski and others 1999;
Skov and Baadsgaard 2000). Cutaneous application of lipoteichoic acid isolated from
S. aureus, furthermore, induced Tn2-like inflammation in a mouse model (Matsui and
Nishikawa 2002). Specific IgE antibodies against S. intermedius, the species most
commonly isolated from dogs, have been detected, but their role in canine atopic
dermatitis is unclear (Morales and others 1994). S. intermedius also produces super-
antigens (Adesiyun and Usman 1983), but superantigen activity in canine atopic
dermatitis has not been studied.
Colonisation with Malassezia furfur has been associated with specific IgE and
PBMC proliferation in human atopic patients, but no evidence of superantigen activ¬
ity has been found (Johansson and others 1999). There is evidence that M. pachy-
dermatis acts as a conventional allergen in canine atopic dermatitis (Morris and oth-
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ers 1998; Nuttall and Halliwell 2001). Other studies have identified major and minor
IgG and IgE binding proteins in M. pachydermatis (Chen and others 2002).
Clinically and cytologically significant Malassezia and staphylococcal infections
mostly affected parts of the body previously described as predilection sites in dogs
(DeBoer and Marsella 2001). Malassezia were most commonly seen in the interdigi-
tal skin, axillae, groin, ventral body and ears. Staphylococci were mostly found on
the ventral abdomen and groin, with occasional generalised infections. These are also
all predilection sites for clinical signs in canine atopic dermatitis (Scott and others
2001a). It appears likely, therefore, that alterations to the microenvironment of atopic
skin allows these organisms to establish remote from their mucosal carriage sites
(Bond and others 1994; Harvey and Lloyd 1994). Licking enhances seeding of or¬
ganisms, and excoriation, increased temperature and moisture, altered immune re¬
sponse, or changes in the epidermal lipid profile may all favour colonisation. Once
established, these organisms appear to be important in the pathogenesis of lesional
canine atopic dermatitis, but further investigation will help to define their role in ca¬
nine atopic dermatitis.
3.4.3 Reactions to intradermal allergens
At least one positive reaction to each of the 56 allergens was observed in the in¬
tradermal test positive atopic dogs, emphasising the wide range of potential envi¬
ronmental allergens. Despite this, reactions to house dust mites, particularly Der-
matophagoides species, appeared to be the most prevalent. This finding is consistent
with data from a 1998 survey at the University of Edinburgh, where 49 and 35 of 57
dogs tested reacted to D. farinae and D. pteronyssinus respectively (T.J.Nuttall, un-
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published observations). However, an earlier study reported that only 62% and 58%
of intradermal test positive atopic dogs reacted to house dust mite allergens in Edin¬
burgh and London respectively (Sture and others 1995). The reason for the discrep¬
ancy between this and the present study is unknown. It is unlikely that changes in
indoor environments and genetic factors could have a made a significant difference
in the short time between these studies. Both studies used the same allergen extracts
at the same concentrations, although it is possible that the allergen content could
have differed. Intradermal test allergens are crude protein extracts that can show sig¬
nificant batch variation in allergenicity and irritancy (Hill and DeBoer 2001). It is
possible that frequent sensitisation to human dander reported in the Edin¬
burgh/London survey (Sture and others 1995), which was not observed in this study,
could also have influenced the results. A ten-fold greater dilution of human dander is
now used, as it was felt the higher concentration could be irritant (R.E.W. Halliwell,
K.L. Thoday, P.B. Hill, TJ. Nuttall and S.T. Auxilia, unpublished observations). The
prevalence of intradermal test reactions to dust and dust mites in this study was also
higher than the 60-70% of positive reactions reported for these allergens in North
America (DeBoer 1989; Hill and DeBoer 2001; Scott and others 2001a). These data,
however, must be interpreted in light of the high frequency of responses to moulds,
pollens and fleas seen in North America (Hill and DeBoer 2001).
Reactions to other mites were less common. Eurogylphus maynei is widespread, but
much less numerous than Dermatophagoides mites (Le Mao and others 1998; Smith
and others 1999). This and the forage mites Acarus, Lepidoglyphus and Tyrophagus,
are less important in human (Thomas and others 1998a) and canine atopic diseases
(Sture and others 1995).
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Responses to other allergens were of much less significance. Reactions to insect al¬
lergens were largely accounted for by fleas and Simuliutn species Blackflies. A study
in the US similarly found that reactions to insects other than fleas were uncommon
(DeBoer 1989). A recent review also concluded that reactions to arthropods other
than Dermatophagoides mites and fleas are uncommon and that their relevance to
atopic dermatitis remains unproven (Sousa and Halliwell 2001). This review also
concluded that atopic dermatitis might predispose to flea allergy dermatitis. The low
level of sensitisation to fleas among the atopic dogs in this study does not support
this conclusion. However, until the true prevalence of flea exposure and sensitisation
among atopic and non-atopic dogs in the UK is studied, these findings must be inter¬
preted with care. Reactions to house dust mite and other allergens were also seen in
all of the flea allergen positive dogs. None of them, furthermore, had a response to
flea control programmes and all had clinical signs that were compatible with atopic
dermatitis rather than flea allergic dermatitis.
Reactions to pollen allergens were particularly uncommon. Positive reactions to
weed pollens appeared to be more common than reactions to grass or tree pollens,
but may be increased by the number of responses to Red Clover (Trifolium pratense).
This too may be an irritant at the concentration used or could represent a clinically
irrelevant reaction. If reactions to this allergen are deleted, the overall response to
weed pollens falls to 11.1% and 14.7% of all atopic and intradermal test positive
atopic dogs respectively, which are closer to the figures for other pollens.
The frequency of reactions to danders, insect, pollen and mould allergens are consis¬
tent with the 1998 survey, suggesting that these figures represent a stable picture of
sensitisation in atopic dogs from Scotland and the North of England. Despite this, an
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earlier study of intradermal test reactions in Edinburgh and London (Sture and others
1995) found that reactions to tree, grass and weed pollens were seen in approxi¬
mately 20% of intradermal test positive dogs. Again, the reasons for these discrepan¬
cies are not clear, although conifers, the dominant tree species in Scotland, may be
less allergenic than deciduous species (Hyde 1956).
The prevalence of pollen reactions in the UK are consistently lower than those re¬
ported in North American surveys (Hill and DeBoer 2001; Scott and others 2001a).
The reason for this is unclear. There has been little effort to standardise allergen ex¬
tracts and techniques in veterinary dermatology, although similar allergens are often
used at similar concentrations on both sides of the Atlantic. Furthermore, there was a
good correlation between reactions to Greer and ARTU tree pollen extracts. How¬
ever, the low frequency of reactions to tree pollens means that this data should be
confirmed with a larger sample size. The relative frequency of pollen reactions could
also be influenced by the presence of a few highly allergenic species. The highly al¬
lergenic Ragweeds {Ambrosia species) are common allergens in the US (Scott and
others 2001a). Similarly, pollen reactions in Japanese atopic dogs are dominated by
Japanese Cedar {Cryptomeria japonica) and Japanese Cypress {Chamaecyparis ob-
tusa) (Masuda and others 2000). Short Ragweed {Ambrosia artemisifolia) has be¬
come locally established in the UK (Mabey 1997), but there are no reports of wide¬
spread sensitisation in atopic dogs.
Reactions to intradermally injected allergens do not mimic clinical and histopa-
thological findings in canine atopic dermatitis. Nevertheless, it is accepted that posi¬
tive reactions demonstrate IgE mediated hypersensitivity to environmental allergens
(Hill and others 2001). Despite this, eleven out of the 45 dogs tested in this study did
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not react to any allergens. This is higher than the 12% non-response rate reported in a
large study of intradermal tests in North America, although only 75% of dogs tested
had reactions to allergens other than fleas (DeBoer 1989). Similar results were re¬
ported in a study of intradermal tests in Edinburgh and London (Sture and others
1995). In humans, the intrinsic (non-IgE mediated) form accounts for 15-45% of
cases of atopic dermatitis (Wollenberg and others 2000; Schmid-Grendelmeier and
others 2001).
It was not possible to evaluate six and 24 hour late phase responses in this study.
These responses closely resemble atopic dermatitis and may be more clinically rele¬
vant (Olivry and others 2001), although less sensitive than immediate responses
(Hillier and others 2000). A recent review speculates that this may be due to the ef¬
fects of dose and route of allergen exposure and/or differential mediator release be¬
tween immediate responses, late phase responses and spontaneous atopic dermatitis
(Hill and others 2001). The relationship between these clearly needs further study.
3.4.4 The epidemiology of canine atopic dermatitis
This study confirms the view that a young age of onset is a feature of canine atopic
dermatitis. It is generally accepted that the age of onset lies between six months and
three years of age in 75% or more cases of canine atopic dermatitis (Griffin and De-
Boer 2001; Scott and others 2001a). The mean age seen in this study was at the upper
end of this range, but the figures refer to age at presentation, rather than age of onset.
A previous study found that the mean interval from onset of clinical signs to presen¬
tation at the University of Edinburgh Hospital for Small Animals was 27 months
(Nuttall and others 1998).
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The mean age of the healthy dogs was higher than that of the two groups of atopic
dogs. There were, however, no significant differences between the three groups and
the age range was similar in each case. Age related changes in immune function, in¬
cluding PBMC proliferation and antibody titres, but not delayed type hypersensitivity
or in vitro cytokine production, are reported in dogs (Kearns and others 1999). An¬
other study reported a decrease in lymphocyte numbers and proliferative responses
with age (Greeley and others 1996). However, it is likely that these changes would
contribute to intra- rather than inter-group variation in this project.
Males outnumbered females in the intradermal test positive atopic dogs compared to
the other two groups, in which the sexes were evenly balanced. However, there were
no significant differences in the numbers of male and female dogs in each group.
Conflicting reports have suggested both a female and a male bias in canine atopic
dermatitis, but these findings have not been consistently observed (Griffin and De-
Boer 2001; Scott and others 2001a).
Canine atopic dermatitis is widely regarded as a familial disease. One standard text
quotes Labradors, Golden Retrievers, West Highland White Terriers, Boxers, English
Setters and German Shepherd Dogs as predisposed breeds (Scott and others 2001a).
However, these data were taken from a large number of studies in different countries,
where the gene pools may differ. In addition, there is often no reference to the fre¬
quency of breeds in the local canine population. A recent review of data controlled
for the local population concluded that Beauceron, Boston Terriers, Boxers, Cairn
Terriers, Shar Pei, Dalmatians, English Bulldogs, English Setters, Irish Setters, Fox
Terriers, Labradors, Labrit, Lhasa Apso, Miniature Schnauzers, Pugs, Scottish Terri¬
ers, Sealyham Terriers, West Highland White Terriers, and Yorkshire Terriers were
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all predisposed to atopic dermatitis (Griffin and DeBoer 2001). The most common
breeds seen in the present study were Labradors and German Shepherd Dogs. This
may, however, simply reflect the general canine population as these are two of the
most popular dog breeds in the UK (Pet Food Manufacturers Association data; URL
- http://www.pfma.com/petownership.htm). In all, the 45 atopic dogs in this study
were from 22 breeds, the majority of which were represented by one or two individu¬
als. This suggests that atopic traits are common to a large number of breeds. Alterna¬
tively, atopic traits per se could be less important than environmental factors. Multi¬
centre studies involving larger numbers of dogs from different breeds and interven¬
tion studies looking at the effect that environmental manipulation has on the devel¬
opment of atopic dermatitis would be needed to answer this question. Similar studies
are currently underway in human medicine (Custovic and others 1998).
3.4.5 Histopathological findings in atopic and healthy skin
Histopathology of healthy skin in this study was consistent with previous descrip¬
tions of normal canine skin (Scott and others 2001b). This suggests that the healthy
dogs were not suffering from sub-clinical inflammatory skin disease and were, there¬
fore, appropriate controls.
Non-lesional atopic skin was taken from the flank. This is not a predilection site in
canine atopic dermatitis, and is not commonly involved except in severe, generalised
disease. Despite this, there was histopathological evidence of mild inflammatory
changes. There was also an increase in the number of dermal cells compared to
healthy skin, although this did not reach significance. Mild inflammatory changes
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and mononuclear cell infiltration have been noted in non-lesional skin from human
atopic dermatitis (Thestrup-Pedersen and others 1997; Leung 1999; Leung 2000).
Lesional skin was marked by obvious histopathological changes and a significant
increase in the number of dermal cells. This supports the clinical assessment of non-
lesional versus lesional skin and confirms there is a valid difference between these
sites. As these were dogs recruited in a clinical setting, reliable differentiation be¬
tween acute and chronic lesions proved impossible. However, uncomplicated atopic
lesions were selected as far as possible by avoiding obviously excoriated or infected
skin. The findings are consistent with previous reports of acute and chronic lesional
skin in human (Leung 1999; Leung 2000) and canine (Olivry and others 1997; Sinke
and others 1997; Olivry and others 1999a; Olivry and Hill 2001) atopic dermatitis.
Eosinophils were rarely observed, even in lesional skin, although special stains such
as sirrius red or immunohistochemistry may have helped to distinguish them. Some
atopic dogs exhibit eosinophilic exocytosis and microabcesses, but eosinophils are
not as marked a feature of canine compared to human atopic dermatitis (Olivry and
others 1997). However, it may be difficult to detect degranulated cells and as their
granule contents are highly damaging to surrounding tissues, a very few eosinophils
could have a disproportionate effect (Olivry and Hill 2001). A recent study reported
marked eosinophil infiltration in the early stages of intradermal allergen induced late
phase inflammatory responses (Olivry and others 2001). Further study of the role
eosinophil derived mediators play in atopic skin is clearly needed.
In keeping with a previous study (Olivry and others 1997) neutrophils were uncom¬
mon. Neutrophil rich infiltrates are thought to be a response to secondary bacterial
infection and trauma (Olivry and Hill 2001), which were avoided in this study.
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No differences between the histopathology of skin biopsies from intradermal test
positive and intradermal test negative animals were seen in this study. Histopa-
thological findings are also similar in extrinsic and intrinsic human atopic dermatitis
(Akdis and others 1999a; Schmid-Grendelmeier and others 2001). Fas-Fas ligand
mediated apoptosis of keratinocytes induced by infiltrating T-cells has recently been
associated with the development of lesional atopic dermatitis (Trautmann and others
2000). The mononuclear cell infiltrate into lesional atopic skin observed in this study
may therefore play a crucial role in pathogenesis. This may disrupt the epidermal
barrier and induce lesions common to both allergic and non-allergic atopic dermati¬
tis. The difference between the two would then lie with the factors that recruit mono¬
nuclear cells to the skin.
3.4.6 Conclusion
This study has demonstrated that canine atopic dermatitis is largely a pruritic and
erythematous disease that predominantly affects ventral, sparsely haired skin. The
development of chronic lesions is strongly associated with secondary bacterial and
Malassezia infections. This study also provides evidence for the existence of clini¬
cally indistinguishable allergic and non-allergic forms of canine atopic dermatitis.
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4. Characterisation of major and minor




It is clear from the findings in Chapter 3 and other studies (reviewed in Hill and De-
Boer 2001) that the most important allergens in canine atopic dermatitis are the
house dust mites D. pteronyssinus and D. farinae. More than 16 Dermatophagoides
allergens relevant to humans have been identified (Chapter 1; Table 1.1), but the
most important are group 1 and group 2 allergens (Thomas and Smith 1999). The
spectrum of allergens relevant to dogs is less clear. Several studies suggest that high
molecular weight proteins are more important allergens than the low molecular
weight group 1 and 2 proteins (Noli and others 1996; McCall and others 2000; Shaw
2000), whereas other studies report a high frequency of reactions to group 1 and 2
allergens (Masuda and others 1999; McCall and others 1999). The antisera used in
these studies could, however, have influenced the results as different antisera can
vary in specificity and sensitivity (Steward and Male 1998). In addition, SDS-PAGE
was originally described using reducing conditions (Laemmli 1970), which can dena¬
ture IgE epitopes and reduce IgE binding to group 1 and 2 Dermatophagoides aller¬
gens (Lombardero and others 1990).
The allergen extracts used may also be important. The allergen content varies de¬
pending on the source, mite life cycle and proportion of mites to media (O'Hehir
1988; Le Mao and others 1998). Furthermore, IgE and T-cell epitope polymorphisms
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have been found in a range of Dermatophagoides allergens (Smith and others 1997;
Le Mao and others 1998). This has important implications for research, diagnosis
and immunotherapy, as different mite extracts may not contain all relevant epitopes.
It is thus difficult to compare results between studies using different reagents and
mite extracts. The aim of this study, therefore, was to characterise and compare IgE
binding proteins detected on both reduced and non-reduced western blots of Der¬
matophagoides extracts from a number of sources using both monoclonal and poly¬
clonal anti-canine IgE antibodies.
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4.2 Materials and Methods
4.2.1 Study population and sample collection
Dogs with atopic dermatitis (n=33) and healthy dogs (n=26) were recruited and clini¬
cal data recorded according to the inclusion criteria described in Chapter 2.1. Serum
samples were collected and stored as described in Chapter 2.2.1.
4.2.2 SDS-PAGE analysis of the Dermatophagoides extracts
The sources of the crude D. farinae, D. pteronyssinus and D. microceras extracts,
and the purified group 1 and group 2 allergens are listed in Chapter 2, Table 2.2. The
freeze-dried extracts were reconstituted to lmg/ml in sterile PBS as described in
Chapter 2.3. SDS-PAGE was performed using 10pg of each extract in reducing and
non-reducing loading buffer as outlined in Chapter 2.4. Duplicate gels were stained
with 2.5% Coomassie Blue and Silver and imaged as described in Chapter 2.4.3.
4.2.3 Immunoblotting
western blots of each extract diluted in reducing and non-reducing buffer were pre¬
pared and probed with monoclonal or polyclonal anti-canine IgE (Chapter 2.5).
4.2.3.1 Validation
A single allergen source (Greer D. farinae under reducing conditions) and a known
positive serum sample were initially used to validate the technique. The sample was
strongly reactive to D. farinae in ELISAs and on western blots (T.J. Nuttall, T.-M.
Lian and P. Cameron; unpublished data). The appropriate channels of the MN28
miniblotter® (Chapter 2.5.2.2) were incubated for one hour at room temperature with
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85jll1 of a 1/5, 1/10, 1/20 or 1/50 dilution of serum. Each serum dilution channel was
then incubated for one hour at room temperature with a 1/50, 1/100, 1/500, 1/1000 or
1/5000 dilution of either the mouse monoclonal or goat polyclonal anti-canine IgE.
The appropriate portions of each membrane were incubated at room temperature for
one hour with 20ml of the horseradish peroxidase conjugated bovine monoclonal
anti-mouse IgG or mouse monoclonal anti-goat IgG diluted 1/500, 1/1000, 1/5000 or
1/10,000 respectively. The membranes were then developed and imaged as described
(Chapter 2.5.2.3). Blanks and control channels with no serum, no anti-canine IgE or
no anti-IgG were included in each assay. Duplicate blots were performed using the
positive control serum heated at 56°C for one hour. The absence of binding to these
blots confirmed the specificity of the both the polyclonal and monoclonal antibodies
for heat labile IgE epitopes (Tizard 1996).
Optimum binding was seen with serum diluted 1/5, the mouse monoclonal anti-
canine IgE diluted 1/500, the goat polyclonal anti-canine IgE diluted 1/100, the bo¬
vine anti-mouse IgG diluted 1/1000 and the mouse anti-goat IgG diluted 1/5000.
There was no non-specific binding to serum or allergens at these dilutions, which
were used in the rest of the study.
4.2.3.2 Screening of sera from atopic and healthy dogs for allergen
specific IgE
Western blots of each allergen were prepared and blocked as previously described.
The appropriate channels of the MN28 miniblotter® were incubated for one hour at
room temperature with 85pl of a 1/5 dilution of serum, then 85|itl of either a 1/500
dilution of the mouse monoclonal or a 1/100 dilution of the goat polyclonal anti-
-160-
canine IgE. The membranes were then incubated at room temperature for one hour
with 20ml of the horseradish peroxidase conjugated bovine monoclonal anti-mouse
IgG or the mouse monoclonal anti-goat IgG diluted 1/1000 and 1/5000 respectively.
The membranes were then washed, developed and imaged as described previously.
Blanks and control channels with no serum, no anti-canine IgE and positive control
serum were included in each assay.
4.2.4 Data Analysis
Four replicates of each allergen extract immunoblot were generated for both atopic
and healthy sera. These were reducing buffer with monoclonal anti-canine IgE; re¬
ducing buffer with polyclonal anti-canine IgE; non-reducing buffer with monoclonal
anti-canine IgE; and non-reducing buffer with polyclonal anti-canine IgE. The num¬
bers of positive sera identified on each of these immunoblots were compared using
Fisher's exact test with significance set at p<0.05 (Instat®). Mann-Whitney tests were
used where appropriate to compare the number of positive atopic and healthy sera
that recognised each allergen extract (Instat®).
Standard curves for each blot were constructed by plotting the loglO molecular
weight of each molecular weight marker against the distance migrated by each
marker divided by the distance migrated by the loading dye. Regression equations
from the standard curves (MS Excel 2000®) were used to calculate the molecular
weight of the allergens recognised by each serum sample. The mean molecular
weight of each allergen was plotted against the percentage of positive sera that rec¬
ognised the allergen on the reduced and non-reduced blots of each extract. Major al¬




The majority of the dogs with atopic dermatitis had positive reactions to D. farinae
and D. pteronyssinus (Table 4.1). Occasional reactions were also seen to a variety of
other mite, insect, pollen and mould extracts. Only four dogs out of the 33 with clini¬
cal atopic dermatitis in this study did not react to a least one allergen. No dog reacted
to D. pteronyssinus in the absence of a reaction to D. farinae. Two dogs, however,
had reactions to D. farinae, but not D. pteronyssinus.
Table 4.1 - Intradermal test (IDT) reactions to Dermatophagoides farinae and
D. pteronyssinus in dogs with atopic dermatitis (n=33)
Allergen extract IDT result
Positive Negative
D. farinae 24 9
D. pteronyssinus 22 11
4.3.2 SDS-PAGE of the Dermatophagoides extracts
The protein content varied widely between all the extracts, even those from the same
source. Protein bands were clearly identified on gels of all the extracts (Figure 4.1a-
e). Multiple bands were identified on the Greer D. farinae, and Greer and AP D.
pteronyssinus gels, although the migration patterns were not identical. Far fewer
bands, which were predominantly low molecular weight proteins, were seen on the
ALK D. farinae, ALK and IG D. pteronyssinus, and ALK D. microceras gels.
Prominent bands of the expected molecular weight were seen with the purified AP
and IG Der p 1, and AP Der p 2 extracts. Clear bands of the appropriate size were
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seen with the purified ALK Der f 1 and Der f 2 extracts, although faint lower and
higher molecular weight bands were also present, especially in the Der f 2 extract.
Different migration patterns were seen on non-reduced gels, although the overall pat¬
tern was similar to the corresponding reduced gel. There were few differences be¬
tween duplicate gels stained with silver and Coomassie blue.
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Figure 4.1 - SDS-PAGE analysis of crude and purified Dermatophagoides
extracts (2.5% Coomassie blue stain transilluminated by white light)
a - Dermatophagoides farinae
Source of allergen
MWM A
200kD — -*= i
116kD —- : gyj F?5!l
97kD """ I ■







R NR R NR
MWM - Molecular weight markers (Broad range; Biorad Laboratories); R - Reduc¬
ing buffer; NR - Non-reducing buffer. Source of allergens: A - Greer Laboratories; B
- ALK-Abello.
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MWM - Molecular weight markers (Broad range; Biorad Laboratories,); NR. - Non-
reducing buffer. Source of allergens: A - Greer Laboratories; B - ALK-Abello; C -
Allergo-Pharma; D - Immunobiology Group.
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MWM - Molecular weight markers (Broad range; Biorad Laboratories); NR - Non-
reducing buffer. Source of allergen: ALK-Abello.
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R NR R NR R NR
MWM - Molecular weight markers (Broad range; Biorad Laboratories); R - Reduc¬
ing buffer; NR - Non-reducing buffer. Source of allergens: C - Allergo-Pharma; D
Immunobiology Group; Der f 1 - ALK-Abello.
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e - Purified group 2 allergens










R NR R NR
MWM - Molecular weight markers (Broad range; Biorad Laboratories); R - Reduc¬
ing buffer; NR - Non-reducing buffer. Source of allergens: ALK-Abello.
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4.3.3 Immunoblotting
Only one serum sample from an atopic dog that had no response to house dust mites
on skin testing detected D. farinae allergens under all blotting conditions (i.e. reduc¬
ing and non-reducing buffer, mono- and polyclonal anti-canine IgE). Two further
sera from IDT negative dogs detected allergens on single blots using reducing
buffer/monoclonal anti-canine IgE and non-reducing buffer/polyclonal anti-canine
IgE respectively. One sample detected D. pteronyssinus allergens using reducing
buffer and monoclonal anti-canine IgE only. Representative examples of the im-
munoblots are illustrated in Figure 4.2.
There were no significant differences in the number of positive sera identified using
either polyclonal or monoclonal anti-canine IgE for any of the extracts under reduc¬
ing or non-reducing conditions (Table 4.2). The results were therefore combined to
give four replicates (i.e. monoclonal anti-canine IgE/reduced blot, monoclonal anti-
canine IgE/non-reduced blot, polyclonal anti-canine IgE/reduced blot and polyclonal
anti-canine IgE/non-reduced blot) for each allergen extract in the following analyses.
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Figure 4.2 - Representative immunoblots
a - Greer D. farinae, atopic sera, polyclonal anti-IgE, non-reducing buffer; b - Greer
D. farinae; healthy sera, polyclonal anti-IgE, non-reducing buffer; Greer D. farinae,
atopic sera, monoclonal anti-IgE, reducing buffer; Greer D. farinae, healthy sera,
monoclonal anti-IgE, reducing buffer; e - IG Der p 1, atopic sera, polyclonal anti-
IgE, non-reducing buffer; f - AP Der p 2, atopic sera, polyclonal anti-IgE, non-
reducing buffer;




Figure 4.2 contd. - Representative immunoblots
g - ALK Der f 1, atopic sera, polyclonal anti-IgE, non-reducing buffer; h - g - ALK
Der f 2, atopic sera, polyclonal anti-IgE, non-reducing buffer; i - Greer D. ptero-
nyssinus, atopic sera, monoclonal anti-IgE, reducing buffer; j - Greer D. pteronyssi-
nus, healthy sera, monoclonal anti-IgE, reducing buffer.
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4.3.3.1 IgE binding to D. farinae extracts
Significantly more atopic than healthy sera recognised IgE binding proteins on the
Greer and ALK D. farinae blots (p<0.05) (Figure 4.3a). In addition, significantly
more atopic sera bound to the Greer than to the ALK extract (p<0.05).
4.3.3.2 IgE binding to the D. pteronyssinus extracts
Significantly more atopic than healthy sera recognised IgE binding proteins in each
of the Greer, ALK and AP D. pteronyssinus extracts (p<0.05) (Figure 4.3b). There
was no significant difference in the frequency of binding between these extracts.
However, significantly fewer atopic sera recognised the IG compared to the other
extracts (p<0.05), nor was there any significant difference between the numbers of
atopic and healthy sera that bound to this extract. Significantly more atopic sera rec¬
ognised the Greer D. farinae extract compared to the Greer D. pteronyssinus extract
(p<0.05), but there was no significant difference between the ALK D. farinae and D.
pteronyssinus extracts. No serum sample from a Dermatophagoides skin test positive
dog bound to D. pteronyssinus in the absence of binding to D. farinae.
4.3.3.3 IgE binding to the D. microceras extract
There was no significant difference in the number of atopic and healthy sera that
bound to the D. microceras blots (Figure 4.3c). Significantly fewer atopic sera, fur¬
thermore bound to the ALK D. microceras extract than to the ALK D. farinae and D.
pteronyssinus extracts (p<0.05).
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4.3.3.4 IgE binding to the purified Group 1 and 2 allergens
A few atopic sera bound to western blots of the ALK Der f 1 and Der f 2 extracts
(range 8-29%) (Table 4.2). However, this was largely accounted for by binding to
high molecular weight allergens that were also present in these extracts rather than to
low molecular weight Der f 1 and Der f 2. Very few sera recognised any of the other
purified group 1 and 2 extracts (range 0-4%) (Table 4.2) and there was no significant
difference in binding between atopic and healthy sera. In addition, significantly
fewer atopic sera bound to any of the group 1 or 2 allergen preparations than to the
appropriate crude D.farinae or D. pteronyssinus extracts (p<0.05).
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Figure 4.3 - Percentage of atopic and healthy sera that bound to western
blots of Dermatophagoides allergens
a - Dermatophagoides farinae
Atopic sera -■ ; Healthy sera - A - Greer Laboratories; B - ALK-Abello; Bar







b - Dermatophagoides pteronyssinus
Atopic sera -■ ; Healthy sera - ■; A - Greer Laboratories; B - ALK-Abello; C -
Allergo-Pharma; D - Immunobiology Group; Bar - sem; * - p<0.05.
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c - Dermatophagoides microceras
Bar - sem; ■ - Atopic sera; ■ - Healthy sera.
100-i
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4.3.4 Major and minor allergens
A range of major allergens from 44kD to 150kD were identified on blots of the Greer
D. farinae and D. pteronyssinus extracts under reducing conditions. No major aller¬
gens under 98kD were identified on blots under non-reducing conditions. Major al¬
lergens at 97-98kD and 103-104kD were common to both reduced and non-reduced
blots of D. farinae and D. pteronyssinus. A number of minor allergens from 15-
150kD were identified in both D. farinae and D. pteronyssinus. The distribution of
minor allergens was not markedly different between the reduced or non-reduced
blots (Table 4.3; Figure 4.4 a and b). Results for the other D. farinae, D. pteronyssi¬
nus, and D. microceras extracts were very similar.
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Table 4.3 - Major and minor allergens identified in the Greer Dermato-
phagoides farinae and D. pteronyssinus extracts
a. D. farinae
Major allergens (kD) Minor allergens (KD)
Reduced blot Non-reduced blot Reduced blot Non-reduced blot
151 139 116 151
134 103 65 120





Major allergens (kD) Minor allergens (kD)
Reduced blot Non-reduced blot Reduced blot Non-reduced blot
103 104 115 150










4.4.1 Characterisation of major and minor Dermatophagoides allergens in
canine atopic dermatitis
This study characterised in detail the pattern of recognition of major and minor Der¬
matophagoides allergens by canine atopic sera. Major allergens common to D. fari-
nae and D. pteronyssinus were detected as double bands at 97-98kD and 103-104kD
on both reduced and non-reduced blots. These bands seem relatively resistant to re¬
duction and are probably the double band previously reported as a major allergen in
studies using anti-canine IgGd and recombinant FcsRIa (Noli and others 1996;
McCall and others 2000). This was recently sequenced and identified as a chitinase
named Der f 15 (McCall and others 2000). An unidentified 95-1 OlkD allergen and a
98kD major allergen structurally similar to paramyosin (termed Der f 11) were re¬
cently identified on D. farinae blots probed with human sera (Le Mao and others
1998; Tsai and others 1999). Further analysis is needed to determine if these are in¬
dependent allergens, or whether canine and human atopic sera recognise similar high
molecular weight allergens.
The canine D. farinae major aiiergen detected at 134-139kD in fnis study has no ob¬
vious homologue. The 98kD chitinase is heavily glycosylated with a native protein
molecular weight of approximately 63kD (McCall and others 2000). Multiple bands
can be associated with variably glycosylated allergens (Le Mao and others 1998), so
this may represent an alternately glycosylated form of the 97-104kD allergen. Other
major allergens at 84-85kD, 65-69kD and 44-45kD were only recognised on reduc¬
ing blots, suggesting these are fragments or denatured forms of the larger allergens.
However, it is possible that the 65-69kD allergen is similar to a 60kD allergen re-
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cently described in D. farinae (Weber 2001) or the native Der f 15. Most allergens
possess a number of different IgE epitopes (Bufe 1998), which in this case appear to
be intact and located on one or more of these smaller fragments. Degradation prod¬
ucts have also been identified on D. farinae blots probed with human sera (Le Mao
and others 1998). The distribution of minor allergens was similar on both reduced
and non-reduced blots. Only a low frequency of binding to low molecular weight
bands representing group 1 and 2 allergens was seen. Other minor allergens were
identified at 115-121kD and 150-151kD. Further study is required to determine
whether these are independent allergens or alternately glycosylated forms of the
97/104kD allergen.
These results also show that, in contrast to humans, group 1 and 2 Dermatophagoides
allergens are of limited relevance to canine atopic dermatitis. There was little binding
of atopic or healthy sera to the IG D. pteronyssinus extract, which is prepared from
spent mite media and largely consists of Der p 1 and Der p 2 (G. Hoyne, Immunobi-
ology Group, University of Edinburgh Centre for Inflammation Research; personal
communication), and very few sera recognised any of the purified group 1 and 2 al¬
lergens from D. farinae and D. pteronyssinus. Reducing conditions can decrease IgE
binding to group 1 and 2 allergens (Lombardero and others 1990; Olsson and others
1998), but no difference was seen between reduced and non-reduced blots in this
study. No reliable positive control canine sera were available for these allergens, but
appropriate protein bands were identified on each blot by staining with Coomassie
Blue. Furthermore, these allergens have been used in immunoblotting with human
sera and proliferation studies with human and murine PBMCs (G. Nordskov Hansen,
ALK-Abello; O. Cromwell, Allergo-Pharma; N. Savage, Immunobiology Group,
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University of Edinburgh Centre for Inflammation Research; personal communica¬
tions). The few atopic sera that bound to the Der f 1 and Der f 2 blots mostly recog¬
nised the 97-104kD double band discussed earlier. No contamination at this position
was evident on the stained gels and blots, but enough allergen was obviously present
for detection by strongly reactive sera. Another study reported that Der f 1 and Der f
2 extracts that elicited positive intradermal tests bound IgGd in ELISAs but not west¬
ern blots (Noli and others 1996). Impurities are easily identified on western blots,
where protein bands are separated by mass, but they could lead to false positive re¬
sults where proteins are not separated. This may explain the high frequency of bind¬
ing of canine atopic sera to group 1 and 2 allergens reported in a study using dot
blots and ELISAs (Masuda and others 1999).
D. farinae and D. pteronyssinus seem to be the major indoor allergens for atopic dis¬
eases in both dogs and humans. If certain proteins are held to have intrinsic aller¬
genic properties (Comoy and others 1999), it is at first sight perhaps surprising that
the spectrum of relevant allergens should differ between dogs and humans. IgE pro¬
duction is dependent on T-helper cells that recognise short sequences of 10-15 amino
acids cornpiexed with MHCII molecules. These T-cell epitopes are derived from
processing of allergen by APCs, which profoundly influences the subsequent speci¬
ficity and quantitative nature of immune responses (Carrasco-Mann and others 1998;
Maekawa and others 1998; Huby and others 2000). T-cell epitopes are also MHC
class II restricted (Renz 1995; van Neerven and others 1996). The amino and car-
boxyl termini of these peptides (peptide flanking residues), furthermore, also influ¬
ence T-cell activation (Carson and others 1999). Alterations in peptide flanking resi¬
dues can switch subsequent T-cell responses from stimulation to anergy. It is possi-
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ble that biological variation in antigen processing between individuals could yield
peptides with varying peptide flanking residues and T-cell responses. If canine
APCs, therefore, present a different array of peptides or have T-cell receptor and
MHCII repertoires that are very distinct from humans, the specificity of allergen rec¬
ognition could also differ.
Allergenic proteins tend to be ovoid, stable in the environment and possess disul-
phide bonds that contribute to the conformational stability of IgE epitopes (Smith
and others 1997; Huby and others 2000). Many allergens are also glycosylated,
which can enhance binding to IgE and increase uptake by APCs (Huby and others
2000). Furthermore, the biological activity of many allergens is thought to contribute
to their allergenicity (Huby and others 2000). Der p 1 degrades tight junctions,
cleaves al-antitrypsin, CD23 and CD25 (the IL-2 receptor), and can directly activate
mast cells and basophils (Schulz and others 1999; Wan and others 2000). This in¬
creases epithelial permeability, enhances protease activity, IgE production, inflam¬
matory mediator release and inhibits Thi differentiation (Bufe 1998; Shakib and
Gough 2000). In addition, the 98kD paramyosin Der f 11 can inhibit complement CI,
which may influence subsequent immune responses (Tsai and others 1999). The
98kD chitinase Der f 15 appears to be glycosylated, but it is unknown if any of the
allergens identified with canine sera are biologically active or what their effects in
vivo might be. It is difficult to extrapolate from studies in humans and rodents as en¬
zyme activity may be substrate restricted and species specific. Furthermore, even
though Der p 1 and Der f 1 are minor allergens in canine atopic dermatitis, it is pos¬
sible that they could affect inflammatory responses in a non-immunogenic fashion
(Schulz and others 1999). In mice, the proteolytic activity of Der p 1 enhances the
- 185-
IgE response to unrelated antigens (Gough and others 2001). Studies on the in vivo
biological activity of the 98/104kD allergen, and the effect of group 1 and 2 allergens
on canine skin are therefore warranted.
4.4.1 Dermatophagoides specific IgE in atopic and healthy canine sera
Significantly more atopic sera than healthy sera bound to allergens in all the whole
mite preparations of D. farinae and D. pteronyssinus, whereas the few sera that rec¬
ognised D. microceras were equally distributed between atopic and healthy dogs.
This suggests that IgE responses in atopic dogs are either specific to individual D.
farinae and D. pteronyssinus allergens or to cross-reacting allergens present only in
these two species. There is generally 80-90% homology between D. farinae and D.
pteronyssinus allergens (Thomas and Smith 1999). This study did not discriminate
between independent sensitisation and cross-reaction, but a cross-inhibition study
with canine sera found that D. farinae and D. pteronyssinus allergens strongly cross-
react (Masuda and others 1999). The absence of intradermal test reactivity and IgE
titres to D. pteronyssinus independent of D. farinae in this study also suggests that
separate sensitisation to D. pteronyssinus is uncommon in canine atopic dermatitis.
These results show that Dermatophagoides specific serum IgE antibodies were
largely restricted to sensitised atopic dogs. There was good correlation between skin
tests and immunoblotting among the atopic dogs, although it was not ethically possi¬
ble to perform skin tests in the healthy dogs. Using intradermal testing as the stan¬
dard to detect sensitisation, immunoblots were highly specific, but less sensitive for
detecting sensitisation to both D. pteronyssinus and D. farinae. Reasons for this
could include gel separation and blotting making allergens less available and allergen
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specific IgG blocking IgE binding. IgG was not measured in this study but generally
parallels allergen specific IgE in canine sera (Day and others 1996).
Only a few skin test negative atopic dogs had one or more positive immunoblots,
which may have been due to technical problems. They could also be genuine false
positives as allergen specific IgE has been reported in healthy dogs and skin test
negative atopic dogs (Day and others 1996; Halliwell and others 1998). A number of
healthy dogs also had Dermatophagoides specific IgE. It remains to be proven
whether these dogs develop sub-clinical sensitisation or whether there are isoforms
of canine IgE or FceRI with different binding affinities. One study reported that a
high proportion of healthy dogs have positive skin tests (Halliwell and others 1998),
suggesting that downstream mechanisms were of more importance in tolerance.
4.4.3 The allergen content of different Dermatophagoides extracts
Recognition of the D. farinae extracts by atopic sera was influenced by the source of
the allergen. The SDS-PAGE migration patterns also revealed differences in the al¬
lergen content between each extract. This could be due to variable recovery of aller¬
gens between culture and extraction protocols, but there may be significant differ¬
ences in the expression of certain allergenic proteins between the various Dermato¬
phagoides species and strains used for allergen extracts (O'Brien and others 1995;
Smith and others 1997; Le Mao and others 1998). Polymorphisms of these allergens
could also contribute to the observed variation, but it is unlikely that relatively minor
amino acid substitutions or deletions would make much difference to the SDS-PAGE
banding pattern. There was, however, no difference in binding to the different D.
pteronyssinus extracts, despite a similar variation in protein migration patterns.
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It is widely accepted that D. farinae is a more important allergen to dogs, even
though less common than D. pteronyssinus in the UK (Sture and others 1995). How¬
ever, a recent study in a warm and humid area of Brazil thought to be low in D. fari¬
nae found equal levels of Der f 1 and Der p 1 in house dust. The authors speculated
that the ostensible low prevalence of D. farinae in some studies may be due to sea¬
sonal population fluctuations (Sopelete and others 2000). The apparent importance of
D. farinae in canine dermatology could also reflect the concentration of key allergens
in widely used extracts (Thomas and Smith 1999). However, a recent study has
shown that Der f 1 and Der p 1 have different protease activity and substrate prefer¬
ences, which could influence their relative importance in different species (Pernas
and others 2000). Further work to define and standardise the allergen content of
Dermatophagoides extracts is clearly needed.
4.4.4 Allergen identification on reduced and non-reduced blots using poly¬
clonal and monoclonal anti-canine IgE
The differences in identification of major and minor allergens on reducing and non-
reducing blots suggest that results from reducing blots should be interpreted with
care. The differences in the pattern of protein migration between reducing and non-
reducing gels for each allergen extract show that reducing conditions can profoundly
affect the protein structure of Dermatophagoides allergens. For example, reducing
conditions increased the apparent size of the purified group 1 and 2 allergens by ap¬
proximately 5-10kD in this and prior studies (Lombardero and others 1990). Reduc¬
ing agents also denature IgE epitopes (Lombardero and others 1990). Despite this,
there were no significant differences in the numbers of atopic and healthy sera that
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bound to reducing and non-reducing blots of each allergen, suggesting that both
techniques are equally sensitive.
Both polyclonal and monoclonal anti-canine IgE antibodies were used in this study.
Monoclonal reagents are generally regarded as more specific, whereas polyclonal
reagents can be more sensitive (Steward and Male 1998). Nevertheless, there was no
significant difference in sensitivity or specificity between the antisera in detecting
Dermatophagoides specific IgE in atopic and healthy canine sera.
4.4.5 Conclusion
This study has shown that major Dennatophagoides allergens in canine atopic der¬
matitis are restricted to proteins greater than 95kD. Group 1 and 2 allergens appear to
be of limited importance. Using purified and standardised major and minor allergens
will be important in understanding the role of mononuclear cells, identifying immu¬
nodominant peptides and in the diagnosis and treatment of canine atopic dermatitis.
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5. Isolation and culture of canine peripheral
blood mononuclear cells
5.1 Introduction
Lymphocyte responses to specific allergens can be investigated by isolating and cul-
turing PBMCS, which are separated from erythrocytes and granulocytes by density
centrifugation over 1.077 (human) - 1.083 (rodent) g/L ficoll solutions (Steward and
Male 1998). Density centrifugation over 1.077 g/L ficoll has been used to isolate ca¬
nine PBMCs in a number of studies (Kristensen and others 1982a; Martinez-Moreno
and others 1995; Corato and others 1997; Poitout and others 1997). However, other
studies report that density centrifugation results in contamination with granulocytes,
which in dogs have a similar density to PBMCs (Letwin and Quimby 1987; Rivas
and others 1995). These authors used carbonyl iron, which is taken up by phagocytes,
to eliminate neutrophils. However, this also depletes up to two-thirds of the mononu¬
clear phagocytic cells that are necessary for antigen presentation in PBMC cultures
(Krakowka and Ringler 1985).
A preliminary investigation was therefore undertaken to compare PBMC yield and
responses to mitogen and specific antigens after density centrifugation with and
without carbonyl iron treatment.
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5.2 Materials and Methods
5.2.1 PBMC isolation and culture
Atopic (n=16) and healthy dogs (n=16) were recruited according to the criteria de¬
scribed in Chapter 2.1. Blood samples were collected as described in Chapter 2.2.2.
Each sample was diluted 1:1 with sterile citrated PBS. Half of each diluted sample
was incubated with 20mg/ml carbonyl iron (Sigma) in an Erlenmeyer flask with gen¬
tle mixing at 37°C for one hour. The other half was stored at 4°C.
PBMCs were isolated from each sample and cultured as previously described (Chap¬
ter 2.6). lxlO5 cells were cultured in 200pl volumes with tenfold dilutions of ConA
from 0.0005-50pg/ml and 1/10-1/100,000 dilutions of Bordetella bronchiseptica (In-
trac®), canine parvovirus (Nobivac ParvoC®), Leptospira (Nobivac L®) and mixed
canine distemper, parainfluenza, adenovirus and parvovirus (DHPPi) (Nobivac
DHPPi®) vaccine antigens. Duplicate plates were cultured for three and five days
(ConA) or five and seven days (vaccine antigens).
5.2.2 Data analysis
Cell proliferation was assessed as previously described (Chapter 2.6.2.3). PBMC pro¬
liferation was expressed as a delta count; i.e. (mean cpm per test wells - mean cpm
background wells) - (mean cpm resting wells - mean cpm background wells).
Unpaired t-tests with Welch's correction for unequal variance (Instat®) were used to
compare the PBMC yield and proliferation between atopic and healthy blood samples
incubated with and without carbonyl iron.
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5.3 Results
5.3.1 Overall cell yield and viability
The total cell yield per ml of blood varied from 0.72 - 2.5 xlO6 cells/ml of blood for
samples without carbonyl iron and from 0.3 - 1.82 xlO6 cells/ml for those incubated
with carbonyl iron. Significantly fewer cells were isolated by density centrifugation
after incubation with carbonyl iron (p<0.05) (Table 5.1 and Figure 5.1). In all cases
the viability of the isolated cells exceeded 95%.
Table 5.1 - Cell yields after PBMC isolation from whole blood
Mean (SD) yield x10e cells/ml blood





Figure 5.1 - Total number of PBMCs isolated with and without prior incuba¬
tion with carbonyl iron
■I Without carbonyl iron (n=16)
















Prior incubation of whole blood with carbonyl iron significantly increased the pro¬
portion of lymphocytes and decreased contamination with neutrophils in the PBMC
populations (p<0.05) (Table 5.2 and Figure 5.2). The percentage yields of monocytes
and eosinophils were also reduced, although the differences were not significant.
However, the mean number of lymphocytes and monocytes significantly declined
from 1.2 to 0.79 x 106 cells/ml of blood after treatment with carbonyl iron (p<0.05).
Table 5.2 - PBMC cell population with and without prior incubation with car¬
bonyl iron
Mean (SD) percentage of PBMCs
Lymphocytes Monocytes Neutrophils Eosinophils
Without carbonyl 60.7 7.9 25.1 6.4
iron (n=16) (15.6) (5.7) (15.4) (12.1)
With carbonyl 83.5 5.4 9.4 1.7
iron (n=16) (7.5) (3.4) (5.6) (2.2)
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Figure 5.2 - PBMC populations isolated from whole blood by density centrifu-
gation over 1.077g/L ficoll





















5.3.3 PBMC responses to ConA
Dose response curves to ConA were established for PBMC cultures at three and five
days (Table 5.3a and b; Figure 5.3a and b). At each concentration the PBMCs iso¬
lated after incubation with carbonyl iron exhibited less proliferation than the corre¬
sponding PBMCs isolated without carbonyl iron. Optimum responses were seen with
0.5pg/ml ConA. At this concentration PBMCs isolated without carbonyl iron had a
significantly greater response at both days three and five compared to those isolated
with carbonyl iron (p<0.05). There were, however, no significant differences in the
response to ConA between PBMC cultures from atopic and healthy dogs, or between
three and five day cultures.
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Figure 5.3 - Responses to ConA in PBMC cultures isolated with and without
prior incubation with carbonyl iron
a - Day three of culture
Healthy dogs with carbonyl iron
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5.3.4 PBMC responses to vaccine antigens
Vaccine antigen specific PBMC proliferation was assessed at days five and seven of
culture. The response to all the vaccines at day five was very low (Table 5.4a-d; Fig¬
ure 5.4 a-d). Furthermore, there were no significant differences between atopic and
healthy PBMCs or PBMCs isolated with and without carbonyl iron.
Proliferation after seven days of culture was much higher for all the vaccine extracts
(Table 5.5a-d; Figure 5.5a-d). Nevertheless, the response to the Leptospira vaccine
was still very poor, whether or not the PBMCs had been isolated after carbonyl iron
incubation. For the other vaccines, the proliferative response of PBMCs isolated
without carbonyl iron was higher than for PBMCs isolated with carbonyl iron. Opti¬
mum proliferation was seen with a 1/100,000 dilution of DHPPi, a 1/10,000 dilution
of canine parvovirus and a 1/10 dilution of B. bronchiseptica. At these concentra¬
tions, the proliferation of PBMCs isolated without carbonyl iron was significantly
greater than PBMCs isolated with carbonyl iron for parvovirus and B. bronchiseptica
(p<0.05), but not for DHPPi. The PBMC response to all the vaccines at day seven
was very variable between individuals, some of which did not show any responses to
one or more of the vaccines. There were, however, no significant differences in the
responses between PBMCs isolated from atopic or healthy dogs.
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Table 5.4 - PBMC responses to vaccine antigens at day five of culture
a - DHPPi
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=5) (n=5) (n=5) (n=6)
1/10 80 8 0 143
(179) (19) (0) (200)
1/100 75 23 0 809
(106) (51) (0) (1614)
1/1000 193 158 452 530
(240) (354) (887) (1077)
1/10,000 336 475 538 464
(290) (632) (1078) (585)
1/100,000 461 415 988 43
(391) (362) (995) (67)
b - Parvovirus
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=5) (n=5) (n=5) (n=6)
1/10 63 9 28 1 c s1JU
(141) (21) (68) (143)
1/100 654 358 336 225
(1429) (498) (588) (292)
1/1000 582 91 735 127
(692) (203) (1215) (473)
1/10,000 953 336 262 1069
(911) (559) (304) (1549)
1/100,000 702 197 560 1224
(308) (277) (749) (1676)
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Table 5.4 contd. - PBMC responses to vaccine antigens at day five of cul¬
ture
c - B.bronchiseptica
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=5) (n=5) (n=5) (n=6)
1/10 669 67 930 872
(803) (71) (765) (1476)
1/100 451 75 762 1758
(507) (59) (2853) (1371)
1/1000 413 133 1558 513
(528) (173) (664) (1856)
1/10,000 369 150 789 383
(553) (210) (667) (818)
1/100,000 543 104 341 482
(701) (222) (977) (302)
d - Leptospira
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=5) (n=5) (n=5) (n=6)
1/10 0 0 0 47
(0) (0) (0) (106)
1/100 0 0 0 10
(0) (0) (0) (23)
1/1000 0 0 0 4
(0) (0) (0) (8)
1/10,000 13 60 0 81
(31) (134) (0) (157)
1/100,000 449 138 0 227
(503) (257) (0) (349)
- 200-
Table 5.5 - PBMC responses to vaccine antigens at day seven of
culture
a - DHPPi
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=6) (n=5) (n=8) (n=8)
1/10 0 0 6 61
(0) (0) (16) (173)
1/100 0 6 129 45
(0) (13) (366) (76)
1/1000 161 73 624 268
(336) (163) (956) (335)
1/10,000 925 62 2395 1766
(1337) (136) (2910) (2452)
1/100,000 1687 0 2801 3644
(2524) (0) (2901) (5063)
b - Parvovirus
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyi iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=6) (n=7) (n=8) (n=8)
1/10 745 28 0 198
(1190) (67) (0) (378)
1/100 725 220 553 673
(610) (382) (1484) (1081)
1/1000 659 295 1699 2161
(1006) (378) (1860) (2485)
1/10,000 857 520 4043 3668
(1179) (821) (3980) (3872)
1/100,000 1453 259 3616 3126
(2935) (335) (2524) (3549)
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Table 5.5 contd. - PBMC responses to vaccine antigens at day seven of
culture
c - B. bronchiseptica
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=6) (n=7) (n=8) (n=8)
1/10 234 196 5080 6025
(380) (441) (3426) (8676)
1/100 877 209 4387 7199
(1731) (489) (3968) (13752)
1/1000 122 219 3932 2547
(163) (513) (3921) (4581)
1/10,000 30 473 1095 1388
(46) (1048) (1474) (1949)
1/100,000 8 66 1811 681
(18) (141) (1952) (966)
d - Leptospira
Vaccine Mean (SD) PBMC delta counts (cpm)
dilution With carbonyl iron Without carbonyl iron
Atopic Healthy Atopic Healthy
dogs dogs dogs dogs
(n=6) (n=6) (n=8) (n=7)
1/10 0 0 0 0
(0) (0) (0) (0)
1/100 0 133 0 0
(0) (326) (0) (0)
1/1000 0 0 0 133
(0) (0) (0) (353)
1/10,000 0 0 1691 319
(0) (0) (4270) (652)
1/100,000 366 19 2298 887
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5.4.1 PBMC responses to ConA
Variable responses to mitogens have been previously reported in canine PBMC cul¬
tures (Helfand and others 1992), but all the PBMC cultures in this study exhibited
robust responses to ConA. This stimulates T-cell proliferation in a manner that
closely mimics antigen stimulation, and is used to demonstrate that PBMCs are ca¬
pable of in vitro proliferation (Lydyard and Grossi 1998). There were no significant
differences between the dose response curves to ConA established for PBMCs iso¬
lated from atopic and healthy dogs at both three and five days. This shows that
PBMCs isolated from both groups of dogs behave in similarly in vitro. Any differ¬
ences in later experiments, therefore, are likely to be allergen specific.
5.4.2 PBMC responses to vaccine antigens
The vaccine antigens were used to demonstrate that the PBMC cultures were capable
of an antigen specific recall response in vitro. Only limited PBMC proliferation was
seen after five days of culture. Proliferation after seven days, however, was much
greater, with marked differences emerging between PBMCs isolated with and with¬
out carbonyl iron. Significantly greater responses to B. bronchiseptica and parvovi¬
rus were seen in the PBMCs isolated without carbonyl iron in both healthy and
atopic dogs. This indicates these antigens are capable of stimulating a recall re¬
sponse. Although the responses were quite variable between individual dogs, these
findings further indicate that PBMCs isolated from atopic and healthy dogs are capa¬
ble of quantitatively similar antigen specific responses in vitro. In contrast, responses
to Leptospira were still low after seven days and responses to DHPPi were highly
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No significant differences, furthermore, were observed in the response to these two
antigens between any of the groups of PBMCs.
Both atopic and healthy dogs are likely to have been exposed to these antigens. Lep¬
tospira, parvovirus and DHPPi are commonly included in canine vaccination proto¬
cols. Vaccination with a live attenuated strain of B. bronchiseptica is commonly per¬
formed prior to entry into boarding kennels. Most of the atopic and healthy dogs in
this study had received at least one primary course of vaccination, but it was not al¬
ways clear whether they had received booster vaccinations or been vaccinated against
B. bronchiseptica according to the data sheet recommendations. Natural exposure to
B. bronchiseptica, adenovirus 1 and parainfluenza (in DHPPi) is common in domes¬
tic and kennelled dogs, but natural and vaccine immunity wanes after 6-12 months
(Ford and Vaden 1990). Infection with distemper and parvovirus is relatively un¬
common, but naturally acquired and vaccine immunity is robust for at least 12
months (Hoskins 1990). However, distemper virus has been reported to inhibit ca¬
nine PBMC proliferation in vitro (Kristensen and others 1982b). Leptospira and
DHPPi, therefore, are probably unsuitable as recall stimuli. A previous study using
vaccine antigens in canine PBMC cultures also reported a variable response (Corato
and others 1997). This may be due to sub-optimal culture conditions or cytopathic
effects, although the cultures in that and the present study that did respond did so
very well. No reliable and universal recall antigen has been established in dogs and
the effects of vaccination and natural exposure on the cellular responses to these an¬
tigens are unclear.
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5.4.3 The effect of incubation with carbonyl iron on PBMC yield and culture
Prior incubation with carbonyl iron significantly reduced PBMC responses to both
the non-specific mitogen ConA and specific vaccine antigens, making this technique
unsuitable for studying canine PBMC proliferation. This may be due to depletion of
phagocytic monocytes, which are necessary for PBMC proliferative responses to mi¬
togens or antigens in vitro (Hogenesch and Felsburg 1989). B-cells may also act as
APCs in culture, but at least 4% monocytes are considered necessary for in vitro
PBMC proliferation (Letwin and Quimby 1987). The mean yield in this study after
carbonyl iron treatment was 5.4%, which is close to this minimum figure. In addition,
ingestion of particulate iron, or trace amounts carried over from the washing steps,
could inhibit in vitro antigen presentation and subsequent cell proliferation. These
findings are in contrast to a previous study where prior incubation with carbonyl iron
increased the PBMC response to ConA (Krakowka and Ringler 1985). However, al¬
though the response to ConA in PBMCs isolated with carbonyl iron was similar to
that in the present study, the response in PBMCs isolated without carbonyl iron was
only 20% of that reported here.
In line with previous findings (Letwin and Quimby 1987; Rivas and others 1995),
density centrifugation over 1.077g/L ficoll gave rise to a degree of granulocyte con¬
tamination. However, as terminally differentiated cells these shouldn't contribute to
cell proliferation. Release of cytokines and other mediators could affect PBMC re¬
sponses, but whole blood stimulation assays have been used to investigate cell medi¬
ated immunity in canine leishmaniosis (Martinez-Moreno and others 1995) and there
is no significant difference in proliferation or cytokine production between whole
blood and PBMC responses to mitogens in humans (Yaqoob and others 1999). Other
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authors have advocated the use of 62.5% Percoll® (Amersham-Pharmacia Biotech,
Amersham, UK) (Wagner and others 1999) (S.C. Bell, University of Liverpool, per¬
sonal communication). However, in the author's hands this technique led to very
poor cell yields (<2.0 xlO5 cells/ml of blood) and viability {<15%) and was not ex¬
plored further.
Cell yields using both techniques were considerably lower than circulating leucocyte
populations in dogs (6-15 xl06/ml; reference range, Royal [Dick] School of Veteri¬
nary Studies Clinical Laboratory, University of Edinburgh), suggesting a consider¬
able number of cells are lost during density centrifugation over 1.077g/L ficoll. Fur¬
thermore, the number of cells isolated after carbonyl iron incubation was 0.89
xl06/ml. This is lower than the reference range for lymphocytes (1.0-6.0 xl06/ml),
suggesting that there is also loss of mononuclear cells with this technique. Neverthe¬
less, the viability of the isolated cells exceeded 95% and density centrifugation ap¬
pears to be a reliable technique for the isolation of viable canine PBMCs.
5.4.4 Conclusion
This study has shown that incubation of whole blood with carbonyl iron reduces neu¬
trophil contamination of PBMC populations, but as it also inhibits in vitro prolifera¬
tive responses, is not suitable for investigating PBMC proliferation. ConA is an ap¬
propriate non-specific stimulus to ensure that canine PBMCs are capable of in vitro
proliferation, whereas canine parvovirus and B. bronchiseptica can be used to assess
their ability to mount an antigen specific recall response. Antigen specific responses
appear to require seven days of culture using these protocols.
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6. Peripheral blood mononuclear cell re¬
sponses to Dermatophagoides species aller¬
gens in canine atopic dermatitis
6.1 Introduction
Canine atopic dermatitis has been viewed as an IgE/mast cell mediated disease (Scott
and others 2001a). However, IgE production is dependent on allergen specific CD4+
Th cells (Lydyard and Grossi 1998) and infiltration of CD4+ and CD8+ lymphocytes
is observed in lesional atopic skin in both dogs (Olivry and others 1997) and humans
(Leung 2000). Several studies in humans have demonstrated PBMC proliferation to
crude Dermatophagoides extracts and purified allergens (Leung 2000). In one un¬
published study, PBMCs isolated from dogs with atopic dermatitis proliferated in
response to both a crude D. pteronyssinus extract and the 98/104kD major allergen,
but not Der p 1 or Der p 2 (Shaw 2000).
The aim of this study was to determine if allergen specific T-cells were involved in
the pathogenesis of canine atopic dermatitis by investigating PBMC responses to D.
farinae in dogs with atopic dermatitis that were skin test positive to D. farinae, skin
test negative to D. farinae and healthy dogs. The study also compared the responses
of PBMCs from dogs with atopic dermatitis to group 1 and 2 allergens and the
98/104kD major allergen purified from D. farinae, as well as to crude extracts of D.
farinae, D. pteronyssinus and D. microceras.
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6.2 Materials and Methods
6.2.1 Isolation of the 98/104kD major allergen from D. farinae
The 98/104kD D. farinae major allergen (discussed in Chapter 4.4) was purified
from the crude Greer D. farinae extract by high-pressure liquid chromotography
(Waters 486/600S/626 system; Waters-Millipore, Macclesfield, UK) carried out by
A.D. Pemberton, The University of Edinburgh Department of Veterinary Clinical
Studies. Twenty fractions were collected into sterile PBS and separated by SDS-
PAGE using individual wells (Chapter 2.4). Western blots of these gels were probed
with a single positive serum sample and imaged as described in Chapter 2.5. The
98/104kD fraction was diluted to lmg/ml in sterile PBS and stored at -20°C as de¬
scribed in Chapter 2.3.
6.2.2 PBMC isolation and culture
Atopic (n=30) and healthy dogs (n=10) were recruited according to the criteria de¬
scribed in Chapter 2.1. Blood samples were collected as described in Chapter 2.2.2.
PBMCs were isolated from each sample and cultured as previously described (Chap¬
ter 2.6). IxlO5 cells were cultured in 200p! volumes with tenfold dilutions of the
Greer D. farinae extract from 500-0.05pg/ml. In the second part of the study, 1x10s
cells were cultured in 200pl volumes containing 50pg/ml of the Greer D. farinae,
Greer D. pteronyssinus and ALK D. microceras extracts, and 5.0pg/ml of the ALK
Der f 1, ALK Der f 2 and the 98/104kD major allergen purified from the Greer D.
farinae. Positive control wells with 0.5pg/ml ConA, 1/10 dilution of B. bronchisep-
tica (Intrac®) and 1/10,000 dilution of canine parvovirus (Parvo C®) were included in
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each plate. lxlO5 cells in 200|Ltl of medium and wells with 200pl medium only were
included as negative controls and background respectively (Chapters 2.6 and 5.4).
6.2.3 Data analysis
Cell proliferation was assessed as previously described (Chapter 2.6.2.3). PBMC
proliferation was expressed as: (mean cpm per test wells - mean cpm background
wells) - (mean cpm resting wells - mean cpm background wells). One-way analyses
of variance with Tukey's post tests were used to compare cell proliferation between
groups (Instat®). Significance was set at p<0.05.
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6.3 Results
6.3.1 Intradermal tests (IDT)
For the first part of the study, dogs with a clinical diagnosis of atopic dermatitis were
divided into those with a positive IDT for D. farinae (n=10), and those with a nega¬
tive IDT (n=7). In the second set of experiments all of the 13 atopic dogs had a posi¬
tive IDT for D. farinae and D. pteronyssinus. Individual responses were occasionally
seen to variety of other mite, insect, epidermal, pollen and mould allergens, although
none were noted in the IDT negative group.
6.3.2 Purification of the 98/104kD major allergen from D. farinae
On the basis of the protein migration patterns after SDS-PAGE, it appeared that the
98/104kD major allergen co-purified in two out of the 20 fractions with a 128kD pro¬
tein. Western blots with a single strongly positive serum sample, however, revealed
that the IgE binding to these fractions was specific for the 98/104kD major allergen
(Figure 6.1).
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Figure 6.1 - Purification of the 98/104kD major allergen from D. farinae
a - Western blot (reducing buffer)
1 2 3 4 5 6 7
BT
fl".. ..
b - Immunoblot (non-reducing buffer)
Lane 1 - molecular weight markers (kD; Biorad broad range); lane 2 - fraction 1; lane
3 - fraction 2; lane 4 - fraction 3; lane 5 - fraction 4; lane 6 - fraction 5; lane 7 - frac¬
tion 6. Coomassie blue stain.
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6.3.3 PBMC yield and responses to control stimuli
The protocols used in this study yielded a mean population of 83% PBMCs with
greater than 95% viability. PBMCs from atopic and healthy dogs had comparable
responses to the control stimuli in both parts of the study (see Table 6.1). However,
whilst all the PBMC cultures responded to ConA, only 9/23 IDT positive, 3/7 IDT
negative and 6/13 healthy dogs had a response greater than lOOOcpm above resting to
canine parvovirus, and only 10/23 IDT positive, 6/7 IDT negative and 8/13 healthy
dogs responded to B. bronchiseptica.
Table 6.1 - Peripheral blood mononuclear cell responses to ConA and vac¬
cine antigens
DF - Dermatophagoides farinae; sd - standard deviation; cpm - counts per minute
(for conA, Bordetella bronchiseptica and Parvovirus expressed as [test wells-
background] minus [resting wells-background]).
a - Part one of the study (Chapter 6.3.4)
Mean (sd) dellta counts (cpm)
Resting ConA Bordetella Parvovirus
DF positive atopic i909 49935 5736
^ ah r
jy j D
dogs (n=10) (1848) (23178) (6535) (4485)
DF negative 1144 38830 2541 3629
atopic dogs (n=7) (883) (20880) (3564) (3704)
Flealthy dogs 1176 45587 2901 2979
(n=10) (1314) (32037) (4418) (3787)
b - Part two of the study (Chapters 6.3.5 and 6.3.6)
Mean (sd) dell a counts (cpm)
Resting ConA Bordetella Parvovirus
Dogs with atopic 2562 49571 1295 2013
dermatitis (n=13) (1618) (20307) (3823) (2799)
Flealthy dogs 2101 27354 168 0
(n=3) (2013) (12235) (291) (0)
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6.3.4 PBMC responses to D. farinae in atopic and healthy dogs
Dose response curves to D. farinae were established for PBMCs isolated from atopic
dogs with positive IDT reactions, atopic dogs with negative IDT reactions and
healthy dogs. PBMCs from the IDT positive atopic dogs (n=10) showed greater pro¬
liferation to all concentrations of the D. farinae extract than did PBMCs from either
IDT negative atopic dogs (n=7) or healthy dogs (mMO) (Figure 6.2). Optimum pro¬
liferation was seen with 50pg/ml D. farinae. At this concentration there was signifi¬
cantly greater proliferation ofPBMCs from the IDT positive dogs with atopic derma¬
titis than either the IDT negative dogs with atopic dermatitis or healthy dogs
(p<0.05). There was no significant difference between the latter two groups.
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Figure 6.2 - PBMC responses to D. farinae in atopic and healthy dogs
# - Atopic dogs with positive IDT reactions to D.farinae (n=10);B - atopic dogs with
negative IDT reactions (n=7); A- healthy dogs (n=10); cpm - counts per minute (ex¬
pressed as [mean cpm test wells - background] - [mean cpm resting wells - back¬
ground]); bar - sem; * - p<0.05
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6.3.5 PBMC responses to D. farinae, D. pteronyssinus and D. microceras in
dogs with atopic dermatitis
There was significantly greater proliferation in the PBMC cultures from dogs with
atopic dermatitis (n=13) to the crude extracts ofD. farinae and D. pteronyssinus than
to the crude extract of D. microceras (p<0.05). There were, however, no significant
differences between the responses to D. farinae and D. pteronyssinus (Table 6.2 and
Figure 6.3). None of the control PBMCs isolated from three healthy dogs responded
to any of the crude Dermatophagoides extracts.
Table 6.2 - In vitro responses of PBMCs isolated from dogs with atopic der¬
matitis and healthy dogs to crude and purified Dermatophagoides allergens
sd - standard deviation; cpm - counts per minute (expressed as [mean cpm test wells
- background] - [mean cpm resting wells - background]).
Allergen
Mean delta counts (cpm) (sd; number of dogs)
Atopic dermatitis Healthy dogs
Dermatophagoides farinae 9288 (3926; 13) 630 (1091; 3)
D. pteronyssinus 11111 (9309; 13) 418 (632;3)
D. microceras 2003(2767;13) 77(132; 3)
98/104kD D. farinae allergen 5517 (2945; 7) 0 (0; 3)
Derf 1 1570(1422; 11) 36 (62; 3)
Der f 2 252 (325; 11) 0 (0; 3)
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Figure 6.3 - PBMC responses to D. farinae, D. pteronyssinus and D. micro-
ceras dogs with atopic dermatitis (n=13) and healthy dogs (n=3)
■ - D. farinae, ■ - D. pteronyssinus; ■ - D. microceras, cpm - counts per minute
expressed as (mean test wells - background) - (mean resting wells - background);




6.3.6 PBMC responses to major and minor D. farinae allergens in dogs with
atopic dermatitis
When PBMCs isolated from dogs with atopic dermatitis dogs were incubated with
purified D. farinae extracts, there was significantly greater response to the 98/104kD
allergen than to either Der f 1 or Der f 2 (p<0.05). There was no significant differ¬
ence between the responses to Der f 1 and Der f 2 (Table 6.2 and Figure 6.4). None
of the PBMCs isolated from three healthy dogs reacted to the purified allergens.
-220-
Figure 6.4 - PBMC responses to major and minor allergens purified from D.
farinae
■- 98/104kD major allergen (atopic dogs n=7; healthy dogs n=3); ■ - Der f 1 (atopic
dogs n—11; healthy dogs n=3); ■ - Der f 2 (atopic dogs n=l 1; healthy dogs n=3);
Solid bars - atopic dogs; hatched bars - healthy dogs; cpm - counts per minute, ex¬
pressed as (mean test wells - background) - (mean resting wells - background); bar










6.4.1 PBMC responses to D. farinae in canine atopic dermatitis
To the author's knowledge these results document for the first time the presence of
circulating D. farinae specific T-cells in canine atopic dermatitis. PBMC responses
to a crude D. farinae extract under optimum conditions were significantly greater in
atopic dogs with positive IDT reactions to D. farinae than in either IDT negative
atopic dogs or healthy dogs. This suggests that circulating T-cell responses to D.
farinae are greater in sensitised dogs, supporting a role for allergen specific T-cells
in the pathogenesis of canine atopic dermatitis. Furthermore, the association of D.
farinae specific PBMC proliferation with skin test reactivity implies that these cells
are supporting specific IgE production (Lydyard and Grossi 1998).
6.4.2 PBMC responses to major and minor D. farinae allergens in canine
atopic dermatitis
This study also demonstrated that memory T-cells in canine atopic dermatitis are
specific to the 98/104kD allergen purified from I), farinae, rather than to Der f 1 or
Der f 2. This is in contrast to humans, where T-ceiis from 80% or more of atopic pa¬
tients will respond to group 1 and 2 allergens (Thomas and others 1998a), but similar
to a study in which T-cells from atopic dogs responded to a 98kD allergen purified
from D. pteronyssinus, but not Der p 1 or Der p 2 (Shaw 2000). Immunoblotting
studies have also shown that the 98/104kD protein is a major Dermatophagoides al¬
lergen in canine atopic dermatitis, whereas group 1 and group 2 proteins appear to be
minor allergens (Noli and others 1996; McCall and others 2000; Nuttall and others
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2001a). Possible explanations for the variation in major and minor allergens between
canine and human atopic dermatitis were discussed in Chapter 4.4.
Canine T-cell responses appear, therefore, to strongly correlate with IgE levels, sug¬
gesting that they support specific IgE production. This, however, is not necessarily
the case in humans, where the frequency of T-cell responses to the minor allergen
Der p 7 are comparable with those to the major allergen Der p 1 (Thomas and others
1999). The authors of this study speculate that Der p 7 might act in an IgE independ¬
ent manner.
6.4.3 Comparative PBMC responses to D. farinae, D. pteronyssinus and D.
microceras
PBMCs isolated from dogs sensitised to D. farinae and D. pteronyssinus showed sig¬
nificantly greater responses to the crude D. farinae and D. pteronyssinus extracts,
than to the crude D. microceras extract. It was not possible to skin test the atopic
dogs with the D. microceras extract, but an earlier study (Nuttall and others 2001a)
demonstrated that canine serum IgE specific to D. farinae and D. pteronyssinus did
not bind to western blots of D. microceras. These results suggest that both B- and T-
cell epitopes are either specific to individual D. farinae and D. pteronyssinus aller¬
gens or to cross-reacting allergens present only in these two species, as discussed in
Chapter 4.4.
It is widely accepted that D. farinae is a more important allergen to dogs, even
though less common than D. pteronyssinus in the UK (Sture and others 1995). An
Australian study in humans also found that T-cell responses to D. farinae matched
those to D. pteronyssinus despite a similar paucity of D. farinae in the environment
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(Thomas and others 1999). However, a recent survey in an area of Brazil thought to
be low in D. farinae found equal levels of Der f 1 and Der p 1 in house dust (Sope-
lete and others 2000). Another study found that indoor Der f 1 and Der p 1 levels
were only weakly correlated, and were highly variable both within and between geo¬
graphical areas (Gross and others 2000). Interestingly, high levels of Der f 1 in this
study were associated with the presence of a dog, raising the possibility of a specific
relationship between these species. However, the apparent predominance of D. fari¬
nae in canine dermatology could reflect the allergen concentration in extracts widely
used for IDTs and serology, as discussed in Chapter 4.4.
6.4.4 PBMC responses to D. farinae in IDT negative atopic dogs
A few D. farinae negative atopic dogs did have appreciable PBMC responses to D.
farinae. This could have been due to false negative skin tests (due to poor technique,
degraded allergens, anti-inflammatory medication etc.). This, however, is unlikely as
these were performed by experienced dermatologists (R.E.W. Halliwell, K.L. Tho-
day, P.B. Hill, A.W. Carter, P. Forsythe and S. Colombo; Dermatology Service Uni-
u c— o 11 a i„\ ta; j *. „ u ~i ~ ~
vcibiiy vji jl/Uiiiuuigii rau^jjiicii iui oiiiaii 2-viimia.isj. i^i^uvjiucuu ic^pvjiibcb tuuiu uimj
be due to false positive PBMC proliferation assays, although cultures where prolif¬
eration of the resting cells was similar to the positive controls were discarded.
An alternative hypothesis is that these dogs have a predominantly cell-mediated im¬
mune response to D. farinae with circulating cells of a Tni-type phenotype. In one
mouse model of atopic dermatitis, CD8+ and CD4+ T-cell infiltration could be in¬
duced in the absence of an IgE response (Spergel and others 1999). This suggests
that allergen specific type IV hypersensitivity can develop in some individuals. Al-
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lergen specific type IV responses, however, have also been associated with protective
immunity in humans (Maggi 1998). Despite this, the distribution of clinical signs and
epidermal focussing of Langerhans' cells and lymphocytes in canine atopic dermati¬
tis are evidence of percutaneous allergen uptake (Olivry and others 1997). It is possi¬
ble some dogs develop a type IV hypersensitivity reaction akin to contact dermatitis
rather than an IgE response (Kalish and Askenase 1999). A recent report speculated
that skin lesions in canine atopic dermatitis are triggered and maintained by allergen
specific type IV inflammatory reactions, although IgE was considered important in
initial sensitisation (Sinke and others 2002). Late phase inflammatory responses and
chronic lesions in human atopic dermatitis are also dominated by THi-type cell-
mediated reactions (Thepen and others 1996). It is unclear if these are allergen spe¬
cific or not (Cooper 1994), but if cell-mediated immunity plays role in the patho¬
genesis of atopic dermatitis, some individuals could have allergic atopic dermatitis
without the production of serum antibodies. Diagnostic tests such as intradermal or
skin prick tests and serology might not, therefore, be appropriate for all patients. The
role of THi cells and cell-mediated immune responses in canine atopic dermatitis
clearly needs further study.
6.4.5 PBMC responses to D. farinae in healthy dogs
There was very little response to D. farinae in PBMCs from healthy dogs, even
though most individuals should be exposed to ubiquitous allergens such as house
dust mites. A low level of reactivity is also reported in PBMCs from healthy humans
(Horneff and others 1996). However, PBMC responses to Der p 1 have been detected
in both atopic and healthy humans using serum free media (Upham and others 1995;
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Kawamura and others 1998). This suggests that serum components selectively inhibit
proliferation of PBMCs from healthy individuals. No serum free medium has been
evaluated for canine PBMC cultures, so it remains to be seen if widespread responses
to ubiquitous allergens occur in dogs.
Poor responses in allergen specific PBMC proliferation assays may also be due to
peripheral tolerance. It is thought that allergen specific T-regulatory cells producing
IL-10 and TGF(3 inhibit inflammatory responses in healthy individuals (Muraille and
Leo 1998; Hoyne and others 2000; Koulis and Robinson 2000). These cells may also
limit in vitro responses to allergens in PBMCs isolated from those subjects. The role
of IL-10 and TGF(3 in canine atopic dermatitis is explored in Chapter 7.
6.4.6 Responses to control stimuli and cell yield
It is unlikely that these results reflect differential mitogenic activity in the Dermato-
phagoides extracts, as PBMCs from healthy dogs did not respond to any of the ex¬
tracts, despite comparable responses to ConA, canine parvovirus and B. bronchisep-
tica. Inhibition by any of the extracts is also unlikely as some PBMC cultures did re¬
spond and all are routinely used in other studies (G.Nordskov Hansen; ALK, H0r
sholm, Denmark, personal communication). All the PBMC cultures in this study re¬
sponded to ConA, which stimulates T-cell proliferation in a manner that closely
mimics antigen stimulation (Lydyard and Grossi 1998). This demonstrates that
PBMCs from all three groups of dogs were capable of quantitatively similar re¬
sponses. Vaccine antigens were used to demonstrate that the PBMC cultures were
capable of specific recall responses. However, despite similar responses in all three
groups, the majority of PBMC cultures responded poorly. This may be due to sub-
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optimal culture conditions or cytopathic effects, although, as described in Chapter 5,
the cultures that did respond did so very well. No reliable and universal recall antigen
has been established in dogs (Corato and others 1997) and the effects of vaccination
and natural exposure on PBMC responses are unclear.
It was not possible to phenotype the reactive cells in this study. Canine PBMC popu¬
lations vary between individuals, but are approximately 15-30% B-cells, 25-50%
CD4+ T-cells and 20-40% CD8+ T-cells (Kristensen and others 1982a; Rivas and
others 1995). Granulocytes are also frequent as canine PBMCs and granulocytes
have very similar densities (Letwin and Quimby 1987) and are difficult to separate
by density centrifugation (Chapter 5). PBMC cultures in this study included 5-25%
granulocytes, although these cells shouldn't contribute to overall cell proliferation as
discussed in Chapter 5.4.
Both B- and T-cells could contribute to cell proliferation, although B-cells require
interaction with activated CD4+ TH cells (Lydyard and Grossi 1998). Most of the re¬
sponse to the Dermatophagoides allergens seen in this study should be due to CD4+
cells, particularly as exogenous antigens are usually presented by APCs in the con¬
text of an MHCII molecule to CD4+ cells (Kalish and Askenase 1999). However, ex¬
ogenous antigens can also be presented in the context of MHCI molecule to CD8+
cells (Kalish and Askenase 1999). Furthermore, CD8+ cells can provide help for B-
cell activation and differentiation in certain circumstances (Kemeny 1998), so it is
difficult to make conclusions about the relative contributions of allergen specific
CD8+ and CD4+ cells in PBMC proliferation assays.
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6.4.7 Conclusions
In conclusion, this study has shown that PBMC responses to D. farinae allergens are
specific to D. farinae sensitised atopic dogs. The T-cell responses in this study have
also confirmed serological data that a 98/104kD allergen, rather than Der f 1 or Der f
2, is the most important D. farinae allergen in canine atopic dermatitis. This strongly
suggests that allergen specific circulating T-cells are involved in the pathogenesis of
canine atopic dermatitis. Investigating the cytokine responses induced by D. farinae
in PBMC cultures should shed further light on the role of Thi/Th2 deviation and pe¬
ripheral tolerance in atopic and healthy dogs. Studies of the allergenic nature of the
98/104kD protein will also further our understanding of the relationship between al¬
lergens and skin disease.
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7. The expression of T-helper 1, T- helper 2
and immunosuppressive cytokine gene
transcripts in canine atopic dermatitis
7.1 Introduction
Recent interest has focused on the role of CD4+ Thi and Tm cells in human atopic
dermatitis (Leung 2000). Several studies have detected Th2 polarisation in the skin
and PBMCs of atopic humans (van der Heijden and others 1991; van Reijsen and
others 1992; Neumann and others 1996; Koning and others 1997a; Koning and oth¬
ers 1997b) and mouse models (Spergel and others 1999; Vestergaard and others
1999). In dogs, a study using non-quantitative RT-PCR demonstrated a TH2-type cy¬
tokine pattern in 25% of atopic and a Tni-type pattern in 25% of healthy canine skin
samples (Olivry and others 1999b).
Thi cytokines inhibit Th2 differentiation (Mosmann and Coffman 1987). Tni-type
cells, however, are found in chronic human atopic lesions (Werfel and others 1996)
and dominate atopy patch test sites after 48 hours (Thepen and others 1996), suggest¬
ing they also participate in the pathogenesis of chronic atopic dermatitis. Further¬
more, healthy individuals do not develop Thi induced cell-mediated inflammatory
reactions to environmental allergens (Borish and Rosenwasser 1997). Instead, toler¬
ance in healthy individuals may be mediated by the immunosuppressive cytokines
IL-10 and TGF(3l (Muraille and Leo 1998; Koulis and Robinson 2000).
Allergen induced activation of mast cells is widely believed to initiate inflammatory
reactions in atopic skin (Welle 1997). SCF/c-Kit interactions enhance in vitro sur-
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vival, proliferation, granularity, cytokine expression and degranulation of human
(Brody and Metcalfe 1998) and canine (Brazfs and others 2000) mast cells, although
their importance in atopic dermatitis is unclear.
This study used semi-quantitative RT-PCR to compare the expression of the THi-type
cytokines IFNy, TNFa, IL-2 and IL-12, the T^-type cytokines IL-4 and EL-6, and
the immunosuppressive cytokines IL-10 and TGF(3l, as well as SCF and c-Kit in
atopic and healthy canine skin. The aim was to determine if canine atopic dermatitis
is associated with polarised THi/TH2 responses as seen in humans.
-230-
7.2 Materials and Methods
7.2.1 Animals and samples
Twenty-eight dogs with atopic dermatitis and 16 healthy dogs were recruited accord¬
ing to the inclusion criteria described in Chapter 2.1. All the dogs with a clinical di¬
agnosis of atopic dermatitis had an intradermal test with 56 allergens (Table 2.1) per¬
formed as described in Chapter 2.1.5.
Blood samples were collected from each dog as described in Chapter 2.2.2. Skin bi¬
opsies of non-lesional and lesional skin, where present, and control tissues were col¬
lected into RNA Later® from each healthy and atopic dog as described in Chapters
2.2.3 and 2.2.4 respectively.
7.2.2 PBMC cultures
PBMCs were isolated from whole blood as outlined in Chapter 2.6.2.1. The cells
were cultured, collected into Tri-Reagent® and stored as described in Chapter 2.6.2.4.
7.2.3 Primer Design
Forward and reverse primers (Table 7.1) were designed from published canine se¬
quences (Genbank®; accession numbers listed in Table 2.5) and generated as de¬
scribed in Chapter 2.7.2.1. Internal probes for each cytokine (Table 7.1) were gener¬
ated and digoxigenin labelled as previously described (Chapter 2.7.2.2).
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7.2.4 RNA extraction and reverse transcription
RNA was extracted from the skin biopsies and control tissues as described in Chapter
2.7.3. RNA preparations with less than 120ng/pl RNA or 260nm:280nm absorbance
ratios persistently less than 1.5 were discarded. The quality of each RNA preparation
was assessed on a Northern gel (Chapter 2.7.3.2). RNA preparations from skin and
control tissues were heparinased using the protocol described in Chapter 2.7.4. The
heparinased (skin and positive control tissue) and non-heparinased (PBMCs) RNA
samples were reverse transcribed and stored as described in Chapter 2.7.5.
7.2.5 PCR optimisation
PCRs were carried out in 50pl volumes as outlined in Chapter 2.7.6. The optimum
MgCb concentration, pH and annealing temperature for each primer pair were de¬
termined as follows. PCRs for each primer pair were carried out with positive control
cDNA using the PCR buffers listed in Table 7.2. Identical PCR reactions were run
for 35 cycles at annealing temperatures of 55°C, 60°C and 65°C. The PCR products
were separated on 1.2% agarose gels and imaged as described in Chapter 2.7.7. The
optimum reaction conditions (Table 7.1) were those yielding the greatest PCR prod¬
uct intensity and fidelity.
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Table 7.2 - PCR optimisation buffers (PCR Optimisation Kit®; Roche)

















The identity of each PCR product was confirmed by Southern blotting and hybridisa¬
tion to digoxigenin labelled internal probes as described in Chapter 2.7.
To determine the optimum number of cycles for semi-quantitative PCR, 26 to 44
PCR cycles for each primer pair were performed using positive control cDNA under
optimum conditions and the gels imaged as described. Standard curves were gener¬
ated by plotting the number of PCR cycles against the log2 net band intensity of each
PCR product (Figure 7.1). The optimum number of cycles (Table 7.1) for each cyto¬
kine primer pair was selected from the straight-line portion of the plot.
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Figure 7.1 - Abundance of gene transcripts after 26 - 44 PCR cycles
Net band intensity = net intensity of fluorescence for each PCR product under 590nm
ultra-violet light (Kodak IS440CF imaging system) and analysed using Kodak ID







































7.2.6 Selecting the optimum time point for cytokine gene expression in
canine PBMCs cultures
The optimum time points for mRNA expression of each cytokine were determined
by culturing PBMCs isolated from six atopic dogs with 0.5pg/ml ConA under opti¬
mum conditions for one, three, five and seven days. RNA was isolated from each
culture, PCR reactions performed for each cytokine and the PCR products imaged as
previously described. The level of expression of cytokine mRNA was determined by
calculating net band intensity (cytokine)/net band intensity (GAPDH) for each sam¬
ple. The optimum time point for mRNA expression of each cytokine was that yield¬
ing the greatest mean expression compared to GAPDH (Table 7.3 and Figure 7.2).
Table 7.3 Optimum length of PBMC cultures for isolation of cytokine mRNA















Figure 7.2 - Expression of cytokine gene transcripts by PBMCs cultured for
1 - 7 days
Relative intensity = cytokine band intensity/GAPDH band intensity (imaged under
590nm ultra-violet light Kodak IS440CF imaging system analysed using Kodak ID
software - Chapter 2.7.7);#- number of cultures with quantifiable gene transcription
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Figure 7.2 contd. - Expression of cytokine gene transcripts by PBMCs cul¬
tured for 1 - 7 days
IL-12p40

















































7.2.7 Semi-quantitative PCR to determine the level of cytokine gene tran¬
scription in canine skin and PBMCs from atopic and healthy dogs
PCRs for each cytokine primer pair were performed with cDNA from each skin sam¬
ple and PBMCs cultured for the appropriate length of time. Positive control cDNA
samples and negative control wells (no DNA) were included in each PCR. PCR
products were run on gels and imaged as before. Gels with no positive control signal
or a negative control signal were discarded.
7.2.8 Data analysis
Cytokine expression in each sample was expressed as:
• Net band intensity (cytokine) / net band intensity (GAPDH)
After ensuring data were normally distributed one way analyses of variance with
Tukey's post-tests (Instat®) were used to compare the level of cytokine gene transcri-
tion in healthy, lesional atopic and non-lesional atopic skin, and between freshly iso¬
lated, mitogen and allergen stimulated PBMCs isolated from atopic and healthy dogs.
The level of significance was set at p<0.05.
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7.3 Results
7.3.1 Intradermal test reactivity
All the dogs with a clinical diagnosis of atopic dermatitis had positive skin tests to D.
farinae and D. pteronyssinus. There were also a number of individual reactions to a
range of other dust mites, epithelia, pollens and moulds.
7.3.2 PCR optimisation
The optimum reaction conditions established for each primer pair are detailed in Ta¬
ble 7.1. Single bands of the expected size for each cytokine were seen on the PCR
gel and hybridisation blots using positive control material (Figure 7.3). This verified
expression of mRNA for each cytokine in the positive control samples and confirmed
primer specificity.
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7.3.3 Cytokine gene transcription in atopic and healthy dogs
Variable levels of mRNA expression for all the cytokines were detected in each of
the samples tested. Table 7.4 summarises the cytokine mRNA expression relative to
GAPDH in lesional atopic, non-lesional atopic and healthy skin. Cytokine mRNA
levels in freshly isolated, mitogen and allergen stimulated PBMCs from atopic and
healthy dogs are summarised in Table 7.5.
Table 7.4 - Mean expression of cytokine mRNA relative to expression of







IL-2 0.23 (0.17; 12) 0.07 (0.12; 22) 0.09 (0.05; 12)
IFNy 0.24 (0.23; 12) 0.05 (0.05; 25) 0.07 (0.07 12)
TNFcc 2.16(1.36; 8) 0.82 (0.58; 26) 0.58 (0.61 10)
IL-12p35 0.18 (0.1; 12) 0.23 (0.29; 26) 0.28 (0.46 12)
IL-12p40 0.59 (0.99; 12) 0.27 (0.57; 24) 0.67 (0.87 12)
Th2 cytokines
IL-4 0.89 (1.1; 9) 0.54 (0.87; 25) 0.03 (0.05; 10)
IL-6 0.25 (0.25; 12) 0.23 (0.33; 26) 0.11 (0.1; 12)
Immunosuppres¬
sive cytokines
TGF(31 0.46 (0.53; 8) 0.60 (0.39; 26) 1.07 (0.47; 12)
IL-10 0.66 (0.3; 12) 0.48 (0.42; 26) 0.41 (0.52; 12)
SCF 1.15 (1.08; 12) 1.46 (1.19; 26) 1.06 (0.63; 12)
c-Kit 0.61 (0.81; 8) 0.24 (0.26; 26) 0.12 (0.18; 11)
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7.3.3.1 Expression of TH2-type cytokines
Expression of IL-4 was largely restricted to atopic skin. Significantly higher levels of
IL-4 mRNA were detected in both lesional and non-lesional atopic skin compared to
healthy skin (p<0.05) (Figure 7.4a), although there was no significant difference in
expression between lesional and non-lesional atopic skin. IL-6 mRNA expression
was also greatest in atopic skin (Figure 7.4b). However, IL-6 was also expressed in
healthy skin and differences between the three groups failed to reach significance.
Significantly higher levels of IL-4 mRNA were detected in D. farinae stimulated
atopic PBMCs compared to healthy PBMCs (Figure 7.5a). In contrast, much lower
levels were detected in resting and ConA stimulated PBMCs, and no significant dif¬
ferences between atopic and healthy PBMCs were noted. IL-6 mRNA expression by
PBMCs was highly variable between individuals (Figure 7.5b). Stimulation with
ConA or D. farinae increased expression compared to resting cells, but levels in
atopic and healthy PBMCs were otherwise very similar.
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Figure 7.4 - Abundance of TH2 cytokine gene transcripts in atopic and healthy
canine skin
| - Lesional atopic dermatitis; - non-lesional atopic dermatitis; | - healthy










Figure 7.5 - Abundance of TH2 cytokine gene transcripts in atopic and
healthy canine PBMCs
- Atopic PBMCs; | - Healthy PBMCs; bar - standard error of the mean;
*
- p<0.05; resting - freshly isolated cells; ConA - cultured with 0.5pg/ml concana-
valin A; DF - cultured with 50pg/ml Greer D.farinae extract.
a-IL-4
Resting ConA DF
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7.3.3.2 Expression of THrtype cytokines
There was a similar pattern of mRNA expression for the Tni-type cytokines IFNy
(Figure 7.6a), IL-2 (Figure 7.6b) and TNFa (Figure 7.6c) in all three groups of skin
samples. Significantly higher levels of mRNA for each cytokine were detected in le-
sional atopic skin compared to either non-lesional atopic or healthy skin (p<0.05).
Variably low levels, which did not significantly differ, were detected in non-lesional
and healthy skin.
The pattern of transcription of these Tm cytokines in PBMCs was more complex.
There was a significantly greater level of IFNy transcription in D. farinae stimulated
healthy PBMCs compared to atopic PBMCs (p<0.05) (Figure 7.7a). Levels of
mRNA were also higher in resting and ConA stimulated PBMCs from healthy dogs,
although the differences between groups did not reach significance. Levels of mRNA
for IL-2 were significantly higher in resting PBMCs isolated from healthy compared
to atopic dogs (p<0.05) (Figure 7.7b). IL-2 mRNA levels were also higher in ConA
and D. farinae stimulated healthy PBMCS, but transcription was highly variable and
differences between atopic and healthy PBMCs did not reach significance. Transcrip¬
tion of TNFa was greatest in resting cells from healthy dogs, and in stimulated cells
from atopic dogs (Figure 7.7c). However, the degree of transcription was highly
variable and the differences did not reach significance.
Levels of IL-12p35 and IL-12p40 mRNA were highly variable in both atopic and
healthy skin. IL-12p35 mRNA expression did not appear to differ between lesional
atopic, non-lesional atopic and healthy skin (Figure 7.6d). IL-12p40 mRNA expres¬
sion was highest in lesional atopic and healthy skin, but there was no significant dif¬
ference between the three groups of samples (Figure 7.6e).
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There was no significant difference in IL-12p35 mRNA expression between resting
PBMCs isolated from healthy and atopic dogs. In contrast, transcription was signifi¬
cantly higher in ConA and D. farinae stimulated cells from healthy dogs (p<0.05)
(Figure 7.7d). However, IL-12p40 mRNA levels were highly variable between indi¬
viduals, and no significant differences were observed between resting, ConA stimu¬
lated and D. farinae stimulated cells from atopic and healthy dogs (Figure 1.16).
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Figure 7.6 - Abundance of Thi cytokine gene transcripts in atopic and healthy
canine skin
| - Lesional atopic dermatitis; - non-lesional atopic dermatitis; | - healthy








































Figure 7.7 - Abundance of THi cytokine gene transcripts in atopic and
healthy canine PBMCs
- Atopic PBMCs; | - Healthy PBMCs; bar - standard error of the mean;
*
- p<0.05; resting - freshly isolated cells; ConA - cultured with 0.5pg/ml concana-





























































Healthy skin was associated with expression of the immunosuppressive cytokine
TGFpi. Levels of TGFpi mRNA were significantly higher in healthy compared with
atopic skin (Figure 7.8a). There was, however, no significant difference between the
lower levels of expression in lesional and non-lesional atopic skin.
Levels of TGFpi mRNA were very similar in resting and ConA stimulated PBMCs
isolated from atopic and healthy dogs (Figure 7.9a). Levels in D. farinae stimulated
PBMCs, however, were significantly higher in healthy dogs compared to atopic dogs
(p<0.05).
Levels of mRNA for IL-10 in skin were highly variable, and no significant difference
in expression was detected between any of the three groups (Figure 7.8b). In con¬
trast, IL-10 transcription was significantly higher in both ConA and D. farinae stimu¬
lated PBMCs isolated from healthy dogs compared to those from atopic dogs (Figure
7.9b) (p<0.05). Transcription in resting cells, however, was similar in healthy and
atopic dogs.
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Figure 7.8 - Abundance of immunosuppressive cytokine gene transcripts in
atopic and healthy canine skin
| - Lesional atopic dermatitis; - non-lesional atopic dermatitis; | - healthy






Figure 7.9 - Abundance of immunosuppressive cytokine gene transcripts in
atopic and healthy canine PBMCs
- Atopic PBMCs; | - Healthy PBMCs; bar - standard error of the mean;
*
- p<0.05; resting - freshly isolated cells; ConA - cultured with 0.5pg/ml concana-




n = 11 8 5 10 9 7
b-IL-10
Resting ConA DF
n= 12 8 12 8 8 7
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7.3.3.4 SCF and c-Kit
The level of SCF mRNA expression was very similar between all three groups of
skin samples (Figure 7.10a). In contrast, gene transcription was consistently higher in
resting, ConA and D. farinae stimulated PBMCs isolated from atopic dogs compared
to those from healthy dogs (Figure 7.1 la). The level of expression was very variable
between individuals, however, and the differences were not statistically significant.
Expression of mRNA for c-Kit was highest in lesional atopic skin. Although the ex¬
pression was quite variable between individuals, there was a significantly higher
level ofgene transcription in lesional atopic compared to healthy skin (Figure 7.10b).
There were, however, no significant differences between non-lesional atopic skin and
either lesional atopic or healthy skin. Levels of c-Kit mRNA expression in PBMC
cultures were very variable between individuals. In contrast to the skin samples, sig¬
nificantly higher levels were observed in resting healthy compared to atopic cells.
Despite this, levels in Con A and D. farinae stimulated atopic and healthy cells were
comparable (Figure 7.1 lb).
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Figure 7.10 - Abundance of SCF and c-Kit gene transcripts in atopic and
healthy canine skin
| - Lesional atopic dermatitis; - non-lesional atopic dermatitis; | - healthy
skin; bar - standard error of the mean; * - p<0.05.
a-SCF
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Figure 7.11 - Abundance of mast cell factor gene transcripts in atopic and
healthy canine PBMCs
- Atopic PBMCs; | - Healthy PBMCs; bar - standard error of the mean;
*
- p<0.05; resting - freshly isolated cells; ConA - cultured with 0.5pg/ml concana-
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7.4 Discussion
7.4.1 Th2 responses in canine atopic dermatitis
Studies in humans and experimental mouse models suggest that IL-4 expression is a
hallmark of atopic dermatitis (Leung 2000). IL-4+ CD4+ T-cells are also found in fe¬
line allergic skin disease (Roosje and others 2002). In dogs, a non-quantitative study
found that IL-4 mRNA was expressed in both atopic and healthy skin samples
(Olivry and others 1999b). Using semi-quantitative RT-PCR, however, this study has
shown that much higher levels of IL-4 mRNA are expressed in skin and PBMCs
from dogs with atopic dermatitis compared to healthy dogs. These results suggest
that IL-4 is likely to be involved in the pathogenesis of canine atopic dermatitis. This
implies that human and canine atopic dermatitis share a similar pathogenesis and that
the dog may be a naturally occurring model for human atopic dermatitis. In contrast
to these findings, however, one study using quantitative RT-PCR failed to demon¬
strate IL-4 mRNA in canine skin (Maeda and others 2002). This dichotomy may rep¬
resent differences in methodology, case selection or gene pools. Immunohistochem-
istry and proteomic analysis should, in the future, confirm whether there is expres¬
sion of IL-4 protein in canine skin. In some dogs, however, TH2 polarisation and IgE
production could be associated with IL-13. We were unable to identify IL-13 mRNA
in control samples using consensus primers derived from human, murine, rat and bo¬
vine IL-13 sequences. A canine IL-13 sequence has now been published (Genbank*
accession number AF244915 - www.ncbi.nlm.nih.gov) and further studies should
reveal whether this cytokine has a role in canine atopic dermatitis.
This study found high levels of IL-4 mRNA expression in both non-lesional and le-
sional atopic skin. IL-4 is also found in non-lesional skin from human patients
-262-
(Leung 2000). It is not clear, however, if IL-4 expression in atopic skin is constitu¬
tive or as a result of exposure to specific allergens. Evidence of default Th2 responses
comes from the impaired delayed type IV hypersensitivity responses observed in
atopic humans and animals (Cooper 1994). Constitutive expression of IL-4 in mice,
furthermore, is associated with increased numbers of mast cells, Langerhans' cells,
acanthosis and hyperkeratosis (Elbe-Burger and others 2002), which might enhance
cutaneous sensitisation and inflammation. In this study, however, differences in the
level of IL-4 mRNA expression in atopic and healthy PBMCs appeared to be aller¬
gen specific. Levels in resting and mitogen stimulated PBMCs, in contrast, were
similar in both atopic and healthy dogs. These findings suggest that Th2 responses in
atopic dogs are the result of interaction with specific allergens rather than the result
of global TH2 polarisation. Studies in humans have shown that THi and TH2 responses
co-exist in the same individual, further suggesting that these responses are antigen
specific (Ismail and Bretscher 1999). In addition, TH2 responses in atopic patients are
allergen specific and are not associated with non-sensitising antigens (Jenmalm and
others 2001). Certain allergens may drive TH2 differentiation. Der p 1, for example,
increases epithelial permeability, enhances protease activity, IgE production, in¬
flammatory mediator release and inhibits Thi differentiation (Bufe 1998; Shakib and
Gough 2000). Studies on the in vivo biological activity of group 1 allergens and Der f
15 on Th2 differentiation in atopic dogs are therefore warranted.
Allergen specific IgE and PBMC responses are largely restricted to sensitised atopic
dogs (Nuttall and others 2001a; Nuttall and others 2001b). The findings from this
study suggest that following allergen exposure these cells express IL-4, which drives
allergen specific IgE production. It is not, however, clear from these results which
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cells are expressing IL-4 mRNA. Further studies to phenotype the allergen reactive
and IL-4 mRNA and protein expressing cells are therefore required.
In some atopic dogs intradermal test reactivity can be demonstrated in the absence of
detectable circulating IgE. IL-4 expression in atopic canine skin suggests that IgE
production might take place in the skin. However, the paucity of B-cells and plasma
cells in the cutaneous mononuclear cell infiltrate in canine atopic dermatitis (Olivry
and others 1997), suggests that most IgE production takes place at extra-cutaneous
lymphoid sites (Hill and Olivry 2001). Immunohistochemistry, furthermore, indicates
that most IL-4 producing cells in the dermis are mast cells, rather than T-helper cells
(Sinke and others 2002).
Consistent with the hypothesis that IL-4 expression is associated with IgE produc¬
tion, elevated IL-4 levels are not found in the intrinsic (non-IgE mediated) form of
human atopic dermatitis (Schmid-Grendelmeier and others 2001). The findings de¬
scribed in Chapters 3 and 6 suggest that IgE and non-IgE mediated forms of canine
atopic dermatitis also exist. Unfortunately, it was not possible to evaluate gene tran¬
scription in samples from non-allergen reactive dogs in this study. Further studies are
therefore needed to definitively link IL-4 expression, IgE production and allergen
reactivity in canine atopic dermatitis.
In contrast to a previous investigation (Olivry and others 1999b), IL-6 mRNA was
readily detected in this study. However, unlike IL-4, there was no significant differ¬
ence in expression between atopic and healthy canine skin, resting and mitogen or
allergen stimulated PBMCs. Although IL-6 is regarded as a Tn2-type cytokine
(Maggi 1998), it is also produced by APCs, fibroblasts, macrophages, endothelial
cells and keratinocytes (Kirman and Le Gros 1998). In a mouse model IL-6 was
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shown to have both pro- and anti-inflammatory effects (Wang and others 2000b).
The activity of IL-6 may, therefore, depend on the precise temporal and spatial rela¬
tionship between cells. Furthermore, IL-6 could support B-cell proliferation and al¬
lergen specific IgG production in healthy humans and dogs (Upham and others 1995;
Day and others 1996).
7.4.2 Immunosuppressive cytokines in canine atopic dermatitis
This study has shown for the first time that there are lower levels of gene transcrip¬
tion for the immunosuppressive cytokines TGFpi and IL-10 in atopic compared to
healthy dogs. This could result in the altered skin reactivity that has been associated
with clinical atopic dermatitis (Hyland 2001; Sinke and others 2002). A recent study,
furthermore, linked a low TGFpi producer phenotype with atopic dermatitis in chil¬
dren (Arkwright and others 2001).
TGFpi, produced by T-cells and keratinocytes, is thought to be important in periph¬
eral tolerance to environmental allergens in humans and rodent models (Yeo and
Lamb 1995). Atopic dermatitis in humans and dogs is associated with hyper¬
reactivity to irritant stimuli (Leung 2000; Scott and others 2001a). The low level of
cutaneous TGFpi mRNA found in this study could, therefore, reflect a breakdown of
anti-inflammatory mechanisms. In contrast, constitutive expression of TGFpi in
healthy skin could inhibit inappropriate inflammatory responses to environmental
allergens. In a murine model of atopic dermatitis, administration of recombinant
TGFPi resulted in decreased serum IgE levels, IFNy production and amelioration of
skin lesions although it also caused acanthosis and fibrosis (Sumiyoshi and others
2002). The balance of its anti-inflammatory and stimulatory activity may, therefore,
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depend on the degree of differentiation or activation of a target cell as well as the
overall cytokine and cellular milieu (Ling and Robinson 2002). TGF|3l, however, is
secreted in an inactive form and is subject to post-transcription regulation (Umetsu
and DeKruyff 1997; Ling and Robinson 2002). Confirmation of its importance,
therefore, awaits demonstration of active TGF(3l in canine skin and PBMCs.
The role of IL-10 in canine skin is less clear. An earlier investigation failed to dem¬
onstrate IL-10 mRNA in canine skin (Olivry and others 1999b). In contrast, IL-10
mRNA was expressed in most samples in this study, although there was no differ¬
ence in the level of expression between atopic and healthy skin. The role of IL-10 is
also unclear in humans and rodent models. Decreased IL-10 expression has been as¬
sociated with colitis and cutaneous inflammation in mice (Borish 1998), and atopic
dermatitis in people (Koning and others 1997b; Jenmalm and others 2001). In con¬
trast, increased IL-10 expression has been found in TH cells from patients with atopic
dermatitis (Sato and others 1998) and in the airways and skin after allergen challenge
in mice and humans (Koulis and Robinson 2000; van Scott and others 2000). IL-10 is
constitutively expressed in normal mouse skin, but only in late phase reactions in a
model of atopic dermatitis (Wang and others 1999), which may fail to resolve estab¬
lished allergen induced inflammation (Borish 1998; Muraille and Leo 1998).
Significantly greater TGF(3l and IL-10 gene expression was observed in allergen
stimulated PBMCs from healthy compared to atopic dogs. TGFpi and IL-10 inhibit
the proliferation and activation of T-cells (Herz and others 1998), which may account
for the anergic response in PMBCs from healthy dogs to Dermatophagoides aller¬
gens (Nuttall and others 2001b). An early study also reported that PBMCs isolated
from atopic dogs exhibited less suppressor activity than those from healthy dogs
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(Nimmo Wilkie and others 1992). Allergen induced IL-10 and TGF(3l expression in
canine PBMCs is consistent with activation of T-regulatory cells in healthy individu¬
als. It has been proposed that these play an important role in tolerance to environ¬
mental allergens (Hoyne and others 2000). Low IL-10 mRNA expression in the mi¬
togen stimulated PBMCs from atopic dogs, furthermore, might indicate there is a
constitutive defect in immunosuppressive gene expression in these individuals. This
was not, however, associated with widespread dysregulation, as IL-10 mRNA ex¬
pression was readily detected in atopic skin. Low expression in PBMCs, however,
may allow unregulated activation of Th cells and a breakdown in tolerance.
7.4.3 The role of THi cytokines in canine atopic dermatitis
High levels of mRNA for the THi cytokines IL-2, IFNy and TNFa were seen in le-
sional atopic skin. Chronic lesions in human atopic dermatitis also exhibit a mixed
pattern of cytokines, including IL-4, IL-13, IL-5, IL-2, IFNy, and IL-12 (Werfel and
others 1996). Furthermore, Thi cytokines dominate atopy patch tests after 48 hours
(Thepen and others 1996; Junghans and others 1998). Another recent study has also
shown that IFNy and TNFa, as well as IL-lp and TARC (Thymus and Activation
Regulated Chemokine), are up regulated in lesional atopic compared to non-lesional
atopic and healthy canine skin (Maeda and others 2002).
THi cytokines appear, therefore, to be important in the establishment and mainte¬
nance of chronic lesions. IL-2 is a crucial factor in the activation and expansion of T-
cells (Huston 1997). Lesional skin in humans is characterised by Fas-dependant
keratinocyte apoptosis and disruption of the epidermal barrier, increasing exposure to
allergens, irritants and microbes. IFNy, in particular, induces expression of Fas on
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keratinocytes, which interacts with Fas-ligand present on infiltrating T-cells
(Trautmann and others 2000). In one study, keratinocytes from humans with atopic
dermatitis were more sensitive to IFNy than those from healthy individuals (Pastore
and others 1998). TNFa produced by human and rodent epidermal cells triggers ex¬
pression of adhesion molecules including ICAM-1 and VCAM-1 as well as pro¬
inflammatory cytokines and chemokines (Robert and Kupper 1999). TNFa also
stimulates Langerhans cell activation, maturation, migration, antigen presentation
and survival (Kimber and others 1998).
The trigger for Thi cytokine expression in chronic lesions is not fully understood.
Skin lesions in human and canine atopic dermatitis include erythema, papular erup¬
tions, alopecia, scaling, crusting, hyperpigmentation and lichenification (Rothe and
Grant-Kels 1996; Scott and others 2001a). However, the clinical findings described
in Chapter 3 suggest that uncomplicated canine atopic dermatitis is largely a pruritic
and erythematous disease. Other authors have also concluded that most lesions result
from self-trauma and microbial colonisation (Rothe and Grant-Kels 1996; Griffin
and DeBoer 2001). Self-trauma can induce inflammatory cytokines, including IL-1,
TNFa and GM-CSF from keratinocytes (Robert and Kupper 1999) that could result
in the recruitment of mononuclear cells and the development of chronic lesions. His¬
tamine, furthermore, can promote Thi proliferation and inhibit Th2 cells in vitro
(Jutel and others 2001).
These results clearly demonstrate that Thi cytokine mRNA is up regulated in lesional
skin. It is tempting to surmise that there is a correlation between the severity of in¬
flammation and Thi cytokine expression. Further study comparing the degree of cel-
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lular infiltration into the skin with the level of Thi cytokine mRNA expression will
begin to answer this question.
It was suggested in Chapter 3 that lesional atopic dermatitis is associated with secon¬
dary infection. The severity of human atopic dermatitis is also associated with
staphylococcal colonisation (Herz and others 1998). In a mouse model, furthermore,
Staphylococcus aureus preferentially bound to sites of IL-4 mediated inflammation
(Cho and others 2001), suggesting that they play an important role in the switch from
Th2 to THi-type inflammatory reactions. Staphylococcal superantigens in humans in¬
duce CLA expression on T-cells, MHCII, IL-1, TNFa and IL-12 expression by
mononuclear cells and up-regulate endothelial ICAM-1 and VCAM-1 (Herz and oth¬
ers 1998; Leung 2000; Skov and others 2000). The role of staphylococcal superanti¬
gens in canine atopic dermatitis, however, has not yet been studied.
Superantigen activity in Malassezia species has not been demonstrated, but
Malassezia have been shown to induce IgG, IgE, immediate and late phase skin reac¬
tivity and PBMC proliferation in human (Kieffer and others 1990; Nordvall and Jo¬
hansson 1990; Rokugo and others 1990; Wessels and others 1991; Tengvall Linder
and others 1998) and canine (Morris and others 1998; Nuttall and Halliwell 2001;
Chen and others 2002) atopic dermatitis. Malassezia also induce IL-1 (3, IL-6, IL-8
and TNFa production from human keratinocytes (Watanabe and others 2001). M.
pachydermatis appeared to be more pathogenic than M. furfur in this study, but this
may reflect host adaptation, rather than virulence.
Together, these findings suggest an important role for micro-organisms in enhancing
leucocyte adhesion and migration, pro-inflammatory cytokine release and the devel¬
opment of chronic skin lesions.
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The Tni-type cytokines IL-2, IFNy and TNFa are associated with cell-mediated in¬
flammation and inhibition of Tm differentiation (Fiorentino and others 1989). These
results, however, do not suggest that TH2 skewing in canine atopic dermatitis results
from defective expression of THi cytokines. There was, however, significantly
greater transcription of IFNy by allergen stimulated PBMCs from healthy dogs, sug¬
gesting that there is a TH2 polarised circulating allergen specific PBMC population in
atopic dogs. A recent study also found decreased IFNy production in PBMCs isolated
from IgE associated but not non-IgE associated human atopic dermatitis (Simon and
others 2002). Compared to healthy children, furthermore, atopic children not only
have fewer IFNy producing CD4+, CD8+ and NK cells in their peripheral blood, but
they also expressed less IFNy per cell (Campbell and others 1999).
APC derived IL-12 is a critical factor in Thi differentiation, IFNy production, and
CLA expression on circulating T-cells (Blaher and others 1995; De Becker and oth¬
ers 1998; Snijders and others 1998). Down regulation of IL-12 has been associated
with TH2 polarisation (Muraille and Leo 1998), but there was no significant differ¬
ence in the overall expression of IL-12 mRNA in healthy and atopic canine skin in
this study. Whilst this does not preclude post-transcription down regulation of IL-12
production or function, THi-type cytokine expression in lesional skin suggests that
this is not the case. IL-12p35 transcription was, however, significantly lower in mi¬
togen and allergen stimulated PBMCs from atopic compared to healthy dogs. Re¬
duced IL-12p35 expression in atopic PBMCs could favour TH2 differentiation as IL-
12p40 dimers inhibit IL-12 activity (Piccotti and others 1996).
The findings in this study do not suggest that expression of THi cytokines down regu¬
lates TH2 expression in healthy individuals. An earlier non-quantitative investigation
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detected IL-2 expression more frequently in healthy than atopic canine skin samples,
although the numbers expressing IFNy and TNFa did not differ (Olivry and others
1999b). In contrast, only low levels of IL-2, IFNy and TNFa mRNA were expressed
in healthy canine skin in this study. These results are not consistent with Thi polari¬
sation in healthy skin, although it would unusual to find high levels of these pro¬
inflammatory cytokines expressed in healthy skin. This further supports the hypothe¬
sis that it is expression of the immunosuppressive cytokines IL-10 and TGF(3l that is
important in tolerance.
7.4.4 The expression of SCF and c-Kit in canine atopic dermatitis
In human atopic dermatitis there is a correlation between SCF expression, mast cell
numbers and dermal histamine content (Rossi and others 1998; Galli and others
1999). An immunohistochemical study also found higher levels of extracellular SCF
protein in atopic compared to healthy canine skin (Hammerberg and others 2001).
Labelling was particularly intense in lesional skin. Despite this, there was little dif¬
ference in the expression of SCF mRNA between atopic and healthy dogs in this
study. Immunohistochemistry, however, is more sensitive than RT-PCR at detecting
preformed, stored and released mediators.
As well supporting mast cell development, SCF potentiates IgE dependent degranu-
lation in rat mast cells (Hill and others 1996) and both IgE dependent and independ¬
ent mast cell activation in atopic humans (Brody and Metcalfe 1998; Galli and others
1999; Kanbe and others 1999). However, whilst one study has shown that SCF aug¬
ments mast cell activation in dogs (Brazfs and others 2000), in another it did not
(Hammerberg and others 2001). The latter demonstrated that anti-IgE increased in-
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tradermal test wheal diameter in atopic but not healthy dogs, although earlier work
found that in vitro sensitised mast cells from atopic and normal canine skin had a
similar response to anti-IgE (Brazfs and others 1998). This suggests that in vivo sen-
sitisation was more important than inherent activity. Mast cell involvement in atopic
dermatitis, therefore, may be secondary to allergen specific IgE production driven by
TH2 differentiation.
The study also found increased c-Kit mRNA transcription in lesional atopic skin. Ex¬
pression of c-Kit mRNA was, conversely, decreased in atopic compared to healthy
PBMCs. This may be because gene transcription in PBMCs was very low and image
analysis less accurate. Increased cutaneous c-Kit mRNA expression may be due to
mast cell hyperplasia, although other work suggests that mast cell numbers are not
significantly elevated in atopic compared to healthy skin (Hammerberg and others
2001). Increased c-Kit expression could also be a pathway to enhance SCF activity in
lesional atopic skin.
7.4.5 The pathogenesis of canine atopic dermatitis
These results allow us to postulate a pathogenetic sequence for canine atopic derma¬
titis. Activation of TH2 polarised cells promotes allergen specific IgE production in
atopic dogs, whereas IL-10 and TGF(3l expression induces tolerance in healthy indi¬
viduals. Atopic skin, furthermore, is associated with increased expression of IL-4 and
decreased expression of TGF(3l, leading to allergic-type inflammatory reactions.
With chronicity, lesional skin exhibits a mixed inflammatory cytokine pattern that
may be due to self-trauma and secondary infection. Ongoing exposure to environ¬
mental allergens sets in train a vicious circle of inflammation, trauma and microbial
- 272 -
infection that fails to resolve. Some caution should be exercised, however, as semi¬
quantitative RT-PCR is only an approximate measure of mRNA expression. Tech¬
niques that accurately quantify mRNA are more accurate and should be applied to




This thesis describes the clinical and immunological features of 45 dogs with con¬
firmed atopic dermatitis. Until very recently little was known of the pathogenesis of
this disease, although the presence of circulating and cutaneous mast cell bound al¬
lergen specific IgE was well recognised. The most common allergens are the house
dust mites Dermatophagoides farinae and D. pteronyssinus, but the major protein al¬
lergen for atopic dogs seems to be a 98kD chitinase (Der f 15) rather than group 1 or
2 allergens (Noli and others 1996; McCall and others 2000; Shaw 2000). It is also
becoming apparent that canine atopic dermatitis is a T-cell mediated disease. CD4+
and CD8+ T-cells dominate the cutaneous infiltrate (Olivry and others 1997) and D.
pteronyssinus specific PBMC proliferation was demonstrated in vitro (Shaw 2000).
Analysis of the cytokine profile and THi/TH2 polarisation in canine atopic dermatitis
has been limited though. One study using RT-PCR demonstrated a THi-like pattern in
25% of healthy skin samples, a TH2-like pattern in 25% of atopic skin samples and a
mixed cytokine pattern in the rest (Olivry and others 1999b). Others detected IL-4 in
atopic lesional skin by immunohistochemistry (Sinke and others 1998) and patch test
sites (Rutten and others 2001). Despite this, a recent study failed to detect IL-4
(Maeda and others 2002) in atopic skin. Other authors speculated that THi-type cell
mediated inflammatory reactions also participated in the pathogenesis of chronic
atopic dermatitis (Olivry and others 1999b; Sinke and others 2002).
The findings in this thesis have extended our knowledge in these key areas. Canine
atopic dermatitis appeared be an allergen mediated disease in most of the studied
dogs. It was strongly associated with intradermal test reactivity, allergen specific se-
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rum IgE and in vitro PBMC proliferation to the house dust mites D. farinae and D.
pteronyssinus (Nuttall and others 2001a; Nuttall and others 2001b). The immunoblot-
ting and PBMC proliferation studies, furthermore, demonstrated that the major target
of immune recognition in atopic dogs is a 98/104kD allergen that is probably Der f
15 (Nuttall and others 2001a; Nuttall and others 2002a). The correlation between the
presence of allergen specific IgE and PBMC proliferation implies that these cells
support IgE production, confirming the role of T-cells in the pathogenesis of atopic
dermatitis. Semi-quantitative RT-PCR specific for canine cytokines was used to in¬
vestigate cytokine profiles in skin and PBMCs. This demonstrated increased expres¬
sion of the mRNA encoding the Th2 cytokine IL-4 and decreased expression of the
mRNA encoding the immunosuppressive cytokine TGF(3l in atopic skin. Expression
of mRNA for the Thi cytokines IFNy, TNFa and IL-2 was restricted to lesional
atopic skin (Nuttall and others 2002b). In vitro culture of atopic PBMCs with an ex¬
tract of D. farinae induced up regulation of IL-4 mRNA and down regulation of
mRNA encoding the Thi cytokine IFNy. In contrast, allergen stimulation of healthy
PBMCs induced expression of mRNA encoding the immunosuppressive cytokines
TGFpl and IL-10.
8.2 The pathogenesis of canine atopic dermatitis
The findings suggest that canine atopic dermatitis is associated with a TH2 polarised
phenotype that leads to the production of IgE antibodies specific to environmental
allergens. Cross-linking of IgE antibodies on the surface of cutaneous mast cells trig¬
gers an immediate phase inflammatory reaction. The subsequent inflammatory cas¬
cade results in recruitment and activation of THi-type cells and chronic cell mediated
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inflammation. Other factors that may be important in the development of chronic le¬
sions include self-trauma and colonisation by staphylococcal and Malassezia species.
Having both an atopic phenotype and a failure of peripheral tolerance, however, ap¬
pear key to clinically manifesting the condition. Consistent with this hypothesis a re¬
cent study in high IgE-responder strain of beagles discovered that increased allergen
specific serum IgE levels and allergen exposure were not sufficient by themselves to
induce clinical signs of atopic dermatitis (Egli and others 2002). A breakdown in pe¬
ripheral tolerance without an atopic constitution, in contrast, could explain why some
dogs fulfil the clinical requirements for a diagnosis of atopic dermatitis, yet have per¬
sistently negative IDTs, serology and PBMC proliferation assays.
This hypothetical two step model of atopic dermatitis (i.e. atopic phenotype and a
breakdown of peripheral tolerance) could be tested by studying IDT positive healthy
animals, which should express high levels of IL-4 and IL-10/TGFP1, and IDT nega¬
tive atopic dogs, which should have a low IL-4 and low EL-10/TGF(3l phenotype.
8.3 Tolerance in healthy individuals
Human and murine studies have shown that TGFf3 and IL-10 are critical in the induc¬
tion of CD4+ T-regulatory (Tr or Treg) cells. Recent findings in a mouse model of
peptide immunotherapy for Der p 1 induced responses revealed that TCR ligation in
conjunction with IL-10 expression and activation of the Notch signalling pathway al¬
lows nai've T-cells to differentiate into TR cells. These cells mediate tolerance by
preventing the activation and expansion of T-cell clones. Furthermore, expression of
Notch receptors and ligands is modulated on T-cells following exposure to immuno¬
suppressive cytokines (Hoyne and others 2000). Investigating the role of Notch sig-
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nailing in the regulation of immune responses in atopic and healthy dogs could,
therefore, have major implications for our understanding of tolerance. Analysis of the
relevant balance of immunosuppressive, TH2 or THi influences within an individual
would be greatly enhanced by developing quantitative RT-PCR techniques to accu¬
rately determine the level of cytokine transcription.
Cytokine mRNA, however, does not necessarily correlate with expression of active
protein as post-transcriptional regulation of expression and function can occur.
Analysis of protein expression is hampered by the lack of canine specific reagents
and the limiting nature of selecting likely targets a priori. An alternative approach is
to use proteomics to study global protein expression in tissues from atopic and
healthy dogs. Proteins with differential expression could then be sequenced, identi¬
fied and studied further.
8.4 The role of Dermatophagoides allergens
The most prominent allergen in canine atopic dermatitis appears to be D. farinae
(Sture and others 1995; Nuttall and others 2001a). This species, however, is believed
to be rare in the UK. Cross inhibition studies will be required to determine whether
antibodies to D. pteronyssinus allergens cross react with those from D. farinae. If
there appears to be independent sensitisation to both species it raises the intriguing
possibility that there may be an association between dogs and D. farinae. It would be
interesting, therefore, to compare the prevalence of D. farinae and D. pteronyssinus
as well as Der f 1 and Der p 1 in homes with and without dogs in different geo¬
graphical areas of the UK. Alternatively, significant cross-reaction between these
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two species has implications for allergen standardisation, as allergen tests will exag¬
gerate the importance of extracts with high levels of reactive proteins.
The major allergen Der f 15 and its D. pteronyssinus homologue could be useful
markers to standardise allergen extracts for use in atopic dogs. Investigating the ef¬
fect purified Der f 15 has on canine mononuclear cell lines, PBMCs and skin explant
cultures will also establish if there is any biological activity that could be important
in the pathogenesis of canine atopic dermatitis. Group 1 allergens also warrant study
as some dogs did react to these proteins. Der p 1 can also disrupt epithelial barriers,
and promote TH2 polarisation and sensitisation to other allergens.
8.5 The role of microorganisms in canine atopic dermatitis
The triggers for the switch from Th2 to Thi mediated inflammation are unclear.
Clinically, however, lesional skin in atopic dogs was associated with secondary in¬
fection by staphylococci and Malassezia. This implies that these organisms are im¬
portant in driving Thi mediated chronic inflammation. They are commensal organ¬
isms, but although colonisation of atopic skin is common, no virulence factors have
been found to distinguish isolates from infected and non-infected individuals
(DeBoer and Marsella 2001). Traditional approaches, however, tend to focus on a
few molecules. Using proteomic techniques it would be possible to screen microbial
isolates for differences in protein expression. The identity and role of any potential
virulence factors could then be studied in greater detail. If the isolates prove to be
similar, though, this would imply that the cutaneous microenvironment is more im¬
portant in microbial colonisation.
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Once established, it is clear that microorganisms induce an inflammatory response.
This could result from metabolic by-products and proinflammatory mediators. In ad¬
dition, Malassezia and Staphylococcus specific IgG and IgE antibodies suggest that
these organisms might act as conventional allergens in atopic dogs (Morales and oth¬
ers 1994; Morris and others 1998; Nuttall and Halliwell 2001; Chen and others
2002). Sensitisation could have major implications, as antimicrobial therapy might
not be able to reduce the commensal populations below a critical threshold for sensi¬
tisation. The role of microbial superantigens in canine atopic dermatitis should also
be explored. Staphylococcal superantigens and Malassezia extracts are potent induc¬
ers of PBMC proliferation in dogs (Hendricks and others 2002; Morris and others
2002), but the TCR V(3 chain profile of these cells has not been investigated.
8.6 The epidemiology of canine atopic dermatitis
The 45 dogs with atopic dermatitis in this study were drawn from 22 different breeds.
Whilst this is far from a statistically valid sample, it does suggest that atopic dermati¬
tis is a widespread condition. Several breeds are said to be at risk from the disease
(Scott and others 2001a), but there is little robust epidemiological data to support this
assertion. Individual dog breeds represent outbred and isolated gene pools. Studying
the epidemiology of canine atopic dermatitis could, therefore, be a powerful tool to
investigate the relative importance of different atopic traits between gene pools.
Atopic traits in dogs remain poorly characterised although this study has identified a
number of potential targets. Further studies are currently in progress to detect poly¬
morphisms in DNA isolated from atopic and healthy dogs that might be associated
with altered function in pro-inflammatory or immunosuppressive cytokines. These
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studies will also show if specific MHCII haplotypes are associated with atopic der¬
matitis in dogs.
8.7 Conclusion
The findings reported here significantly advance our understanding of atopic derma¬
titis in dogs. Canine atopic dermatitis, furthermore, should be developed as a valu¬
able, spontaneous model for studying the human disease. Establishing the immu¬
nological mechanisms underlying tolerance will allow canine atopic dermatitis to be
further developed as a powerful model to explore new approaches to therapy in dogs
and humans. Identifying key mediators will also allow the utilisation of molecular
techniques to investigate genetic polymorphisms in between atopic and healthy dogs.
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SUMMARY
Atopic dermatitis is it well-recognised chronic inflammatory skin disease of humans and dogs. Most atopic dogs are
sensitised to Dcmiatopluigoides mites. The aim of this study was to characterise allergens in different Dermalophagoides
species using polyclonal and monoclonal antibodies to canine IgE. Western blots were prepared from crude extracts of D
farinae, D pierimyxsinas and D microceras, and purified group I and 2 allergens under reducing and non-reducing
conditions. They were probed with sera from atopic (11 = 33) and healthy (n = 27) dogs. There was no significant dif¬
ference in the sensitivity or specificity between the polyclonal and monoclonal sera in detecting Dermatophagoide.v-
specific IgE. Major allergens common to both D furinae and D pteronyssinus were detected at 97-98 kDa, 103-11)4 kDa
and 134-139kDa on both reducing and non-reducing blots. Major allergens at 84-85kDa, 65-69kDa and 44-45 kDa
were only recognised 011 reducing blots, suggesting that these are fragments of the larger allergens. Only a few sera
recognised group 1 or 2 allergens on blots of crude extracts or purified allergens. These results confirm that, in atopic
dogs, high molecular weight allergens are the most important Dermttfophityoidcs allergens, rather than the low molecular
weight group I and 2 proteins, c 2001 Harcourt Publishers Ltd
ATOPIC dermatitis (ad) is a well-recognised chronic
inflammatory skin disease of humans and dogs (Rothe
and Grant-Kels 1996, Scott et al 1995), characterised by
cutaneous and circulating IgE specific for various
environmental allergens (Day et al 1999, Leung 2000).
The most important allergens in both human and canine
\d are house dust mites (hdm) (Halbert et al 1995,
oture et al 1995). Dermatophagoidespteronyssinus is the
most common in the UK, although D farinae is also found
(Thomas et al 1998). A third species, D microceras, is
rare in the UK (O'Hehir 1988).
The most important hdm allergens in human ad are
the group 1 and group 2 proteins, Der pi and 2 from D
pteronyssinus, and Der 11 and 2 from D farinae (Thomas
el al 1998). High IgE litres to group 1 and 2 allergens
are present in 70-80 per cent of atopic human sera,
whereas variable litres to other allergens are found in
only 40-50 per cent of sera (Le Mao et al 1998, Thomas
et al 1998).
The identification of hdm allergens in canine ad is
controversial. Studies using anti-canine IgGd (Noli et al
1996) and recombinant FceRIo' (McCall et al 2000,
Shaw 2000) detected major allergens of 60-70 kDa
and 90-109 kDa on Western blots of D farinae and D
pteronyssinus. However, although 69 per cent of atopic
sera also recognised Der fl using FctRIo in one study
(McCall el al 1999), others detected very little binding to
'Corresponding author: Dr. T. J. Nutlall, University of Liverpool Small
Animal Hospital, Crown Street, Liverpool, Mersey side, L7 TEX.
Tel: 0151 7944290: Faxf0151 794 4304.
group 1 and 2 allergens using either FeeRio (Shaw 2000)
or anti-canine IgGd (Noli et al 1996). In contrast, the only
study using anti-canine IgE (in ELISAS and dot blots)
reported that 50 per cent of atopic sera recognised both
Der pi and 2, and Der fl and 2 (Masuda et al 1999).
These conflicting results could arise from the variable
allergen content of different extracts (Le Mao et al
1998) and specificity and sensitivity of different antisera
(Steward and Male 1998). Furthermore, gel separation
of protein extracts under reducing conditions (Laemmli
1970) can denature IgE epitopes on Der pi and 2
(Lombardero et al 1990).
The aim of this study, therefore, was to characterise
further and compare D farinae and D pteronyssinus
allergens on reducing and non-reducing Western blots
of different hdm extracts using both monoclonal and
polyclonal antibodies to canine IgE.
MATERIALS AND METHODS
Study population
Dogs with ad were recruited from the dermatology
clinic at the University of Edinburgh Hospital for
Small Animals. Diagnosis was based on compatible
history and clinical signs, and exclusion of other pruritic
dermatoses (Willemse 1986). Coal brushings, skin
scrapes and trial therapy were used to eliminate ecto¬
parasites. All dogs underwent a 6-week, home-cooked
diet trial to eliminate food intolerance. Seborrhoea,
pyoderma and Malassezia were managed appropriately.
0034-5288/1) 1 /()10051 +07 $35.00/0 ic 2001 Harcourt Publishers Ltd
52 T. J. Nutlall, J. R. Lamb, P. B. Hill
No anti-inflammatory medication was given for at least
3 weeks prior to examination.
All dogs with a clinical diagnosis of ad were skin-
tested with 57 allergens, including D farinae and D
pteronyssinus (Greer Laboratories, Lenoir, usa). Dogs
were sedated with 015mgkg~ xylazine im. Hair was
clipped from the lateral flank and 0.05 ml of each
allergen extract, 1/100,000 w/v histamine (positive con¬
trol) and diluent (negative control) were injected
intradermally. After 20 minutes, test-sites were scored
from 0 to 4 compared to the controls. Reactions > 2
were considered positive (Nuttall et al 1998).
Control samples were taken from healthy dogs pre¬
sented for euthanasia at the University of Edinburgh
Hospital for Small Animals with no history and clinical
signs of pruritus or conditions likely to alter immune
function.
Sample collection
Blood samples from dogs with ad (n = 33) were col¬
lected by jugular venepuncture. Blood samples from
healthy dogs (n = 27) were collected by cardiac punc¬
ture immediately after euthanasia. Serum was sepa¬
rated by centrifugation and stored at — 20 °C.
Allergen extracts
Freeze-dried hdm extracts were obtained from
a number of sources (see Table 1). Each extract was
reconstituted in sterile phosphate buffered saline at
lmgml-1 (bca protein assay; Pierce Laboratories,
Rockford, usa). 100 pi aliquots were stored at —20 °C.
Sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE)
Ten microlitres of each extract was diluted 1 :1 in
either reducing (0125 M tris/HCl, 4 per cent sds, 20 per

















Greer - Greer Laboratories, Lenoir, usa; alk - ALK-Abello,
Horsholm Denmark; ap - Allergo-Pharma, Hamburg, Germany;
Rayne - Rayne Laboratory, University of Edinburgh, UK.
cent glycerol, 0 005 per cent bromophenol blue and 10
per cent 2-mercaptoethanol) or non-reducing (without
2-mercaptoethanol) loading buffer, sds-page was per¬
formed on 10 per cent tris-glycine resolving gels
according to the manufacturers recommendations
(Mini-Protean II"'; Biorad, Hercules, usa). Duplicate
gels were stained with 2-5 per cent Coomassie blue and
silver, transilluminated with white light and photo¬
graphed (The Imager; Appligene Oncor, Chester-le-
Street, uk).
Western blots
sds-page was performed using a single well across
the width of the gel with 200 pg of the D farinae, D
ptcronyssinus and D microceras extracts, and 50 pg of
the purified group 1 and 2 extracts in reducing and non-
reducing loading buffer. Proteins were transferred to
pvdf membranes (Immobilon-P; Millipore, Bedford,
usa) using 0-3 M tris-HCl/20 per cent methanol (pH
10-4) lower anode, 25 rnM tris-HCl/20 per cent metha¬
nol (pH 10-4) upper anode and 25 mM tris-HCl/40 mM
6-amino-n-hexonic acid/20 per cent methanol (pH 9-4)
cathode buffers according to the manufacturers
instructions (Transblot sd; Biorad). Membranes were
dried and stored at 4°C.
lmmunohlotting
The molecular weight markers (Biorad broad range)
and a strip to identify protein bands were removed and
stained with 2-5 per cent Coomassie blue.
The membranes were blocked in 5 per cent skimmed
milk/tris-buffered saline (tbs) for 1 hour at room tem¬
perature, briefly rinsed in tbs, then placed in an mn28
Miniblotter (Immunectics, Cambridge, usa). Appro¬
priate channels were incubated for 1 hour at room
temperature with 85 pi of a 1/5 dilution of serum, then
85 pi of either a 1/500 dilution of mouse monoclonal
(D9*31116; D. J. Deboer, University of Wisconsin)
(Mab) or a 1/100 dilution of goat polyclonal (A40-125;
Bethyl Laboratories, Montgomery, usa) (Pab) anti-
canine IgE. Blanks and control channels with no serum
or no anti-canine IgE were included in each assay.
Channels were washed with 10 ml of 0 05 per cent tween
20/tbs (ttbs) after each step. The miniblotter was
then dismantled and the membranes incubated at
room temperature for 1 hour with 20 ml of horseradish
peroxidase-conjugated bovine monoclonal anti-mouse
IgG (mca1421; Serotec, Kidlington, uk) or mouse
monoclonal anti-goat IgG (GT-34; Sigma, Poole, uk)
diluted 1/1000 and 1/5000 respectively. The membranes
were washed 3 times for 5 minutes in ttbs, then twice
for 5 minutes in tbs. The protein surface of each
membrane was covered with luminol solution (ecl;
Amersham-Pharmacia Biotech, Little Chalfont, uk) for
1 minute and each blot imaged (is440cf; Kodak,
Rochester, usa).
All reagents were diluted in 1 per cent skimmed milk-
tbs. Optimum conditions and reproducibility were
established prior to the study (data not shown).
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Data analysis
Four replicates of each allergen blot were generated
for both atopic and healthy sera-reducing buffer with
Mab and Pab, and non-reducing buffer with Mab and
Pab. The numbers of positive sera identified on the four
replicate blots were compared using Fisher's exact test
(Instat"; Graphpad Inc., San Diego, usa). Mann-
Whitney tests were used to compare the numbers of
positive atopic and healthy sera that recognised each
allergen extract (Instat1''; Graphpad Inc., San Diego,
usa). Significance was set at P < 0 05 for each test.
Standard curves constructed using the molecular
weight markers were used to calculate the mean mole¬
cular weight of allergens recognised by each serum
sample (ms Excel 2000; Microsoft Corp., Seattle, usa).
Major allergens were defined as those recognised by 50
,.er cent or more of positive sera.
RESULTS
Intradermal skin tests
Most dogs with ad had positive reactions to D
farinae and D pteronyssinus (Table 2). Two dogs had
reactions to D farinae but not to D ptcronyssinus. Occa¬
sional reactions were seen to other mites, insects, pollens
and moulds. Four dogs with ad had no positive reactions.
SDS-PAGE of hiDM extracts
The protein content of the allergen extracts varied
widely (Fig 1). In particular, only a few low molecular
weight proteins were detected on the alk D farinae,
alk and Rayne D pteronyssinus, and alk D microceras
gels. The appropriate bands were observed on the
purified allergen gels. Non-reducing gels were similar,
though not identical to the corresponding reducing gels,
"here were few differences between gels stained with
oilver and Coomassie blue (data not shown).
Immunoblotting
There was no non-specific binding by the anti-canine
IgE antibodies or secondary conjugates. Abolishing
binding by pre-heating serum at 56°C for 1 hour con¬
firmed the specificity of both antibodies for IgE (Tizard
1996). One serum sample from a skin-test negative dog
detected Dermatophagoides allergens under all blotting
conditions and three samples detected allergens on
individual blots.
As there were no significant differences in the
number of positive sera identified using either Pab or
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TABLE 2: Intradermal skin test reactions to Dermatophagoides
farinae and D pteronyssinusin dogs with atopic dermatitis (n = 33)
Allergen extract Positive Negative
Dermatophagoides farinae 24 9
D pteronyssinus 22 11
FIG 1: sds-page of crude and purified Dermatophagoides extracts
(2-5 percent Commassie blue stain) A - D farinae', B - Dpteronyssinus',
C - D microceras\ D - Group 1 allergens; E - Group 2 allergens;
mwm - Molecular weight markers (broad range; Biorad, Hercules, usa);
r - Reducing buffer; nr - Non-reducing buffer; Source of allergens:
A - Greer Laboratories, Lenoir, usa; B - alk-Abello, Horsholm, Denmark;
C - Allergo-Pharma, Hamburg, Germany; D - Rayne Laboratory,
Universityof Edinburgh, uk.
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(Table 3), the results were combined to give four
replicates (Mab/reducing blot, Mab/non-reducing blot,
Pab antisera/reducing blot and Pab/non-reducing blot)
for each allergen extract in subsequent analyses.
IgE binding to D farinae extracts
Significantly more atopic than healthy sera recog¬
nised D farinae allergens (P < 0 05), although more
atopic sera bound to the Greer compared to the alk
extract (P < 0 05) (Fig 2A).
IgE binding to the D pleronyssinus extracts
Significantly more atopic than healthy sera bound to
the Greer, alk and ap D pteronyssinus extracts
(P <005) (Fig 2B). Far fewer sera recognised the
Rayne extract compared to the others (P < 0 05). This is
prepared from mite media and largely consists of Der
pi and Der p2 (G. Hoyne, University of Edinburgh,
personal communication). Although more atopic
sera bound to the Greer D farinae extract compared to
the D pteronyssinus extract (P<005), there was no
difference between the alk extracts.
IgE binding to the D microceras extract
Significantly fewer atopic and healthy sera (range
4—21 per cent) recognised the alk D microceras extract
compared to the alk D farinae or D pteronyssinus





IgE binding to the purified Group 1 and 2 allergens
—- Apart from high molecular weight contaminants on
nr the alk Der fl and Der f2 blots (range 8-29 per cent),
very few sera recognised any of the purified group 1 and
2 allergens (range 0-4 per cent).
TABLE 3: Percentage of atopic (n = 33) and healthy (n = 27) sera that bound to Western blots of crude and
purified house dust mite allergens
Allergen extract Atopic sera Healthy sera
Reducing blot Non-reducing blot Reducing blot Non-reducing blot
Mab Pab Mab Pab Mab Pab Mab Pab
Greer of 67 58 52 58 23 12 15 11
ALK df 50 32 25 42 15 15 4 8
Greer dp 50 35 50 24 8 32 4 4
alk dp 30 26 28 32 19 4 15 22 '
ap dp 48 48 32 36 4 7 16 16
Rayne dp 7 0 0 0 4 0 0 0
alk dm 21 8 4 4 4 7 4 7
APDerpI 0 0 0 0 0 0 0 0
Rayne Derpl 0 0 0 4 0 0 4 0
APDerp2 0 0 0 0 0 0 0 0
alk Der f1 12 8 29 12 0 0 0 0
alk Der f2 12 20 15 11 0 0 0 0
of - Dermatophagoides farinae', dp - D pteronyssinus; dm - D microceras; Greer - Greer Laboratories, Lenoir,
usa; alk - alk-Abello, Horsholm Denmark; ap - Allergo-Pharma, Hamburg, Germany; Rayne - Rayne
Laboratory, University of Edinburgh, uk; Mab - monoclonal anti-canine IgE; Pab - polyclonal anti-canine IgE.
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FIG 2: Percentage of atopic and healthy sera that bound to Western
blots of Dermalophagoides allergens A - D farinae: B - D pteronyssinus;
Bar-sem; ■ Atopic sera; □ Flealthysera.
FIG 3: Major and minor allergens in the Greer Dermatophagoides
extracts (bars greater than 50 per cent indicate major allergens). A -
D farinae.B - D pteronyssinus: M Atopic sera; Flealthysera.
TABLE 4: Major and minor allergens identified in D farinaeand
D pteronyssinus
Major allergens (kDa) Minorallergens (KDa)
Reducing blot Non-reducing blot Reducing blot Non-reducing blot
a. D farinae
151 139 116 151
134 103 65 120





103 104 115 150





Major and minor allergens
Major allergens of 97-98 kDa and 103-104 kDa
were common to reducing and non-reducing blots of
D farinae and D pteronyssinus. Major allergens under
97 kDa were only seen on reducing blots. A range of
minor allergens from 15-150 kDa was identified on both
reducing and non-reducing blots of D farinae and D
pteronyssinus (Fig 3, Table 4).
DISCUSSION
This study has, for the first time, characterised in
detail the recognition of major and minor Dermato¬
phagoides allergens by atopic sera using anti-canine
IgE. Major allergens common to D farinae and
D pteronyssinus were delected as double bands at
97-98 kDa and 103-104 kDa on both reducing and non-
reducing blots. These probably represent the double
band previously reported as a major allergen using anti-
canine IgGd and FceRIo (Noli et al 1996, McCall et al
2000, Shaw 2000). This was identified as a chitinase, Der
f 15 (McCall et al 2000), although a 98 kDa allergen
recognised by human sera, Der fl 1, is homologous to a
paramyosin (Tsai et al 1999). Unidentified major D
farinae allergens of 95-101 kDa are also recognised by
human sera (Le Mao et al 1998). It is as yet unclear
whether canine and human atopic sera recognise similar
high molecular weight allergens.
The D farinae major allergen detected at 134—
139 kDa in this study has no obvious homologue, but
may represent an alternately glycosylated form of the
97-104 kDa allergen, whose native structure is
approximately 63 kDa (McCall et al 2000). Other major
allergens al 84-85 kDa, 65-69 kDa and 44-45 kDa were
only recognised on reducing blots, suggesting these are
denatured forms of the larger allergens. Degradation
products have also been identified on D farinae blots
probed with human sera (Le Mao et al 1998). Results
from reducing blots should be therefore interpreted
with care. However, despite the fact that reducing
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agents can alter protein structure and denature IgE
epitopes (Lombardero et al 1990), there were no sig¬
nificant differences in the numbers of sera that bound to
reducing and non-reducing blots of each allergen.
Similarly there was no difference in sensitivity or spe¬
cificity between polyclonal and monoclonal anti-canine
IgE, suggesting all the techniques are equally sensitive
and specific. Our results show that, in contrast to
humans, group 1 and 2 Dermatophagoides allergens
are of limited relevance to canine atopic dermatitis.
No positive control canine sera to these allergens
were available, but protein bands were identified on
each blot and they had been used in human and
murine studies (G. Nordskov Hansen, ALK-Abello;
O. Cromwell, Allergo-Pharma; N. Savage, University of
Edinburgh; personal communications). Although not
visible on the gels, a few atopic sera recognised trace
amounts of the 97-104 kDa major allergens on the Der
fl and 2 blots. This may explain the high frequency of
binding of canine atopic sera to group 1 and 2 allergens
in dot blots and elisas (Masuda et al 1999), where
individual proteins are not separated.
To our knowledge, this is the first study using anti-
canine IgE to demonstrate that different Dermatopha¬
goides allergens arc important in human and canine ad.
This is surprising, as many allergens have intrinsic
allergenic properties (Huby et al 2000). In particular,
Der pi degrades tight junctions, cleaves ml-antitrypsin,
CD23 and CD25, which directly activates mast cells and
basophils, inhibits Tm differentiation and increases
epithelial permeability, protease activity, IgE and
inflammatory mediator release (Schulz et al 1999,
Shakib and Gough 2000, Wan et al 2000). The 98 kDa
chitinase is glycosylated, which enhances IgE binding
and uptake by antigen presenting cells (apcs) (Huby
el al 2000), but it is unknown if any of the allergens
identified with canine sera are biologically active. In
vivo activity could also be substrate and species specific.
Furthermore, unlike B-cells, T-cells recognise short
sequences of 10-15 amino acids associated with class II
mhc molecules (Renz 1995). These are derived from
allergen processed by apcs (Carrasco-Marin et al 1998),
which profoundly influence the subsequent immune
responses (Maekawa et al 1998). If canine apcs present
a different array of peptides or if T-cell receptor and
mhc class II repertoires are very distinct from humans,
the specificity of allergen recognition could also differ.
Far fewer sera recognised D microceras compared to
D farinae and D pteronyssinus. This study did not dis¬
criminate between sensitisation to individual D farinae
and D pteronyssirms allergens or cross-reacting aller¬
gens specific to these miles. However, D farinae and
D pteronyssinus allergens are 80-90 per cent homo¬
logous (Thomas et al 1998) and cross-inhibition with
canine sera has shown that their allergens strongly
cross-react (Masuda et al 1999).
Recognition of the D farinae extracts by atopic
sera was influenced by the allergen source. However,
there was no difference in binding between the
D pteronyssinus extracts, despite a similar variation in
protein content. Moreover, differences in binding
between D farinae and D pteronyssinus were restricted
to a single allergen source. The concentration of key
allergens in certain extracts could explain why D
farinae, despite being less common than D pteronyssinus
in the UK (Thomas et al 1998), is a more prominent
allergen in canine ad (Sture et al 1995). However, a
recent study speculated that an apparently low pre¬
valence of D farinae could be due to seasonal fluctua¬
tions, as equal levels of Der fl and Der pi were present
in house dust (Sopelete el al 2000). Further work to
define and standardise the allergen content of Dermato¬
phagoides extracts is needed.
There was good correlation between skin tests and
immunoblotting for D pteronyssinus and D farinae,
although immunoblots were less sensitive. Epitopes
may be less available after gel separation and blotting or
blocked by allergen specific IgG, which parallels aller¬
gen specific IgE in canine sera (Day et al 1999). The few
positive immunoblots from skin-test negative dogs may
be due to technical problems, but allergen specific IgE
also occurs in healthy and skin-test negative atopic dogs
(Day et al 1999).
In conclusion, this study has shown that major Der¬
matophagoides allergens in canine ad are restricted to
proteins greater than 95 kDa. Group 1 and 2 allergens are
of limited importance. Using standardised allergens will
be important in the future diagnosis and treatment of ad.
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Abstract
Atopic dermatitis is a chronic inflammatory and pruritic skin disease commonly seen in dogs and
humans that is characterised by the presence of allergen-specific IgE. Data from skin tests and
serological analysis suggest that the house dust mite Dennatophagoides farinae is the most
important allergen in dogs with atopic dermatitis. The aim of this study was to determine if D.
farinae specific peripheral blood mononuclear cell (PBMC) responses could be detected in dogs
with atopic dermatitis. PBMCs were isolated by the density centrifugation from dogs with atopic
dermatitis that were skin test positive for D. farinae, dogs with atopic dermatitis that were skin test
negative for D. farinae, and healthy dogs. Cells were cultured with increasing concentrations of the
D. farinae extract, no antigen, vaccine antigens or concanavalin A (ConA). There was significantly
greater responsiveness of PBMCs from the D. farinae positive dogs than from either the D. farinae
negative or healthy dogs (ANOVA, P < 0.05). In contrast, no significant differences were observed
in the control responses between the three groups. This is the first study to demonstrate that D.
farinae specific circulating memory cells are involved in the pathogenesis of canine house dust mite
hypersensitivity. <( j 2001 Elsevier Science B.V. All rights reserved.
Keywords: Dog; Atopic dermatitis; PBMC proliferation; Dermatophagoides farinae
1. Introduction
Atopic dermatitis is a well-recognised chronic inflammatory skin disease of humans
(Rothe and Grant-Kels, 1996) and dogs (Scott el al., 1995). The relative risk of atopic
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dermatitis is strongly correlated to the house dust mite exposure (Cooper, 1994). Between
40 and 80% of human patients have house dust mite specific serum IgE and positive
skin tests (Halbert et al., 1995), and approximately 60% of atopic dogs have positive
skin tests to the house dust mite allergens (Sture et ah, 1995). The major house dust
mite species in temperate areas are Dennatophagoides farinae and Dermatophagoides
pteronyssinus. D. pteronyssinus prefers more humid conditions than D. farinae and is
the most common species in the UK (Thomas et ah, 1998). Despite this, skin test reactions
to D. farinae are more frequent than to D. pteronyssinus in atopic dogs in the UK (Sture
et ah, 1995).
Canine atopic dermatitis has been viewed as an IgE/mast cell-mediated disease (Scott
et ah, 1995). However, IgE production is dependent on the allergen-specific CD4 1 TH-cells
(Lydyard and Grossi, 1998) and infiltration of CD4+ and CD8+ lymphocytes is observed in
lesional atopic skin in both dogs (Olivry et ah, 1997) and humans (Leung, 2000). Several
studies in humans have demonstrated PBMC proliferation to the crude Dennatophagoides
extracts and purified allergens (reviewed in Leung, 2000). Despite this, investigation of
PBMC responses in atopic dogs has been limited. One unpublished report suggested that
PBMCs from atopic dogs had a proliferative response to the crude D. pteronyssinus extract
and major allergens identified on Western blots (Shaw, 2000), but responses to D. farinae
were not investigated.
The aim of this study, therefore, was to determine if allergen-specific T-cells were
involved in the pathogenesis of canine atopic dermatitis by investigating PBMC responses
to D. farinae in dogs with atopic dermatitis that were skin test positive to D. farinae, skin
test negative to D. farinae and healthy dogs.
2. Materials and methods
2.1. Study population
Dogs with atopic dermatitis were recruited from the Dermatology Clinic at the
University of Edinburgh Hospital for Small Animals. Diagnosis was based on compatible
history and clinical signs, and exclusion of other causes of pruritus (Willemse, 1986;
Nuttall et al., 1998). Coat brushings, skin scrapings and trial therapy were used to eliminate
the possibility of ectoparasite infestation. All dogs underwent a 6 weeks, home cooked diet
trial to eliminate the food intolerance. Seborrhoea, staphylococcal pyoderma and Malas-
sezia infections were managed appropriately. No anti-inflammatory medication was given
for at least 3 weeks prior to examination.
All dogs with a clinical diagnosis of atopic dermatitis were intradermally skin tested
with 57 allergens, including a D. farinae extract (Greer Laboratories, Lenoir, USA) as
follows. Dogs were sedated with 0.15 mg/kg xylazine i.m. Hair was clipped from the
lateral flank and 0.05 ml of each allergen extract, 1/100,000 (w/v) histamine (positive
control) and saline with phenol diluent (negative control) were injected i.d. Test sites were
assessed according to standard criteria after 20 min and subjectively scored from 0 to +4
compared to the controls. Reactions greater than or equal to +2 were considered positive
(Nuttall et al., 1998).
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Control samples were taken from healthy dogs presented for euthanasia at the University
of Edinburgh Hospital for Small Animals with no history and clinical signs of pruritus or
conditions likely to alter immune function.
2.2. D. farinae extract
A freeze-dried crude D. farinae extract (Greer Laboratories, Lenoir, USA) was
reconstituted in sterile PBS at 1 mg/ml (BCA protein assay; Pierce Laboratories, Rockford,
USA).
2.3. Sample collection
Blood samples were collected into 1.2% tri-sodium citrate by jugular venepuncture from
atopic dogs with either positive (n = 10) or negative (n = 7) intradermal skin test reactions
to D. farinae. Blood samples from the healthy dogs (n = 10) were collected by cardiac
puncture immediately after euthanasia. Samples were kept on ice and processed within 2 h.
2.4. PBMC separation
Blood samples were diluted 1:1 in chilled PBS/I.2% tri-sodium citrate (citrated PBS). A
volume of 20 ml of each sample was carefully layered over 20 ml of 1.007 g/rnl poly-
sucrose/sodium diatrizoate solution (Histopaque ""-1077; Sigma, Poole, UK) and centri-
fuged at 440 x g for 20 min at 20r'C. Cells were collected from the interface, washed in a
IOx volume of chilled citrated PBS and centrifuged at 250 x g for 10 min at 4"C. The cell
pellet was re-suspended in 1 ml of sterile distilled water for 30 s before adding 9 ml of 1 Ox
PBS. The cell suspension was then washed in a 3x volume of chilled citrated PBS and
centrifuged at 200 x g for 10 min at 4"C. The cell pellet was re-suspended in 5 ml of
Dulbecco's modified Eagle's medium (Sigma), supplemented with 10% FCS (Serotec,
Kidlington, UK), 2 mM L-glutamine (Life Technologies, Paisley, UK), 50 mM 2-mer-
capto-ethanol (Life Technologies, Paisley, UK), 100 IU/ml penicillin, 100 mg/ml strepto¬
mycin, 0.25 mg/ml amphotericin B (lOOx antibiotic-antimycotic solution; Sigma) and 1 %
non-essential amino acids (Life Technologies, Paisley, UK) (hereafter, referred to as
complete medium). A volume of 100 microlitres of the cell suspension was diluted 1:1 with
trypan blue (Sigma, Poole, UK). Viable cells were counted in a modified Neubauer
haemacytometer and the suspension adjusted to 1 x 10A cells/ml in complete medium.
2.5. PBMC cultures
The D. farinae extract was diluted 10-fold from 1000-0.01 micrograms/ml in complete
medium. A volume of 100 microlitres of each dilution was added to the appropriate wells of
a 96-well U-bottomed tissue culture plate (Nunclon Microwell; Fisher Scientific, Lough¬
borough, UK). Wells with 100 microlitres of 1 mg/ml concanavalin A (ConA) (Sigma), 1/
10 Borcletella bronchiseptica (Intrac"; Schering-Plough Animal Health, Uxbridge, UK)
and 1/10.000 canine parvovirus vaccine antigens (Parvo-C"'; Intervet UK Ltd.; Milton
Keynes, UK) diluted in complete medium were included as positive controls. Wells with
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100 microlitres of complete medium were included as negative control resting wells. A
volume of 100 microlitres of the cell suspension (i.e. 1 x 105 cells) was added to each well.
Wells with 200 microlitres of complete medium only were included as background. All
wells were plated in triplicate.
Plates were cultured at 38 C in 5% C02 for 7 days. Methyl-3H thymidine (0.5 pCi)
(Amersham-Pharmacia Biotech, Little Chalfont, UK) was added to each well for the final
4 h of culture. Optimum dilutions and culture conditions were established prior to this
study (data not shown).
Cells were harvested onto a glass-fibre sheet (Harvester 96; Tomtec, Orange, USA), air
dried, sealed in counting bags with 4 ml scintillant (Optiscint HiSafe; Wallac, Turku,
Finland) and the activity of each well recorded as counts per min (cpm) using a beta-
counter (Microbeta Plus; Wallac).
2.6. Data analysis
Results were expressed as the mean cpm per triplicate wells. Mean background cpm
(wells with medium only) was subtracted from all other wells. Cell proliferation was
expressed as, mean cpm (test wells-background — resting wells-background). After ensur¬
ing data were normally distributed, analyses of variance with Tukey's post tests were used
to compare cell proliferation between groups (Instat; Graphpad Inc., San Diego, USA).
Significance was set at P < 0.05.
3. Results and discussion
To our knowledge, this study documents for the first time the presence of circulating
Dennalophagoides farinae specific T-cells in canine atopic dermatitis. PBMCs from D.
farinae positive atopic dogs showed greater proliferation to all concentrations of the D.
farinae extract than PBMCs from either D. farinae negative atopic dogs or healthy dogs
(Fig. 1). Optimum proliferation was seen with 50 micrograms/ml D. farinae. At this
concentration, there was significantly greater proliferation of PBMCs from D. farinae
positive dogs with atopic dermatitis than either D. farinae negative dogs with atopic
dermatitis or healthy dogs (P < 0.05). There was no significant difference between the
latter two groups. This relatively high concentration probably reflects the low concentra¬
tion of the individual immunoreactive polypeptides within the crude D. farinae extract.
These results suggest that circulating T-cell responses are specific to dogs sensitised to D.
farinae, confirming a role for allergen-specific T-cells in the pathogenesis of canine atopic
dermatitis. The association of D. farinae specific PBMC proliferation with skin test
reactivity implies that these cells are supporting D. farinae specific IgE production
(Lydyard and Grossi, 1998).
A few D. farinae negative atopic dogs did have appreciable PBMC responses to D.
farinae. This may have been due to false negative skin tests (due to technique, degraded
allergen, anti-inflammatory medication, etc.) or false positive PBMC proliferation assays.
An alternative hypothesis is that these dogs have a predominantly cell-mediated immune
response to D. farinae with circulating cells of a THrtype phenotype. These have been
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Fig. 1. PBMC responses to D. farinae in atopic and healthy dogs: (0) dogs with atopic dermatitis skin test
positive to D. farinae (n = 10); (O) dogs with atopic dermatitis skin test negative to D. farinae (n = 7); (A)
healthy dogs (n = 10); (*) P < 0.05; bar, S.E.M.; cpm, counts per min (expressed as, test wells-
background — resting wells-background).
associated with protective immunity in humans (Maggi, 1998), but it is not known if this is
the case in dogs. The distribution of clinical signs and epidermal focusing of Langerhans'
cells and lymphocytes in canine atopic dermatitis is evidence of percutaneous allergen
uptake (Olivry et ah, 1997). It is possible that some individuals develop a type IV
hypersensitivity reaction akin to contact dermatitis (Kalish and Askenase, 1999), rather
than an IgE response. Late phase inflammatory responses and chronic lesions in human
atopic dermatitis are also dominated by TH|-type cytokines (Thepen et ah, 1996). It is
unclear, if these responses are allergen-specific or not (Cooper, 1994), but if cell-mediated
immunity plays role in the pathogenesis of atopic dermatitis, some individuals could have
allergic atopic dermatitis without the production of serum antibodies. Diagnostic tests such
as intradermal or skin prick tests and serology might not, therefore, be appropriate for all
patients.
There was very little response to D. farinae in PBMCs from healthy dogs, even though
most individuals are exposed to ubiquitous allergens such as the house dust mites. A low
level of reactivity is also reported in PBMCs from healthy humans (Horneff et ah, 1996).
However, PBMC responses to Der pi have been detected in both atopic and healthy
humans using serum free media (Upham et ah, 1995; Kawamura et ah, 1998). This suggests
that the serum components selectively inhibit proliferation of PBMCs from healthy
individuals. No serum free medium has been evaluated for canine PBMC cultures, so
it remains to be seen if widespread responses to ubiquitous allergens occur in dogs.
Poor responses in allergen-specific PBMC proliferation assays may also be due to
peripheral tolerance. It is thought that allergen-specific T-regulatory cells producing IL-10
and TGF(3 inhibit inflammatory responses in healthy individuals (Koulis and Robinson,
2000; Muraille and Leo, 1999). These cells may also limit in vitro PBMC responses to
allergens.
The protocols used in this study, yielded a mean population of 88% PBMCs with
greater than 95% viability. Canine PBMC populations vary between individuals, but are
278 T.J. Nuttall et al./Veterinary Immunology anel Immnnopalhology 82 (2001) 273-280
Table 1
PBMC responses to ConA and vaccine antigens
Mean (S.D.) proliferation (cpm)a
Resting ConA Bonletella Parvovirus
Dermatophagoides farinae
positive atopic dogs (n = 10)
Dermatophagoides farinae
negative atopic dogs (n = 7)














epm: counts per min (for ConA, BordeteHa and Parvovirus expressed as, test wells-background — resting
wells-background).
approximately 15-30% B-cells, 25-50% CD4+ T-cells and 20-40% CD8+ T-cells
(Kristensen et al., 1982; Rivas et al., 1995). Although both B- and T-cells could contribute
to cell proliferation, B-cells require interaction with activated CD4+ TH-cells (Lydyard and
Grossi, 1998). Most of the response to D. farinae allergens seen in this study should be due
to CD4+ cells, particularly as exogenous antigens are usually presented by antigen
presenting cells in the context of an MHC class II molecule to CD4+ cells (Kalish and
Askenase, 1999). However, exogenous antigens can also be presented with MHC class I
molecules to CD8+ cells (Kalish and Askenase, 1999). Furthermore, CD8+ cells can
provide help for B-cell activation and differentiation in certain circumstances (Kemeny,
1998), so it is difficult to make conclusions about the relative contributions of allergen-
specific CD8+ and CD4+ responses in PBMC proliferation assays.
There were no significant differences in the response of PBMCs isolated from the atopic
and healthy dogs to any of the control stimuli (see Table 1). All the PBMC cultures in this
study responded to ConA, which closely mimics antigen specific T-cell proliferation
(Lydyard and Grossi, 1998). This demonstrates that PBMCs from all three groups of dogs
were capable of quantitatively similar responses. Vaccine antigens were used to demon¬
strate that the PBMC cultures were capable of specific recall responses. Natural exposure to
B. bronchisepticci is common in the domestic and kennelled dogs, but natural and vaccine
immunity wanes after 6 months (Ford and Vaden, 1990). Infection with parvovirus is
uncommon, but natural and vaccine immunity is robust for at least 12 months (Hoskins,
1990). Despite this, only 8/10 D. farinae positive, 3/7 D. farinae negative and 4/10 healthy
dogs had a response greater than 1000 cpm above resting to parvovirus, and only 5/10 D.
farinae positive, 6/7 D. farinae negative and 6/10 healthy dogs responded to B. bronch¬
iseptica. This may be due to sub-optimal culture conditions or cytopathic effects, although
PBMCs that did respond did so very well. No reliable and universal recall antigen has been
established in dogs (Corato et al., 1997) and the effects of vaccination and natural exposure
on PBMC responses are unclear.
D. farinae, despite its low prevalence, is one of the most common skin test reactions in
the UI< (Sture et al., 1995). However, a recent study speculated that an apparent low
prevalence of D. farinae could be due to seasonal fluctuations, as equal levels of Der fl and
Der pi were present in the house dust (Sopelete et al., 2000). Der fJ5, a major D. farinae
allergen recognised by dogs, is heavily glycosylated (McCall et al., 2001), which may
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enhance its allergenicity (Huby et al., 2000). Despite this, a recent study found that
differences in the frequency with which serum IgE from atopic dogs bound to Western
blots of D.farinae and I), pteronyssinus were restricted to a single allergen source (Nuttall
et al., 2001). Further work to evaluate the house dust mite fauna and standardise allergen
extracts is necessary to define the relative importance of these mites in canine atopic
dermatitis.
In conclusion, this study has shown that PBMC responses to D. farinae allergens are
specific to D. farinae sensitised atopic dogs. This confirms that allergen-specific circulating
T-cells are involved in the pathogenesis of canine atopic dermatitis. Investigating the
cytokine responses induced by D.farinae in PBMC cultures should shed further light on
the role of Tm/TH2 polarisation and peripheral tolerance in atopic and healthy dogs.
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Atopic dermatitis is a chronic inflammatory and pruritic skin disease commonly seen in dogs and
humans. Most cases involve hypersensitivity to the house dust mites (HDM) Dermatophagoides
farinae and Dermatophagoides pteronyssinus. Human atopic dermatitis is associated with the HDM
derived allergens Der f 1 and 2, and Der p 1 and 2. Serological data, however, suggest that a
98/104 kD protein is the most important allergen in dogs with atopic dermatitis. The aim of this
study was to characterise the specificity of circulating T-cells in canine atopic dermatitis for HDM
derived allergens. Peripheral blood mononuclear cells (PBMCs) from dogs with atopic dermatitis
that were skin test positive for D. farinae and D. pteronyssinus were cultured with crude extracts of
D. farinae, D. pteronyssinus and D. microceras, a 98/104 kD allergen purified from D. farinae, Der
f 1 and Der f 2. There was significantly greater responsiveness of PBMCs to the D. farinae and
D. pteronyssinus extracts compared to the D. microceras extract, and similarly to the purified
98/104 kD allergen compared to Der f 1 and Der f 2. The close association between serological
findings and PBMC proliferation implies that the 98/104 kD HDM protein is a major target of
immune recognition and that T-cells also participate in the pathogenesis of canine atopic dermatitis
by supporting IgE production. © 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Atopic dermatitis is a universal, chronic inflammatory skin disease of humans (Rothe
and Grant-Kels, 1996) and dogs (Scott et al., 1995), characterised by positive skin tests and
specific serum IgE to Denncitophagoides species house dust mites (HDMs) (Halbert et al.,
1995; Sture et ah, 1995). Dermatophagoides pteronyssinus is the most common species in
the UK (Thomas and Smith, 1999), although skin test reactions to the closely related
species Dermatophagoides farinae are more frequent in atopic dogs (Sture et al., 1995). A
third species, D. microceras, is rare in the UK (O'Hehir, 1988).
The most important Dermatophagoides allergens relevant to humans are the group 1 and
2 allergens (Thomas and Smith, 1999), Der p 1 and 2 from D. pteronyssinus, and Der f 1
and 2 from D. farinae. High IgE titres to these allergens are present in 70-80% of atopic
human sera, whereas variable titres to other groups are found in only 40-50% of sera
(Thomas and Smith, 1999). However, immunoblotting studies with canine sera found that a
98/104 kD major allergen was common to D. farinae and D. pteronyssinus, whereas group
1 and 2 allergens were of minor importance (Noli et al., 1996; McCall et al., 2001; Shaw,
2000; Nuttall et al., 2001a). In contrast, another investigation suggested that both Der p 1
and 2, and Der f 1 and 2 were major allergens (Masuda et ah, 1999).
Canine atopic dermatitis has been traditionally regarded as an IgE/mast cell mediated
disease (Scott et ah, 1995) and investigations of PBMC responses to allergens are limited.
We have recently shown that PBMCs isolated from D. farinae sensitised atopic dogs
proliferated in response to a crude extract of D. farinae, whereas PBMCs from skin test
negative atopic dogs or healthy dogs showed little response (Nuttall et ah, 2001b). In
another, unpublished, study PBMCs isolated from dogs with atopic dermatitis responded to
both a crude D. pteronyssinus extract and the 98/104 kD major allergen, but not Der p 1 or
Der p 2 (Shaw, 2000).
The aim of this study, therefore, was to further characterise the allergen specificity of
circulating T-cells in canine atopic dermatitis by investigating the proliferative response
of PBMCs isolated from dogs with atopic dermatitis to group 1 and 2 allergens and the
98/104 kD major allergen purified from D. farinae, as well as to crude extracts of
D. farinae, D. pteronyssinus and D. microceras.
2. Materials and methods
2.7. Dermatophagoides extracts
Freeze dried crude D. farinae and D. pteronyssinus extracts were obtained from Greer
Laboratories, Lenoir, USA (Greer), and a freeze dried crude D. microceras extract from
ALK-Abello, Hprsbolm, Denmark (ALK). Freeze dried purified Der f 1 and Der f 2
extracts were obtained from ALK-Abello.
The 98/104 kD D. farinae allergen was purified from the Greer D. farinae extract by
high-pressure liquid chromotography (Waters 486/600S/626 system; Waters-Millipore,
Macclesfield, UK). Although it co-purified with a 128 kD protein, Western blotting and
probing with a positive control serum confirmed specificity for the 98/104 kD allergen
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(data not shown). All the extracts were diluted to 1 mg/ml in sterile PBS (BCA protein
assay; Pierce Laboratories, Rockford, USA) and stored at —20 °C.
2.2. Study population
Dogs with atopic dermatitis were recruited from the Dermatology Clinic at the
University of Edinburgh Hospital for Small Animals. Diagnosis was based on compatible
history and clinical signs, and exclusion of other causes of pruritus (Willemse, 1986;
Nuttall et al., 1998). Coat brushings, skin scrapings and trial therapy were used to eliminate
the possibility of ectoparasite infestation. All dogs underwent a 6 weeks, home cooked diet
trial to eliminate the possibility of food intolerance. Seborrhoea, staphylococcal pyoderma
and Malassezia infections were managed appropriately. No anti-inflammatory medication
was given for at least 3 weeks prior to examination.
All dogs with a clinical diagnosis of atopic dermatitis were intradermally skin tested
with 57 allergens, including Greer D. farinae and D. pteronyssinus extracts, as follows.
Dogs were sedated with 0.15 mg/kg xylazine i.m. Hair was clipped from the lateral flank
and 0.05 ml of each allergen extract, 1/100,000 w/v histamine (positive control) and saline
with phenol diluent (negative control) were injected i.d. Test sites were assessed according
to standard criteria after 20 min and subjectively scored from 0 to 4 compared to the
controls. Reactions greater than or equal to 2 were considered positive (Nuttall et ah, 1998).
Negative control samples were taken from three healthy dogs presented for euthanasia at
the University of Edinburgh Hospital for Small Animals with no history and clinical signs
of pruritus or conditions likely to alter immune function.
2.3. Sample collection
Blood samples were collected into 1.2% tri-sodium citrate by jugular venepuncture from
atopic dogs with positive intradermal skin test reactions to D.farinae and D. pteronyssinus
(/? = 13). Blood samples from healthy dogs (n = 3) were collected by cardiac puncture
immediately after euthanasia. Samples were kept on ice and processed within 2 h.
2.4. PBMC separation
Blood samples were diluted 1:1 in chilled PBS/1.2% tri-sodium citrate (citrated PBS).
Twenty millilitres of each sample was carefully layered over 20 ml of 1.007 g/ml
polysucrose/sodium diatrizoate solution (Histopaque ""-1077; Sigma, Poole, UK) and
centrifuged at 440g for 20 min at 20 °C. Cells were collected from the interface, washed
in a lOx volume of chilled citrated PBS and centrifuged at 250g for 10 min at 4 °C. The
cell pellet was re-suspended in 9 ml of sterile distilled water for 30 s before adding 1 ml of
lOx PBS. The cell suspension was then washed in a 3x volume of chilled citrated PBS and
centrifuged at 200g for 10 min at 4 °C. The cell pellet was re-suspended in 5 ml of
Dulbecco's modified Eagle's medium (Sigma), supplemented with 10% FCS (Serotec,
Kidlington, UK), 2 mM L-glutamine (Life Technologies, Paisley, UK), 50 pM 2-mercapto-
ethanol (Life Technologies), lOOIU/ml penicillin, 100 pg/ml streptomycin, 0.25 pg/ml
amphotericin B (lOOx antibiotic-antimycotic solution; Sigma) and 1% non-essential
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amino acids (Life Technologies) (hereafter referred to as complete medium). One hundred
microlitres of the cell suspension was diluted 1:1 with trypan blue (Sigma). Viable cells
were counted in a modified Neubauer haemacytometer and the suspension adjusted to
1 x 106 cells/ml in complete medium.
2.5. PBMC cultures
The crude D. farinae, D. pteronyssinus and D. microcercis extracts were diluted to
100 pg/ml, and the 98/104 kD D. farinae major allergen, Der f 1 and Der f 2 to 10 pg/ml in
complete medium. One hundred microlitres of each extract was added to the appropriate
wells of a 96 well U-bottomed tissue culture plate (Nunclon Microwell; Fisher Scientific,
Loughborough, UK). Wells with 100 pi of 1.0 pg/ml ConA (Sigma), 1/10 Bordetella
bronchiseptica (Intrac"'; Schering-Plough Animal Health, Uxbridge, UK) and 1/10,000
canine parvovirus vaccine antigens (Parvo CIntervet; Milton Keynes, UK) diluted in
complete medium were included as positive controls. Wells with 100 pi of complete
medium were included as negative control resting wells. One hundred microlitres of the
cell suspension (i.e. 1 x 10s cells) was added to each well. Wells with 200 pi of complete
medium only were included as background. All wells were plated in triplicate.
Plates were cultured at 38 °C in 5% C02 for 7 days. 0.5 pCi methyl-3H thymidine
(Amersham-Pharmacia Biotech, Little Chalfont, UK) was added to each well for the final
6 h of culture. Optimum dilutions and culture conditions were established prior to this
study (data not shown).
Cells were harvested onto a glass-fibre sheet (Harvester 96; Tomtec, Orange, CA, USA),
air dried, sealed in counting bags with 4 ml scintillant (Optiscint HiSafe; Wallac, Turku,
Finland) and the activity of each well recorded as counts per minute (cpm) using a beta-
counter (Microbeta Plus; Wallac).
2.6. Data analysis
Results were expressed as the mean cpm per triplicate wells. Mean background cpm
(wells with medium only; range 0-36 cpm) was subtracted from all other wells. After
ensuring data were normally distributed, analyses of variance with Tukey's post tests were
used to compare the response of PBMCs isolated from atopic dogs to the different crude
and purified allergens (Instat; Graphpad, San Diego, USA). Significance was set at
p < 0.05.
3. Results and discussion
This study demonstrates that T-cells specific for the 98/104 kD allergen purified from D.
farinae dominate the peripheral repertoire reactive with HDM in canine atopic dermatitis.
PBMCs isolated from D. farinae sensitised atopic dogs had a significantly greater response
to the 98/104 kD D. farinae major allergen than to either Der f 1 or 2 (Table 1, Fig. 1).
There was no significant difference in the responses to Der f 1 and 2. This is in contrast
to humans, where T-cells from 80% of atopic patients respond to group 1 and 2
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Table 1
In vitro responses of PBMCs isolated from dogs with atopic dermatitis and healthy dogs11
Stimulus Mean cpm (S.D.; number of dogs)
Atopic dermatitis Healthy dogs
D. farinae 1 1850 (4787; 13) 2431 (3392; 3)
D. pteronyssinus 13861 (9085; 13) 2961 (2922; 3)
D. microceras 4208 (3774; 13) 1834 (2473; 3)
98/104 kD D. farinae allergen 8893 (2132; 7) 1056 (1669; 3)
Der f 1 4337 (2154; 11) 1551 (2576; 3)
Derf 2 2394 (1593; 11) 1189 (2011; 3)
ConA 56040 (17566; 13) 29455 (11424; 3)
B. bronchseptica 4114 (3310; 13) 1102 (510; 3)
Canine parvovirus 3344 (4422; 13) 856 (390; 3)
Resting wells 2562 (1618; 13) 2101 (2013; 3)
a S.D.: standard deviation; cpm: counts per minute, expressed as mean per triplicate well—background.
Dermatophagoides allergens (Thomas and Smith, 1999), but similar to an unpublished
study in which canine PBMCs responded to the 98/104 kD allergen purified from D.
pteronyssinus, but not Der p 1 or 2 (Shaw, 2000). These results confirm that the 98/104 kD
protein is a major Dermatophagoides allergen in canine atopic dermatitis, whereas group 1
and 2 allergens are of minor importance. Furthermore, correlation of T-cell responses with
IgE levels implies that they participate in the pathogenesis of canine atopic dermatitis by
supporting specific IgE production.
It is surprising that different Dermatophagoides allergens are important in human and
canine atopic dermatitis, as their allergenic properties are due to their biological activities
(Eiuby et al., 2000). In particular, Der p 1 degrades tight junctions, cleaves a 1-antitrypsin,
CD23 and CD25, which directly activates mast cells and basophils, inhibits THi
I
*
Fig. I. Responses of PBMCs isolated from dogs with atopic dermatitis to purified D. farinae allergens: (S)
98 kD allergen (n = 7 dogs); (□) Der f 1 (n = 11 dogs); (□) Der f 2 (/? = II dogs); (j/3) resting cells (« = II
dogs); bar: S.E.M.; *: p < 0.05; cpm: counts per minute, expressed as mean cpm per triplicate wells—
background.
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differentiation and increases epithelial permeability, protease activity, IgE production and
inflammatory mediator release (Schulz et al., 1999; Shakib and Gough, 2000; Wan et al.,
2000). However, their in vivo activity could be substrate and species specific. It is unknown
if the 98/104 kD allergen is biologically active, although it is glycosylated (McCall et ah,
2001), which enhances IgE binding and uptake by APCs (Huby et al., 2000). Furthermore,
unlike B-cells, T-cells recognise short sequences of 10-15 amino acids associated with
class II MHC molecules (Renz, 1995). Processing of allergen by APCs can profoundly
influence the subsequent immune response (Maekawa et al., 1998). If canine APCs present
a different array of peptides or if T-cell receptor and MHC class II repertoires are very
distinct from humans, the specificity of allergen recognition could also differ.
All the dogs with a clinical diagnosis of atopic dermatitis in this study had positive skin
tests to D. farinae and D. pteronyssinus. There were also isolated reactions to a variety of
other mite, epithelial, pollen and mould allergens. PBMCs isolated from these dogs had
significantly greater responses to the crude D. farinae and D. pteronyssinus extracts than to
the crude D. microceras extract (Table 1, Fig. 2). This confirms an earlier study (Nuttall
et al., 2001a) demonstrating that far fewer atopic canine sera recognised D. microceras
compared to D. farinae and D. pteronyssinus. These results do not discriminate between
specific T-cell epitopes on individual D. farinae and D. pteronyssinus allergens or to cross-
reacting epitopes present only in these two species. However, D. farinae and D. pter¬
onyssinus allergens are 80-90% homologous (Thomas et al., 1998) and cross-inhibition
with canine sera has shown that their allergens strongly cross-react (Masuda et al., 1999).
PBMCs isolated from the healthy dogs did not respond to the Dermatophagoides
allergens despite comparable responses to the control stimuli (Table 1), suggesting that the
differences between the extracts were not due to non-specific mitogenic activity. Inhibition
by any of the extracts is also unlikely as some atopic PBMCs did respond and all are
routinely used in other studies (G. Nordskov Hansen; ALK, Hprsholm, Denmark, personal
communication). Vaccine antigens were used to demonstrate that the PBMCs were capable
of specific recall responses. Exposure to B. bronchiseptica is common in domestic and
















Fig. 2. Responses of PBMCs isolated from dogs with atopic dermatitis to crude Dermatophagoides extracts:
(■) D. farinae (n = 13 dogs); (□) D. ptenmyssinus (n = 13 dogs); (□) D. microceras (n = 13 dogs); (J2i)
resting cells (/? = 13 dogs); bar: S.E.M.; *: p < 0.05; cpm: counts per minute, expressed as mean cpm per
triplicate wells—background.
T.J. Nuttall et at./Veterinary Immunology and Immunopathology 84 (2002) 143-150 149
1990). Parvovirus infections are uncommon, but natural and vaccine immunity is robust for
at least 12 months (Hoskins, 1990). Despite this, the response was very variable (Table 1).
This may be due to sub-optimal culture conditions or cytopathic effects, although PBMCs
that did respond did so very well. No reliable and universal recall antigen has been
established in dogs (Corato et al., 1997) and the effects of vaccination and natural exposure
on PBMC responses are unclear.
The protocols used in this study yielded a mean population of 79% PBMCs with greater
than 95% viability. Canine PBMC populations vary between individuals, but are approxi¬
mately 15-30% B-cells, 25-50% CD4+ T-cells and 20-40% CD8+ T-cells (Kristensen
et ah, 1982; Rivas et ah, 1995). Although both B- and T-cells could contribute to cell
proliferation, B-cells require interaction with activated CD4+ T-cells (Lydyard and Grossi,
1998). Most of the response to Dermatophagoides allergens seen in this study is likely to be
due to CD4+ cells, particularly as exogenous antigens are usually presented by APCs with
an MHC class II molecule to CD4+ cells (Kalish and Askenase, 1999). However,
exogenous antigens can also be presented with MHC class I molecules to CD8+ cells
(Kalish and Askenase, 1999). Furthermore, CD8+ cells can provide help for B-cell
activation and differentiation in certain circumstances (Kemeny, 1998), so it is difficult
to make conclusions about the relative contributions of allergen specific CD8+ and CD4+
responses in PBMC proliferation assays.
In conclusion, this study has shown that PBMC responses to D. farinae allergens are
specific to the 98/104 kD major allergen identified in immunoblotting studies. This
confirms that allergen specific circulating T-cells are involved in the pathogenesis of
canine atopic dermatitis. Investigating the responses to overlapping peptides and the
biological activity of this allergen should shed light on the mechanism of sensitisation.
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Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine
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Summary
Background Atopic dermatitis is a common inflammatory skin disease of humans and dogs.
Human atopic dermatitis is associated with Th2-type responses, although Thl cytokines can be
identified in chronic lesions. In contrast, tolerance to environmental allergens in healthy individuals
is mediated by regulatory T cells.
Objective This study examined the expression of the immunosuppressive cytokines TGF-P and
IL-IO, the Th2-type cytokines IL-4 and IL-6, and the Thl-type cytokines IFN-y, TNF-a, IL-2, IL-
I2p35 and IL-I2p40, in canine atopic dermatitis.
Materials and methods RNA was isolated from lesional atopic, non-lesional atopic and healthy
canine skin samples. Semi-quantitative reverse transcriptase polymerase chain reactions (RT-PCRs)
were carried out using specific primers and one-way analyses of variance used to compare cytokine
expression in each group.
Results Canine atopic dermatitis was associated with over-expression of IL-4 mRNA and reduced
transcription of TGF-P compared with healthy skin (P < 0.05). Higher levels of IFN-y, TNF-a and
IL-2 mRNA were seen in lesional compared with non-lesional and healthy skin (P< 0.05). There
were no significant differences in IL-10, IL-6, IL-12p35 or IL-12p40 transcription between the three
groups.
Conclusions This is the first report to demonstrate that canine atopic dermatitis is associated
with over-production of IL-4. Clinical tolerance in healthy individuals appears to be associated with
TGF-P, although it is unclear if this reflects an active mechanism or simply non-responsiveness of the
immune system. Thl cytokines may be induced by subsequent self-trauma and secondary infections
in atopic skin. We believe that these results better characterize spontaneously occurring canine
atopic dermatitis. We further propose that this should be investigated as a possible animal model
of human atopic dermatitis.
Keywords atopic dermatitis, canine, cytokines, interleukin 4, Thelper 1, Thelper 2, transforming
growth factor beta, T regulatory cells
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Introduction
Atopic dermatitis is a universally recognized, chronic inflamma¬
tory skin disease of humans [1] and dogs [2]. The incidence of
atopic dermatitis in humans has increased dramatically in the
last 30 years [1]. It is difficult to assess whether the incidence of
canine atopic dermatitis has increased to the same extent, as the
development of diagnostic techniques in veterinary dermatol¬
ogy may have increased recognition of the condition, but some
authors estimate that up to 10% of all dogs are now affected [2],
Recent interest has focused on the role of CD4"1 T helper (Th)
cells in human atopic dermatitis [3], Thl cells were first differ¬
entiated from Th2 cells in rats and mice [4, 5]. Unlike rodent Th
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cells, human Th cells secrete a complex variety of cytokines [6],
although Thl - and Th2-type populations can be distinguished
[7], Thl-type cytokines, including IFN-y), IL-2, IL-12 and
TNF-a, promote cell-mediated immunity, whereas the Th2-
type cytokines IL-4, IL-5, IL-6, and IL-13, promote humoral
immunity, including IgE production [6, 8],
Several studies have detected Th2 polarization in peripheral
blood mononuclear cells and skin of atopic humans [9-13] and
mouse models of atopic dermatitis [14,15]. Th2 and Thl re¬
sponses are regarded as mutually exclusive [16], but Thl-type
cytokines have been detected in chronic lesions [17] and domin¬
ate atopy patch test sites after 48 h [18], suggesting they also
participate in pathogenesis of chronic atopic dermatitis.
Furthermore, healthy individuals do not develop Thl-induced
cell-mediated inflammatory reactions to environmental aller¬
gens [19]. Their lack of responsiveness may be mediated by
the immunosuppressive cytokines IL-10 and TGF-p [20,21],
although clinical tolerance could also result from immune
C> 2002 Blackwell Science Ltd 789
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non-responsiveness or a failure of environmental allergens to
penetrate healthy skin.
Studies of cytokine expression in canine atopic dermatitis are
limited. IL-4 has been detected in lesional atopic skin by im-
munohistochemistry [22]. Another study using non-quantita¬
tive reverse transcriptase polymerase chain reaction (RT-PCR)
demonstrated a Th2-like cytokine pattern in 25% of atopic and
a Thl-like pattern in 25% of healthy skin samples [23],
In this study we used semiquantitative RT-PCR to compare
mRNA expression of Till-type (IFN-y, TNF-oc, IL-2 and IL-
12), Th2-type (IL-4 and IL-6), and immunosuppressive cyto¬
kines (IL-10 and TGF-P) in atopic and healthy canine skin. Our
aim was to determine if canine atopic dermatitis was associated
with polarized Thl/Th2 responses similar to those observed in
human diseases. This information would greatly increase our
understanding of the pathogenesis of the canine disease, and
would help characterize this spontaneously occurring condition




Dogs with atopic dermatitis (n = 26) were recruited from the
dermatology clinic at the University of Edinburgh Hospital for
Small Animals. Diagnosis was based on compatible history and
clinical signs, and exclusion of other causes of pruritus [24,25].
Coat brushings, skin scrapings and trial therapy were used to
eliminate the possibility of an ectoparasite infestation. All dogs
underwent a 6-week home-cooked diet trial to eliminate the
possibility of food intolerance. Seborrhoea, staphylococcal
pyoderma and Malassezia infections were managed appropri¬
ately. No anti-inflammatory medication was given for at least 3
weeks prior to examination.
All dogs with a clinical diagnosis of atopic dermatitis were
intradermally skin tested with 57 allergens, including Dermato-
phagoidesfarinae and D. pteronyssinus (Greer Laboratories, Le¬
noir, NC, USA), as follows. Dogs were sedated with 0.15 mg/kg
xylazine injected intramuscularly. Hair was clipped from the
lateral flank and 0.05 mL of each allergen extract, 0.1 mg/mL
histamine (positive control) and saline with phenol diluent (nega¬
tive control) were injected intradermally. Test sites were assessed
after 20min according to standard criteria and subjectively
scored from 0 to 4 compared with the controls. By convention,
reactions greater than 2 were considered positive [25].
Control samples were taken from healthy dogs (n = 12) pre¬
sented for euthanasia at the University of Edinburgh Hospital
for Small Animals with no history and clinical signs of pruritus
or conditions likely to alter immune function.
Sample collection
Skin samples were taken whilst the dogs were sedated as
follows: 0.5-1.0 mL of 1% lignocaine was infiltrated into the
subcutis under the sites marked for biopsy. Non-lesional
samples (n = 26) were taken from the flank. Lesional samples
(/j =12) were taken from areas of erythema and macular-
papular dermatitis, where present. Grossly evident excoriation,
staphylococcal pyoderma and Malassezia dermatitis were
avoided. Six-millimetre diameter skin biopsies were taken and
placed immediately into RNA-later® (Ambion Inc., Austin,
TX, USA). Skin (n = 12) and positive control samples (popliteal
lymph node and tonsil) from healthy dogs were collected into
RNA-later® immediately after euthanasia. Samples in RNA-
later® were kept at 4 °C for 24 h, before storage at — 20 °C.
Primer design
Primers (Table 1) were designed from published canine se¬
quences (Genbank®; National Center for Biotechnology
Information; URL, http://www.ncbi.nlm.nih.gov/Genbank/)
using 01igo6® software (Molecular Biology Insights, Cascade,
CO, USA). Cross-reactive oligonucleotides were eliminated by
screening against known sequences (BLAST®; National Centre
for Biotechnology Information; URL, http://www.ncbi.nlm.
nih.gov/BLAST/).
RNA extraction
Total RNA was extracted from the skin biopsies and control
material by homogenization (Ultra-turrax 125; Janke and
Kunkel IKA, Staufen, Germany) in TRI-reagent® (Sigma,
Poole, UK) [26,27]. Genomic deoxyribonucleic acid was
removed by incubating with 4IU DNAse I per 50 pL RNA
solution according to the manufacturers instructions (DNA-
free®; Ambion Inc.). The RNA concentration was quantified
by ultra-violet absorbance at 260 nm with a 260-nm : 280 nm
ratio greater than 1.5 (DU650 spectrophotometer; Beckman-
Coulter, Fullerton, CA, USA). Heparin was removed by incu¬
bating 4 pg RNA with 4IU heparinase I (Sigma) [28].
Heparinazed RNA was stored at — 70 °C.
RT-PCR
cDNA generated from 1 pg heparinazed RNA (Reverse
Transcriptase System; Promega Corp., Madison, WI, USA)
was diluted to 200 pL in RNAse free water; 1 pg of heparinazed
RNA was diluted to 200 pL without reverse transcription as a
negative control. cDNA and negative control preparations were
stored at — 20 °C.
PCRs were carried out in 50-pL volumes containing 10 mM
Tris-HCl, 2.5IU Taq deoxyribonucleic acid polymerase (Roche
Molecular Biochemicals, Lewes, UK), 200 pM deoxynucleotide
triphosphates, 200 nM of each primer pair and 50 ng cDNA.
Reaction conditions consisted of initial denaturing at 94 °C
for 2 min, then 35 cycles of denaturing at 94 °C for 30 s,
annealing for 30 s and elongation at 72 °C for 1 min, before a
final elongation at 72 °C for 7 min (GeneAmp PCR System
2400; Perkin-Elmer, Cambridge, UK). Optimum MgCL con¬
centration and annealing temperatures for each primer pair
were established prior to the study (Table 1). PCR products
were run on 1.2% agarose gels containing 0.5 pg/mL ethidium
bromide and imaged under 590 nm ultra-violet light (Image
Station 400CF; Kodak, Rochester, NY, USA). PCR using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) specific
primers was performed for each cDNA and negative control
preparation. Samples with no GAPDH signal or a positive
signal from a negative control preparation were discarded.
Southern blotting and hybridization
PCRs for each primer pair using positive control cDNA (de¬
rived from popliteal lymph node and tonsil) were performed as
described previously. Southern blotting and hybridization was
performed using specific digoxigenin-labelled internal oligonu¬
cleotides [26].
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GAPDH Forward - CCTTCATTGACCTCAACTACAT
Reverse - CCAAAGTTGTCATGGATGACC
Internal - CCCTCAAGATTGTCAGCAATGCC
55 2.0 8.6 35 400
IL-4 Forward - TAAAGGGTCTCACCTCCCAACTG
Reverse - TAGAACAGGTCTTGTTTGCCATGC
Internal - CACCAGCACCTTTGTCCACGGA
55 1.5 9.2 36 317
IL-6 Forward - CCACAAGCGCCTTCTCCCTGG
Reverse - TCACGCACTCATCCTGCGACTG
Internal - GAATCACTACCGGTCTTGTGGAG
60 1.0 8.3 35 532
IFN-y Forward - TCGGACGGTGGGTCTCTTTTCG
Reverse - CACTTTGATGAGTTCATTTATCGCC
Internal - CAGCACCAGTAAGAGGGAGGAC
60 2.5 8.9 35 281
IL-2 Forward - CTCACAGTAACCTCAACTCCTGC
Reverse - TTCTGTAATGGTTGCTGTCTCGTC
Internal - ACACGCCCAAGAAGGCCACAGA
55 2.5 8.6 35 461
TNF-a Forward - ACTCTTCTGCCTGCTGCACTTTGG
Reverse - GTTGACCTTTGTCTGGTAGGAGACGG
Internal - CACCCACACCATCAGCCGCTTCGCCG
55 2.5 8.9 35 366
IL-12p35 Forward - AGCCTCACCGAGCCCAGGA
Reverse - TAAGGCACAGGACCGTCATAAAAG
Internal - TGGAGGCCTGCTTACCACTGGA
60 2.0 8.6 34 293
IL-12p40 Forward - GCCCCCGGAGAAATGGTGGTC
Reverse - TTGTGGCACACGACCTTGGCTG
Internal - ACCAGACCCACCCACAAACCTG
65 1.5 8.3 34 783
TGF-P Forward - AGTTAAAAGCGGAGCAGCATGTGG
Reverse - GATCCTTGCGGAAGTCAATGTAGAGC
Internal - GTTCAGTTCCAGCCCGCCGAGGT
55 2.5 9.2 35 434




To determine the optimum number of cycles for semiquantita¬
tive PCR, 26-44 PCR cycles for each primer pair were
performed using positive control cDNA and the gels
imaged as described. Standard curves were generated by plotting
the number of PCR cycles against the log2 net band intensity.
The optimum number of cycles for each cytokine primer pair
was selected from the straight-line portion of the plot (Table 1).
PCRs for each cytokine primer pair were performed with
cDNA from each skin sample for the appropriate number of
cycles. Positive control cDNA and negative controls (water
only) were included in each PCR. PCR products were run on
gels and imaged as before. Gels with no positive control signal
or a negative control signal were discarded. The relative abun¬
dance of cytokine gene transcripts was determined by dividing
the cytokine PCR product signal intensity by that of GAPDH
for each skin sample.
Data analysis
After ensuring data were normally distributed, one-way ana¬
lyses ofvariance withTukey's post-tests (Instat; Graphpad Inc.,
San Diego, CA, USA) were used to compare the relative abun¬
dance of cytokine gene transcripts in healthy, lesional atopic
and non-lesional atopic skin. The level of significance was set at
P< 0.05.
Results
All the dogs with clinical diagnosis of atopic dermatitis had
positive skin tests to D. fctrinae and D. pteronyssinus. There
were also a number of individual reactions to a range of other
dust mites, epithelia, pollens and moulds. Single bands of the
expected size for each cytokine were seen on the PCR gel and
hybridization blots using positive control material. This verified
expression of mRNA for each cytokine in the positive control
samples and confirmed primer specificity (Fig. 1).
Expression of Th2-type cytokines
Expression of IL-4 mRNA was largely restricted to atopic skin.
Significantly higher levels of IL-4 mRNA were detected in both
lesional and non-lesional atopic skin compared with healthy
skin (P<0.05) (Fig. 2a), although there was no significant
difference in transcription between lesional and non-lesional
atopic skin. IL-6 mRNA expression was also greatest in atopic
skin (Fig. 2b). However, IL-6 was also expressed in healthy
skin and differences between the three groups failed to reach
significance.
Expression of Th 7-type cytokines
There was a similar pattern of transcription for the Thl-type
cytokines IFN-y (Fig. 2c), IL-2 (Fig. 2d) and TNF-a (Fig. 2e) in
€> 2002 Black well Science Ltd, Clinical anil Experimental Allergy, 32:789-795





























Fig. 1. Detection of cytokine gene transcription using positive control
cDNA (Image Station 440CF; Kodak), (a) 1.2% agarose gel with 0.5pg/mL
ethidium bromide, (b) Southern blotting and hybridization to digoxigenin
labelled internal probes. Lane 1 = 100 bp DNA markers (Promega Corp.);
lane 2 = GAPDH; lane 3 = IL-4; lane 4 = IL-6; lane 5 = IFN-y; lane 6 = IL-2;
lane 7 = TNF-a; lane 8 = IL-12p35; lane9 = IL-12p40; lane 10 = TGF-fl; lane
11 = IL-10.
all three groups ofsamples. Significantly higher levels ofmRNA
for each cytokine were detected in lesional atopic skin com¬
pared with either non-lesional atopic or healthy skin
(P <0.05). Variably low levels, which did not significantly
differ, were detected in non-lesional and healthy skin.
Levels of IL-12p35 and IL-12p40 mRNA were highly vari¬
able in both atopic and healthy skin. IL-12p35 transcription did
not appear to differ between lesional atopic, non-lesional atopic
and healthy skin (Fig. 2f). IL-12p40 transcription was highest in
lesional atopic and healthy skin but there was no significant
difference between the three groups of samples (Fig. 2g).
Immunosuppressive cytokines
Healthy skin was associated with expression of mRNA for
the immunosuppressive cytokine TGF-p. Levels of TGF-J3
mRNA were significantly higher in healthy compared with
atopic skin (Fig. 2h). There was no significant difference be¬
tween the lower levels of expression in lesional and non-lesional
atopic skin.
Levels of mRNA for IL-10 were highly variable and no
significant difference was detected between any of the three
groups (Fig. 2i).
Discussion
Studies in humans and experimental mouse models suggest that
IL-4 expression is a hallmark of atopic dermatitis [3], In dogs, a
non-quantitative study detected IL-4 transcripts in both atopic
and healthy skin [23]. However, using semiquantitative RT-
PCR, this study has shown that much higher levels of IL-4
mRNA are expressed in atopic compared with healthy canine
skin. This demonstrates for the first time that IL-4 may contrib¬
ute to the pathogenesis of canine atopic dermatitis. The high
levels of IL-4 mRNA expression found in non-lesional as well as
lesional atopic skin in this study are consistent with the pattern
of transcription in human atopic dermatitis [3], It is not
clear, however, if IL-4 expression in non-lesional skin is consti¬
tutive or is a response to specific allergens. The impaired
delayed-type hypersensitivity responses seen in atopic humans
and animals are evidence of a default Th2 response [29].
However, Thl and Th2 responses can also coexist in the same
individual, suggesting that Thl and Th2 responses are antigen-
specific [30].
In contrast to a previous investigation [23], IL-6 mRNA was
readily detected in this study. However, there was no significant
difference in the level of expression between atopic and healthy
canine skin. Although IL-6 is regarded as a Th2-type cytokine
[7], it is also produced by antigen-presenting cells, fibroblasts,
macrophages, endothelial cells and keratinocytes [31], and its
role may depend on the precise relationship between and state
of activation of these different cell types. Furthermore, IL-6
may support production of the allergen-specific IgG found in
healthy humans and dogs [32,33].
Here we report for the first time that much lower levels of
TGF-P mRNA are expressed in canine atopic dermatitis com¬
pared with healthy skin. TGF-P, produced by antigen-present¬
ing cells, T cells and keratinocytes, is thought to be important in
peripheral and mucosal tolerance to environmental allergens in
humans and rodent models [34,35]. Atopic dermatitis in
humans and dogs is also associated with hyper-reactivity to
irritant stimuli [2, 3], which could be explained in part by low
TGF-P expression. In contrast, constitutive expression ofTGF-
P in healthy skin would inhibit inflammatory responses to en¬
vironmental allergens. However, TGF-P is secreted in an in¬
active form and is subject to post-transcription regulation [36].
Confirmation of its importance awaits demonstration of active
TGF-P in canine skin.
Tolerance may also be mediated by IL-10. Although an
earlier investigation failed to demonstrate its presence in canine
skin [23], IL-10 transcripts were present in all the samples in this
study. There was, however, no difference in the level of expres¬
sion between atopic and healthy skin. The role of IL-10 is
unclear in human disease and rodent models. Decreased IL-10
expression has been associated with colitis and cutaneous in¬
flammation in mice [37], and atopic dermatitis in children [12],
However, increased IL-10 expression has also been found in Th
cells from patients with atopic dermatitis [38] and in the airways
and skin after allergen challenge in mice and humans [21,39].
IL-10 is constitutively expressed in normal mouse skin, but only
in late phase reactions in a model of atopic dermatitis [40],
which may fail to resolve established Th2 responses and aller¬
gen-induced inflammation [20, 37],
The Thl-type cytokines IL-2, IFN-y and TNF-a are associ¬
ated with cell-mediated inflammation and inhibition of Th2
differentiation [16], An earlier non-quantitative investigation
detected IL-2 transcripts more frequently in healthy than atopic
canine skin samples, although there was no difference in the
number of samples that expressed IFN-y and TNF-a [23], In
contrast, only low levels of IL-2, IFN-y and TNF-a mRNA
were detected in healthy canine skin in this study. These results
are not consistent with Thl polarization in healthy skin, al¬
though it would be unusual to find high levels of pro-inflamma¬
tory cytokines expressed in healthy skin.
High levels of mRNA for the Thl cytokines IL-2, IFN-y and
TNF-a were restricted to lesional atopic skin. This suggests that




























Fig. 2. Abundance of cytokine gene transcripts in atopic and healthy
canine skin. Results of densitometric analysis (image station 440CF;
Kodak) of cytokine gene transcription as measured by RT-PCR.
Data are expressed as arbitrary units relative to GAPDH. ■ = lesional
atopic dermatitis; □= non-lesional atopic dermatitis;D = healthy skin;
bar = standard error of the mean; 'P < 0.05. a = IL-4; b = IL-6; c = IFN-y;
d = IL-2; e =TNF-a; f = IL-12p35; g =1L-12p40; h = TGF-p; I = IL-10.
Th2 skewing in canine atopic dermatitis is not associated with
poor expression of Thl cytokines. Chronic lesions in human
atopic dermatitis also exhibit a mixed pattern of cytokines,
including IL-4, IL-13, IL-5, IL-2, IFN-y and IL-12 [17].
Furthermore, Thl cytokines dominate atopy patch tests
after 48 h [18,41]. Why Thl cytokines are expressed in chronic
atopic dermatitis is not fully understood. Chronic lesions in¬
clude papules, scaling, crusting and lichenification [1,2],
which may result from self-trauma and microbial colonization
rather than atopic dermatitis per se. Self-trauma induces inflam¬
matory cytokines, including IL-1, TNFa and granulocyte-
macrophage colony-stimulating factor from keratinocytes
[42]. Furthermore, staphylococcal superantigens induce cutane¬
ous lymphocyte antigen expression on T-cells and IL-1, TNFa
and IL-12 from mononuclear cells in humans [3,43].
IL-12 is a critical factor in Thl differentiation, IFNy produc¬
tion and cutaneous lymphocyte antigen expression [44,45].
Down-regulation of IL-12 has been associated with Th2 polar¬
ization [20] but there was no significant difference between
IL-12 transcripts in healthy and atopic canine skin in this
study. Whilst this does not preclude post-transcription dysre-
gulation of IL-12, the expression ofThl -type cytokines suggests
that this is not the case, at least in lesional skin. IL-12 can also
support established Th2 responses [46], which may lead to a
vicious circle of ongoing inflammation in atopic skin.
These results allow us to postulate a pathogenic sequence for
canine atopic dermatitis in which early atopic dermatitis is
associated with increased expression of IL-4 and decreased
expression of TGF-J3. Lesional skin, in contrast, exhibits a
mixed inflammatory cytokine pattern that may be due to self-
trauma and secondary infection. The mechanisms underlying
Th2 polarization in non-lesional skin are unclear, but do not
appear to involve dysregulation of IL-12. Atopic dermatitis
may also reflect a loss of peripheral tolerance to environmental
allergens, which in healthy skin appears to be associated with
TGF-P rather than Thl polarization. We further propose that,
as the human and canine diseases share similar characteristics,
canine atopic dermatitis should be developed as a naturally
occurring model of human atopic dermatitis.
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